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Heme Biosynthesis: Structure–Activity Studies of Murine Ferrochelatase 
Zhen Shi 
ABSTRACT 
 
Ferrochelatase catalyzes the terminal step of heme biosynthesis by inserting 
ferrous iron into protoporphyrin IX.  The current study is aimed at understanding the 
structural basis of porphyrin binding and distortion in ferrochelatase-catalyzed reaction 
by functional analysis of a highly conserved active site loop motif.  The loop was shown 
to contact bound porphyrin based on crystallographic and molecular modelling 
observations, and its role in murine ferrochelatase was assessed by random mutagenesis 
and steady-state kinetic analysis.    To overcome the limitations of conventional kinetic 
assay methods for ferrochelatase, a continuous assay was developed by monitoring 
porphyrin fluorescence decrease using natural substrates ferrous iron and protoporphyrin 
IX under anaerobic conditions.  For wild-type murine ferrochelatase, the assay yielded 
KmPPIX of 1.4 μM, KmFe2+ of 1.9 μM and kcat of 4.0 min-1 at 30 oC.  The results of random 
mutagenesis indicated that all the loop residues spanning Q248-L257 tolerated functional 
substitutions.  While Q248, S249, G252, W256 and L257 possessed high informational 
content, the other five positions contained low informational content.  Selected active 
loop variants exhibited kcat comparable to or higher than that of wild-type enzyme, while 
KmPPIX was increased in most variants.  The kcat/KmPPIX remained largely unchanged, with 
x 
the exception of a 10-fold reduction in variant K250M/V251L/W256Y.  Molecular 
modeling of the active loop variants suggested that loop mutations resulted in alterations 
of the active site architecture.  Distortion of porphyrin substrate, a crucial step in 
ferrochelatase-catalyzed metal chelation, was examined using resonance Raman 
spectroscopy.  The results revealed that both wild-type enzyme and loop variants induced 
saddling of substrate protoporphyrin.  Further, loop mutations generally interfered with 
porphyrin saddling, with the least deformation observed in variant 
K250M/V251L/W256Y.  
N-alkyl porphyrins are potent competitive inhibitors of mammalian 
ferrochelatase.  The present study showed that while N-methyl protoporphyrin strongly 
inhibited the wild-type enzyme with an inhibition constant in the nanomolar range, it was 
less effective in inhibiting variants P255R and P255G.  These results suggest that 
inhibitor binding may be associated with a protein conformational change mediated by 
P255.  Wild-type ferrochelatase is a homodimeric [2Fe-2S] cluster-containing protein.  
Variants S249A/K250Q/V251C and S249A/K250R/G252W were found to retain 
enzymatic activity in the absence of FeS cluster and form active, higher order oligomers.  
These observations raise the possibility that FeS cluster and homodimeric organization 
are not essential to ferrochelatase catalysis.  
1 
 
 
 
Chapter One 
 
Introduction 
 
The importance of heme in biological systems 
Heme, an iron-containing macrocyclic tetrapyrrole compound, serves a wide 
range of important physiological functions in many organisms including oxygen 
transport, electron transfer, detoxification, metabolite production, biological sensing and 
signal transduction.  In hemoglobin and myoglobin the heme prosthetic group acts as an 
oxygen carrier which is crucial to gas transport and exchange in blood and tissues 
(Hardison 1996; Wittenberg and Wittenberg 2003).  Interestingly, hexacoordinated heme 
has been found in the newly identified vertebrate globins including neuronal specific 
neuroglobin and ubiquitously expressed cytoglobin (Pesce et al. 2002).  The primary 
function of neuroglobin has been thought to promote heme-mediated O2 diffusion into 
mitochondria, which confers protection against hypoxic-ischemic attacks in neurons 
(Hankeln et al. 2005).  In various forms of cytochromes associated with the electron 
transport chain, heme provides a redox-active metal center and thereby promotes electron 
transfer in aerobic respiration and photosynthesis to increase energy production via ATP 
synthesis (Rich 2003; Gray and Winkler 2005).  Enzymatic activities of a diverse set of 
heme monooxygenases including cytochrome P450s and nitric oxide synthase depend 
2 
upon protein interaction with the ubiquitous cofactor heme (Poulos 2005).  By supplying 
catalytically active iron, heme plays an essential role in mediating electron transfer and 
O2 activation to facilitate substrate oxidation (Poulos 2005).  In an increasing number of 
proteins the heme moiety has been shown to play a central role in biological sensing of 
small molecules including O2, carbon monoxide (CO) and nitric oxide (NO), which leads 
to modulation of protein activity (Rodgers 1999; Gilles-Gonzalez and Gonzalez 2005).  
For instance, for mammalian neuronal heterodimeric transcription factor NPAS2-
BMAL1, CO binding to heme coordinated in the PAS domain of NPAS2 has been found 
to inhibit DNA binding of the transactivation domain required for circadian rhythmn 
regulation (Dioum et al. 2002; Uchida et al. 2005).  Recently, heme has been implicated 
in regulating the activity of large-conductance calcium-dependent potassium (BKCa) 
channels, which control cerebral arterial smooth muscle excitability (Tang et al. 2003).  
While unliganded heme binds to the protein via a conserved heme-binding motif 
(CXXCH) and blocks channel activity, CO binding to heme relieved this inhibition and 
thus allowing channel activation and possibly leading to vasodilation (Tang et al. 2003).   
In all heme-synthesizing organisms, the heme biosynthetic pathway consists of a 
series of enzymes encoded by the nuclear genes (Dailey 1997).  In eukaryotes, the 
enzymes and reaction intermediates of heme biosynthesis are distributed in both the 
mitochondria and cytosol (Figure 1).  The first committed compound in the pathway is δ-
aminolevulinic acid (ALA) (Dailey 1997).  In animals, fungi and some photosynthetic 
bacteria (α-proteobacteria), ALA is generated via a four-carbon pathway (Shemin 
pathway) from the condensation of glycine and succinyl-CoA catalyzed by δ-
aminolevulinic acid synthase (ALAS) (Shemin and Russell 1953; Avissar et al. 1989).  In 
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Figure 1.  The heme biosynthetic pathway in animal cells.   
The enzymes and the subcellular distribution of the reaction intermediates in the pathway 
are shown in the diagram. Adapted from (Dailey 1997).  
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plants, algae, archaea and most eubacteria, ALA is synthesized using a five-carbon 
pathway which starts from the C5-skeleton of glutamate and involves the action of three 
enzymes (Beale et al. 1975; Kannangara et al. 1988; Frankenberg et al. 2003).  Once 
ALA is formed, the subsequent reactions in the pathway are common to all organisms 
(Frankenberg et al. 2003).  The second step involves the condensation of two ALA 
molecules to form the monopyrrole porphobilinogen (PBG) catalyzed by PBG synthase.  
In the third step, a linear tetrapyrrole, hydroxymethylbilane (HMB), is formed by head-
to-tail condensation of four PBG molecules with concomitant deamination using PBG 
deaminase.  HMB is immediately cyclized by the 4th enzyme uroporphyrinogen III 
synthase to form uroporphyrinogen III, the first tetrapyrrole macrocycle in the pathway.   
In the 5th step, uroporphyrinogen decarboxylase catalyzes the stepwise decarboxylation of 
the four acetyl side chains in uroporphyrinogen III to methyl groups to generate 
coproporphyrinogen III.  Oxidative decarboxylation of coproporphyrinogen III to 
protoporphyrinogen IX is catalyzed by the 6th enzyme coproporphyrinogen IX oxidase.  
Subsequently, protoporphyrinogen IX is oxidized to protoporphyrin IX by the 7th enzyme 
protoporphyrinogen IX oxidase.  In the last step, ferrochelatase catalyzes the insertion of 
iron into the protoporphyrin macrocycle to form protoheme.  In mammals, heme 
biosynthesis takes place primarily in the liver and bone marrow erythroid cells (Ponka 
1997).  Genetic defects in the first enzyme ALAS cause aberrant iron metabolism and 
associated disorders (Alcindor and Bridges 2002).  Enzymatic deficiency in any one of 
the steps after ALAS results in accumulation of porphyrins or porphyrin precursors and 
lead to various forms of a disease state known as porphyria (Kauppinen 2005).   
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In animals, plants and some bacteria, heme catabolism involves oxidative 
degradation catalyzed by heme oxygenase to yield biliverdin, ferrous iron and CO 
(Figure 2).  Mammalian heme oxygenase is associated with biliverdin reductase in a 
microsomal enzyme system, which further reduces biliverdin to bilirubin (Kutty and 
Maines 1981; Maines and Gibbs 2005).  The reaction catalyzed by heme oxygenase uses 
molecular oxygen and requires reducing equivalents from NADPH coupled with a redox 
partner, which is served by cytochrome-P450 reductase in mammals (Colas and Ortiz de 
Montellano 2003) and ferredoxin in some bacteria and plants (Cornejo et al. 1998; 
Wegele et al. 2004).   
In mammals, heme degradation primarily occurs in the reticuloendothelial system 
and hepatic cells.  Heme oxygenase plays a major role in the physiological breakdown of 
hemoglobin and other hemoproteins to bile pigments (Tenhunen et al. 1969; Maines and 
Gibbs 2005).  While the primary catabolite bilirubin is water-insoluble and potentially 
toxic, conjugation of bilirubin with glucuronic acid improves water solubility and 
facilitates excretion into bile (Tukey and Strassburg 2000).  In patients with excessive red 
cell lysis and heptobiliary diseases, bilirubin and its precursors accumulate in the serum 
leading to hyperbilirubinemia, while skin deposition of excess bilirubin gives the 
appearance of jaundice (Kaplan et al. 2003).  In spite of its putative cytotoxicity, 
numerous studies have shown that bilirubin can elicit potent antioxidant effects providing 
cellular protection against tissue injury, oxidative stress, inflammation and apoptosis 
(Otterbein and Choi 2000; Sedlak and Snyder 2004; Miralem et al. 2005).  The gaseous 
catabolic product CO has gained much attention as a versatile paracrine and autocrine 
messenger and neurotransmitter mediating diverse physiological responses such as 
6 
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Figure 2.  The heme degradation pathway in mammalian cells.     
The enzymes and the reaction intermediates in the pathway are shown in the diagram. 
Adapted from (Poulos 2005).  
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muscle relaxation, blood vessel dilation, pain perception and anti-inflammation (Morse et 
al. 2002; Boehning and Snyder 2003).  Heme oxygenase has also been found to play an 
important role in mammalian iron homeostasis (Poss and Tonegawa 1997).  Iron released 
from heme is thought to exit cells via a microsomal Fe-ATPase pump to bind to 
transferrin and to enter recycling route for instance towards hemoglobin synthesis (Ferris 
et al. 1999; Hentze et al. 2004).  In pathogenic bacteria, heme oxygenase allows the 
organism to obtain iron from acquired host heme to enable infection under low iron 
conditions and protects bacteria against heme toxicity (Schmitt 1997; Zhu et al. 2000).  
In the past decade, the structures of all the enzymes in the heme biosynthesis and 
degradation pathways have been determined.  These high resolution crystal structures 
provide many opportunities to study the structural basis of the catalytic mechanism of 
each enzyme and genetic diseases resulted from enzymatic deficiency.  In the following 
sections, recent discoveries are described in terms of structure, function, regulation and 
genetic disorder associated with each of the heme biosynthetic enzymes with an emphasis 
on ferrochelatase, the focus of this dissertation.  
 
Enzymes in the heme biosynthetic pathway 
 
Aminolevulinic acid synthase  
δ-Aminolevulinic acid synthase (ALAS) (EC 2.3.1.37) is the first enzyme in the 
heme biosynthetic pathway in animal cells, fungi and α-proteobacteria including 
Rhodobacter, Agrobacterium, Rhizobium and Rickettsia species (Shemin and Russell 
1953; Avissar et al. 1989).  ALAS catalyzes the condensation of L-glycine and succinyl-
8 
CoA (SCoA) to form δ-aminolevulinic acid (ALA), CO2 and coenzyme A (Gibson et al. 
1958; Shemin and Kikuchi 1958).  The enzymatic reaction generally requires the cofactor 
pyridoxal 5’-phosphate (PLP) (Nandi 1978b; 1978a; Davies and Neuberger 1979).  
Bacterial ALAS is a cytosolic soluble protein consisting of ~400 residues with a 
monomeric molecular mass of ~45-60 kDa (Warnick and Burnham 1971; Tait 1973; 
Nandi and Shemin 1977; Davies and Neuberger 1979; Hornberger et al. 1990).  In 
eukaryotic cells, ALAS is nuclear-encoded, synthesized in the cytoplasm as a precursor 
and translocated to the mitochondrial matrix (Whiting and Elliott 1972; Ades and Harpe 
1981; Urban-Grimal et al. 1986; Ades and Stevens 1988; Munakata et al. 1993).  The 
transport usually involves an N-terminal leader sequence of ~60 residues, which is 
cleaved proteolytically in the mitochondria (Bawden et al. 1987; Cox et al. 1991).  
Additionally, a second targeting signal involving an internal hydrophobic sequence has 
also been suggested (Volland and Urban-Grimal 1988).  The mature form of animal and 
fungal ALAS is typically present as a PLP-containing homodimer with a subunit 
molecular mass of ~50-65 kDa (Whiting and Granick 1976; Volland and Felix 1984; 
Ades and Friedland 1988; Ferreira and Dailey 1993).  
In mammals, there are two forms of ALAS encoded by separate genes (Bishop et 
al. 1981; Watanabe et al. 1983; Yamamoto et al. 1986; Riddle et al. 1989; Bishop 1990).  
The housekeeping form, ALAS-1, is present in all nonerythroid cells (Watanabe et al. 
1983; Yamamoto et al. 1986; Srivastava et al. 1988; Riddle et al. 1989).  ALAS-1 
transcription is upregulated by various hormones, porphyrinogenic drugs and xenobiotics 
(de Verneuil et al. 1983a; Srivastava et al. 1988; Podvinec et al. 2004; Handschin et al. 
2005), whereas product ALA inhibits ALAS-1 expression (Granick 1966; Marks et al. 
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1988; Srivastava et al. 1988).  Notably, mitochondrial import and maturation of ALAS-1 
are inhibited by very low levels of intracellular heme (Kikuchi and Hayashi 1981; Ades 
1983; Ades and Stevens 1988; Fujita et al. 1991).  The inhibitory effect is mediated by 
heme binding to three heme regulatory motifs (HRM) characterized by the Cys-Pro 
dipeptide in the ALAS-1 N-terminal region  (Zhang and Guarente 1995; Munakata et al. 
2004; Dailey et al. 2005).  The second isoform, ALAS-2, is only produced in developing 
erythrocytes and its expression is subject to transcriptional and translational regulation 
(Cox et al. 1991; Sadlon et al. 1999).  Iron has long been known to stimulate ALAS-2 
translation via an iron-responsive element (IRE), a stem-loop structure found in the 5’-
untranslated region of all the ALAS-2 transcripts (Cox et al. 1991; Dandekar et al. 1991; 
Melefors et al. 1993).  While binding of the iron regulatory proteins (IRP1 and IRP2) to 
the IRE typically block ALAS-2 translation, this repression is relieved at high levels of 
intracellular iron, and IRP1-mediated translational regulation has been shown to be 
associated with FeS cluster assembly (Melefors et al. 1993; Sadlon et al. 1999; 
Cooperman et al. 2005; Wingert et al. 2005).  
In spite of major differences in their regulatory mechanisms, both ALAS-1 and 
ALAS-2 share a highly homologous catalytic core, which consists of the C-terminal two-
thirds of the enzyme (Riddle et al. 1989; Cox et al. 1991; Munakata et al. 1993).  In fact, 
the catalytic domain of all ALASs is remarkably conserved throughout evolution with an 
overall sequence identity of ~40 % from bacterial to human enzymes (Duncan et al. 
1999; Astner et al. 2005).  ALAS belongs to a family of PLP-dependent enzymes, which 
include 8-amino-7-oxononanoate synthase (AONS), 2-amino-3-oxobutyrate CoA ligase 
(KBL) and serine palmitoyl transferase (Alexander et al. 1994; Grishin et al. 1995).  
10 
These enzymes are members of the α-oxoamine synthase family of PLP-dependent 
enzymes, which catalyze C-C bond formation or cleavage between an amino acid and an 
acyl-CoA substrate with release of coenzyme A and formation of an enzyme-bound 2-
amino-3-ketoacid intermediate (Alexander et al. 1994; Grishin et al. 1995; John 1995).  
These proteins share a large number of conserved residues, exhibit homologous folding 
patterns and active site geometries, and employ similar catalytic mechanisms (Alexander 
et al. 1994; Grishin et al. 1995; Alexeev et al. 1998).  
For ALAS, the proposed catalytic pathway involves the initial formation of a 
Schiff-base between the enzyme and cofactor PLP, followed by a transimination reaction 
between the enzyme-PLP complex and glycine, subsequent condensation of glycine with 
succinyl-CoA, and decarboxylation of the glycinyl carboxyl group results in release of 
ALA from the enzyme (Scholnick et al. 1972; Nandi 1978c).  Kinetic analysis indicated 
that the enzymatic reaction is initiated upon binding of the first substrate glycine to 
ALAS (Fanica-Gaignier and Clement-Metral 1973; Nandi 1978c).  Glycine forms a 
Schiff-base linkage with PLP to generate an external aldimine (Scholnick et al. 1972; 
Nandi 1978c; Ferreira et al. 1995; Hunter and Ferreira 1999a).  Subsequently the glycine-
ALAS external aldimine is deprotonated on glycine to yield a transient quinonoid 
intermediate (Nandi 1978c; Hunter and Ferreira 1999a).  This complex condenses with 
succinyl-CoA to convert aldimine to α-amino-β-ketoadipate (Hunter and Ferreira 1999b).  
In the subsequent decarboxylation reaction, rearrangement of the α-amino-β-ketoadipate 
results in the release of CO2 and a second quinonoid intermediate (Hunter and Ferreira 
1999b).  Protonation of the second quinonoid intermediate yields a third external ALA-
aldimine (Hunter and Ferreira 1999b).  In the last step, ALA is released from the 
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aldimine and the holoenzyme is regenerated (Nandi 1978c; Hunter and Ferreira 1999b).  
The rate-determining step appears to be product release, or a conformational change of 
the enzyme associated with ALA release (Hunter and Ferreira 1999b).   
This catalytic model is consistent with the recent X-ray crystal structures of 
Rhodobacter capsulatus ALAS holoenzyme and substrate-enzyme complexes (ALASrc) 
(Astner et al. 2005).  As expected, ALASrc bears close resemblance to the crystal 
structures of AONS and KBL (Alexeev et al. 1998; Schmidt et al. 2001) and to a R. 
spheroides ALAS model previously constructed by homology modeling using AONS and 
KBL as templates (Shoolingin-Jordan et al. 2003b).  ALAS is a symmetrical homodimer 
with each monomer folded into 3 domains, all of which contribute to the dimeric 
assembly.  The largest domain is the central catalytic core consisting of a seven-stranded 
mostly parallel β-sheet covered on both sides by nine α-helices in alternating β/α motifs.  
The catalytic core provides the most extensive contribution to the dimer interface.  In the 
vicinity of the dimer interface lies the C-terminal domain which comprises three-stranded 
antiparallel β-sheet and three α-helices.  A small N-terminal domain containing a three-
stranded antiparallel β-sheet and an α-helix is located more distantly from the catalytic 
core.  The PLP cofactor is bound to the catalytic domain near the dimer interface.  The 
active site is proposed to be located in an interdomain cavity between the juxtaposed 
catalytic domains and the C-terminal domain of the PLP-containing monomer (Astner et 
al. 2005).  Glycine binding occurs in this pocket, whereas succinyl-CoA binding occurs 
in a channel which connects the active site to the protein exterior (Astner et al. 2005).  
The active site pocket is enriched with many conserved residues, some of which have 
been found previously to be necessary for catalysis (Astner et al. 2005).   
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As indicated earlier (Nandi 1978c; Ferreira et al. 1993; Ferreira et al. 1995; 
Hunter and Ferreira 1999a), the initial enzyme-cofactor complex involves a Schiff-base 
between PLP and an invariant, catalytically-essential lysine residue.  PLP-binding is 
stabilized by residues from both monomers (Astner et al. 2005).  Consistent with a 
common observation among many PLP-dependent enzymes, the electron withdrawl 
capacity of PLP appears to be enhanced by hydrogen-bonding between its pyridinium 
ring and an adjacent conserved aspartate residue; this hydrogen-bond facilitates PLP to be 
held in the active site while the initial PLP-lysine Schiff-base linkage is replaced with a 
new Schiff-base between PLP and substrate glycine (Gong et al. 1998; Hunter and 
Ferreira 1999a).  In the enzyme-glycine complex, initial binding and orientation of 
glycine is shown to involve a salt bridge between the glycine carboxylate group and a 
conserved arginine, which is consistent with a previous study (Tan et al. 1998).  
Succinyl-CoA binds to a hydrophobic pocket near the protein surface in an extended 
conformation, and a conserved glycine-rich interface loop appears to be crucial in 
positioning the succinate carboxylate group as proposed previously (Gong et al. 1996).  
Both succinyl-CoA and glycine are positioned in close proximity in the active site, which 
makes it feasible for the nucleophilic attack of the succinyl-CoA CS1 by the glycine Cα 
atom in the first quinonoid intermediate to generate a new C−C bond (Astner et al. 2005).  
In mammals, enzymatic deficiency in the erythroid isozyme ALAS-2 leads to X-
linked sideroblastic anemia (XLSA), an X chromosome-linked hypochromic and 
microcytic anemia characterized by the presence of ring sideroblasts in the bone marrow 
(Cotter et al. 1992; Bottomley et al. 1995).  Ring sideroblasts are erythroblasts containing 
iron-laden mitochondria which are generated in response to disrupted heme synthesis 
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(Alcindor and Bridges 2002).  In some patients progressive toxic accumulation of iron in 
many tissues can have fatal consequences (Cotter et al. 1999).  To date more than 40 
mutations in human ALAS-2 have been known to cause XLSA (Astner et al. 2005).  
They include frameshift mutations, nonsense mutations and a large number of missense 
mutations involving nearly 40 highly conserved residues (Cotter et al. 1999; Shoolingin-
Jordan et al. 2003b; Astner et al. 2005)  Missense mutations are primarily located in the 
catalytic domain and appear to directly interfere with PLP and substrate binding (Cotter 
et al. 1999; Shoolingin-Jordan et al. 2003b; Astner et al. 2005).  Some substitutions are 
found in the hydrophobic core or on the enzyme surface and seem likely to destabilize the 
protein fold (Shoolingin-Jordan et al. 2003b; Astner et al. 2005).  Pyridoxine (vitamin 
B6) supplementation has been shown to be an overall effective therapy for XLSA 
particularly in patients with ALAS-2 mutations near the catalytic center (Cotter et al. 
1999; Alcindor and Bridges 2002; Shoolingin-Jordan et al. 2003b)  The treatment can be 
combined with phlebotomy or iron chelation with desferrioxamine to correct iron-
overloading and improve pyridoxine responsiveness (Cotter et al. 1999; Alcindor and 
Bridges 2002).  
 
Porphobilinogen synthase 
The first step common to all tetrapyrrole biosynthetic pathways is catalyzed by 
porphobilinogen synthase (PBGS), also known as ALA dehydratase (ALAD) (EC 
4.2.1.24).  PBGS catalyzes the condensation of two molecules of 5-aminolevulinic acid 
(ALA) to form the monopyrrole porphobilinogen (PBG) (Nandi et al. 1968).  PBG is an 
essential metabolic building block which is incorporated into various tetrapyrrole 
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compounds including heme, chlorophyll and cobalamin (Warren et al. 1998).  From 
bacteria to mammals, the amino acid sequence of  PBGS is highly conserved and 
comprised of ~330 residues (Jaffe 2003).  PBGS is a cytosolic enzyme and typically 
exists in a large homo-octameric assembly with a subunit molecular mass of ~35-40 kDa 
(Wu et al. 1974; Anderson and Desnick 1979; Gibbs et al. 1985; Spencer and Shoolingin-
Jordan 1993).  Metal ions are often found in the active site of PBGS and are commonly 
required for enzymatic activity (Jaffe 2003), although metal-independent PBGS has also 
been identified in some bacterial species (Bollivar et al. 2004).  
The condensation reaction catalyzed by PBGS is initiated with an ordered binding 
of two ALA molecules in the active site (Jaffe 2004b).  The first ALA molecule binds to 
the P-site in PBGS, which involves formation of Schiff-base linkage of ALA with an 
active site lysine (Gibbs and Shoolingin-Jordan 1986; Jaffe 2004a).  The first ALA 
contributes the propionate side chain and the pyrrole nitrogen of PBG  (Shoolingin-
Jordan and Gibbs 1985; Jaffe 2004a).  The second ALA binds to the A-site, giving rise to 
the acetate side chain and the amino nitrogen of PBG (Shoolingin-Jordan and Gibbs 
1985; Jaffe 2004a).  The rate-limiting step of the overall reaction appears to be product 
release or a conformational change of the enzyme that is coupled to product release (Jaffe 
2004a). Interestingly, product formation has been found to occur with a half-of-the-sites 
reactivity (Kundrat et al. 2003; Jaffe 2004a).  
Metal ions typically serve as cofactors in the PBGS-catalyzed reaction, and metal 
binding specificity is largely phylogenetically dependent (Jaffe 2004a).  In animals, 
fungi, archaea and some bacteria, PBGS contains catalytic Zn2+ whose main function is 
to enhance A-site binding of the second ALA substrate molecule possibly by acting as a 
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Lewis acid or electrophile to react with the bound first ALA (Jaffe and Hanes 1986; Jaffe 
1995; Spencer and Shoolingin-Jordan 1995; Erskine et al. 2001b; Erskine et al. 2003).  
The catalytic Zn2+ is coordinated by three cysteine ligands in a conserved C-X-C-X7-C 
motif (Jaffe 2003).  In contrast, Mg2+ has been found in PBGS from photosynthetic 
plants, algae and some bacteria (Boese et al. 1991; Jaffe 2003).  At least some of the 
bound Mg2+ appear to be allosteric rather than catalytic (Boese et al. 1991; Jaffe 2003).  
Additionally, both Zn2+ and Mg2+ have been found to be associated with PBGS from 
many plants and bacteria (Jaffe 2003).   
The structure of PBGS has been determined for the enzyme from a variety of 
organisms (Jaffe 2004b).  To date the crystal structures are available for the enzyme from 
human (Breinig et al. 2003), yeast S. cerevisiae (Erskine et al. 1997; Erskine et al. 2001b; 
Erskine et al. 2003; Erskine et al. 2005), and a number of bacteria including E. coli 
(Erskine et al. 1999; Kervinen et al. 2001), Pseudomonas aeruginosa (Frankenberg et al. 
1999; Frere et al. 2002), and Chlorobium vibrioforme (Coates et al. 2004).  PBGS, either 
in an apo form or with bound inhibitor or reaction intermediate, exhibits homologous 
overall fold and active site structure (Jaffe 2004b).  The holoenzyme is typically 
assembled into a homo-octamer (Erskine et al. 1997; Erskine et al. 1999; Frankenberg et 
al. 1999; Kervinen et al. 2001; Coates et al. 2004).  The eight monomers are organized in 
422 or D4 point group symmetry with the central cavity in each subunit oriented towards 
the solvent.  The holoenzyme is tightly packed into four pairs of “hugging” dimers, in 
which one monomer extends an N-terminal arm to wrap around the adjacent monomer 
(Erskine et al. 1997; Erskine et al. 1999; Frankenberg et al. 1999; Kervinen et al. 2001; 
Coates et al. 2004).  Each monomer adopts a (β/α)8 barrel fold characteristic of the triose 
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phosphate isomerase (TIM) barrel proteins in the adolase superfamily.  The active site is 
located in a deep cavity in the center of the TIM barrel, while an extended loop at the 
exposed end of TIM barrel forms a mobile lid to gate solvent access.  Many conserved 
residues are clustered in the active site cavity and have been shown to mediate substrate 
binding, catalysis and active site conformational change (Erskine et al. 1997; Erskine et 
al. 1999; Frankenberg et al. 1999; Kervinen et al. 2001; Coates et al. 2004).   
Crystal structural analysis has provided further details in the PBGS reaction 
mechanism (Jaffe 2004b).  The initial step of catalysis involves Schiff-base formation of 
the P-site ALA substrate with an invariant lysine located at the bottom of active site 
cavity (Gibbs and Shoolingin-Jordan 1986; Erskine et al. 1997; Erskine et al. 1999; 
Erskine et al. 2001b; Frere et al. 2002; Coates et al. 2004).  This first step is conserved for 
all of the PBGS investigated to date and does not require metal ions (Jaffe 2004b).  The 
next step involves the second ALA binding to A-site, which consists of a solvent-filled 
hydrophilic pocket (Erskine et al. 1999; Erskine et al. 2001b).  It is possible that this 
ALA forms a second Schiff-base linkage with another invariant lysine in the active site 
(Erskine et al. 2001a; Kervinen et al. 2001).  In Zn-dependent PBGS, this step is 
facilitated by the presence of solvent-coordinated catalytic Zn2+ (Erskine et al. 1999; 
Erskine et al. 2001a; Erskine et al. 2001b; Kervinen et al. 2001).  It has been proposed 
that active site closure is promoted by the second ALA binding (Frankenberg et al. 1999; 
Kervinen et al. 2001).  The final steps have been shown to proceed via a five-membered 
ring intermediate held at the active site, and PBG formation and release is facilitated by 
added ALA substrate (Erskine et al. 2003).  Alternatively, a reciprocating motion model 
suggests that a covalently bound almost-product intermediate is transferred to the 
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adjacent active site, which opens the lid and releases a PBG molecule (Jaffe 2004b).  This 
latter hypothesis is consistent with the observation of half-site reactivity in PBGS 
(Kundrat et al. 2003).  
Important features of metal-binding in PBGS have also been revealed by 
structural analysis (Jaffe 2003).  While Zn2+-dependent PBGS requires active site Zn2+ in 
catalysis, Mg-containing PBGS uses Mg2+ for allosteric regulation of enzymatic activity 
(Jaffe 2003).  The binding of Mg2+ has been shown to occur at a remote location near the 
active site flap and is likely to play a role in stabilizing the closed lid conformation 
(Frankenberg et al. 1999; Coates et al. 2004).  Interestingly, an analogous allosteric 
Mg2+-binding site is occupied by a second Zn2+ in E. coli PBGS, which provides a 
structural explanation for the observation that Mg2+ stimulates E. coli PBGS activity 
(Mitchell and Jaffe 1993; Spencer and Shoolingin-Jordan 1993; Erskine et al. 1999; 
Kervinen et al. 2001).  Mammalian PBGS has long been known as a target for lead 
poisoning (Warren et al. 1998).  Human PBGS activity is inhibited by very low 
concentrations of Pb2+ (Simons 1995) (Jaffe 2001).  Structural analysis suggests that this 
inhibition is caused by Pb2+ replacement of the catalytically important, tri-cysteine-
coordinated Zn2+, which leads to alteration of the active site environment and thereby 
interferes with substrate binding and catalysis (Jaffe et al. 2001).  
Hereditary PBGS deficiency, or Doss porphyria, is the most uncommon form of 
all the porphyrias (Doss et al. 1979).  The disease is autosomal recessive and fewer than 
10 cases have been reported to date (Maruno et al. 2001; Doss et al. 2004).  Doss 
porphyria belongs to the acute hepatic porphyrias with characteristic clinical features of 
acute neurovisceral attacks and neuropathy (Nordmann and Puy 2002). Patients  
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generally show elevated urinary excretion of ALA and coproporphyrin, which can be 
used for diagnosis (Nordmann and Puy 2002; Doss et al. 2004).  Only ~10 mutations in 
PBGS have been associated with Doss porphyria including predominantly missense 
mutations and a few frameshift mutations (Maruno et al. 2001; Doss et al. 2004).  Most 
patients are compound heterozygous for the genetic defects (Maruno et al. 2001; Doss et 
al. 2004).  Missense mutations primarily occur near the catalytic zinc-binding site or 
substrate-binding site and result in markedly diminished enzymatic activity (Maruno et 
al. 2001).  A few substitutions are located distant from the active site and appear to 
disrupt protein structure and stability (Maruno et al. 2001).  Intravenous heme arginate 
infusion has been shown to be an effective therapy for the disease leading to reduction of 
urinary ALA and porphyrins and correction of polyneuropathy (Doss et al. 2004).   
 
Porphobilinogen deaminase  
Porphobilinogen deaminase (PBGD), also known as hydroxymethylbilane 
synthase (HMBS) (E.C.4.3.1.8) catalyzes the stepwise head-to-tail condensation of four 
porphobilinogens to form the linear tetrapyrrole, hydroxymethylbilane (HMB) or pre-
uroporphyrinogen (Bogorad 1958b).  PBGD contains ~310-370 residues and exhibits an 
exceedingly high degree of sequence conservation with ~40% sequence identity between 
the E. coli and human sequences (Brownlie et al. 1994; Louie et al. 1996).  The protein is 
a monomer of ~34-39 kDa (Anderson and Desnick 1980; Raich et al. 1986; Grandchamp 
et al. 1987; Louie et al. 1996).  In plants PBGD is localized in the plastid chloroplast 
(Bogorad 1958a; Witty et al. 1996).  Human PBGD is encoded by a single gene, which 
contains two distinct promoters to generate housekeeping and erythroid-specific 
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transcripts by alternative splicing (Grandchamp et al. 1987).  This gives rise to two 
isoforms of PBGD, i.e. the erythroid form and the slightly larger non-erythropoietic form 
(Grandchamp et al. 1987).   
An interesting feature of the PBGD catalytic mechanism is that the reaction is 
primed using a dipyrromethane cofactor that the enzyme assembles from two molecules 
of porphobilinogen (Hart et al. 1987; Shoolingin-Jordan and Warren 1987; Warren and 
Shoolingin-Jordan 1988).  The cofactor is covalently linked to a cysteine residue (Hart et 
al. 1988; Miller et al. 1988).  Polymerization of four PBGs is initiated by linking one 
pyrrole ring to the cofactor, followed by stepwise addition of three pyrroles (Anderson 
and Desnick 1980; Shoolingin-Jordan and Warren 1987; Warren and Shoolingin-Jordan 
1988).  This results in an enzyme-bound hexapyrrole, which is hydrolyzed to release the 
tetrapyrrole product, thus regenerating the holoenzyme (Shoolingin-Jordan and Warren 
1987; Warren and Shoolingin-Jordan 1988).  
The three-dimensional structure of PBGD has been determined for the E. coli 
enzyme (Louie et al. 1992; Louie et al. 1996; Helliwell et al. 2003).  The crystal 
structures reveal a flexible multidomain polymerase with a single active site (Louie et al. 
1992; Louie et al. 1996; Helliwell et al. 2003).  The protein is folded into three domains 
(Louie et al. 1992; Louie et al. 1996; Helliwell et al. 2003).  The active site is located in a 
deep interdomain cleft and contains a dipyrromethane cofactor (Shoolingin-Jordan and 
Warren 1987; Warren and Shoolingin-Jordan 1988; Louie et al. 1992; Louie et al. 1996).   
Domains 1 and 2 exhibit similar folds which resemble transferrins and 
periplasmic binding proteins (Louie et al. 1992; Louie et al. 1996).  Domain 1 contains 
the substrate-binding site and is enriched with catalytically important residues (Louie et 
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al. 1992).  Domain 2 has most of the cofactor-binding residues providing extensive salt-
bridges and hydrogen-bonds to hold the cofactor within  the cleft between domain 1 and 
2  (Louie et al. 1992; Louie et al. 1996).  Domain 3 supplies an invariant cysteine residue 
which forms a covalent link with the dipyrromethane cofactor (Louie et al. 1992; Louie et 
al. 1996).  It also appears to shield domain 1 and 2 from solvent exposure (Louie et al. 
1996).  The multi-domain organization of PBGD thus provides intrinsic flexibility to the 
active site to facilitate substrate entry, cofactor attachment, chain elongation and product 
release (Louie et al. 1996).  Many conserved residues are found in the hydrophobic core 
and are important for protein stability (Brownlie et al. 1994).  Conserved residues 
clustered in the active site cleft have been shown to be catalytically essential (Brownlie et 
al. 1994; Louie et al. 1996).  A group of conserved arginine residues have been found to 
be necessary for binding and positioning of the mono- and poly-pyrrole substrates, 
cofactor binding, chain elongation and product release (Lander et al. 1991; Shoolingin-
Jordan and Woodcock 1991; Louie et al. 1992; Louie et al. 1996; Shoolingin-Jordan et al. 
2003a; Solis et al. 2004). Significantly, an invariant active site aspartate residue has been 
hypothesized to play a key role in facilitating substrate interaction with the cofactor 
(Woodcock and Jordan 1994).  The carboxylate side chain of this aspartate is found at a 
position suitable for hydrogen-bonding with the pyrrole nitrogen groups of both the 
cofactor and substrate and in this manner, allows stabilization of the reaction intermediate 
(Louie et al. 1992; Woodcock and Jordan 1994; Louie et al. 1996).  
Partial deficiency of PBGD causes one of the most common of the porphyrias, 
acute intermittent porphyria (AIP) (Meyer et al. 1972; Tschudy et al. 1975).  AIP is an 
autosomal dominant disease with very low penetrance (Nordmann et al. 1997; Nordmann 
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and Puy 2002).  Patients typically have acute episodes of neuropathic symptoms, most 
frequently with abdominal pains, and at times also with psychiatric manifestations 
(Anderson et al. 2005).  The neurovisceral attacks are often precipitated and sometimes 
exacerbated by alcohol, low caloric intake, sex hormones and porphyrinogenic drugs 
such as barbiturates and sulfonamides (Jover et al. 2000; Anderson et al. 2005; Fraunberg 
et al. 2005).  AIP is usually diagnosed by elevated concentrations of urinary porphyrin 
precursors ALA and PBG during a symptomatic relapse (Tschudy et al. 1975; Anderson 
et al. 2005). Neurologic impairment is often attributed to toxicity of the accumulated 
porphyrin precursors including ALA, although the mechanism is still not very well 
understood (Brennan et al. 1980; Lindberg et al. 1999; Solis et al. 2004).   
Currently more than 240 genetic lesions in PBGD have been described for AIP 
(Kauppinen 2005).  They include splice site mutations, frameshifts, small insertions, 
nonsense mutations, and nearly half of all, missense mutations (Brownlie et al. 1994; 
Floderus et al. 2002; Nordmann and Puy 2002; Fraunberg et al. 2005).  While the 
molecular defects for AIP are highly heterogeneous, a few mutations have been found 
with high prevalence in Sweden, Holland, Canada, Switzerland and France suggesting a 
founder effect (Lee and Anvret 1991; Puy et al. 1997; Schneider-Yin et al. 2000a; 
Cappellini et al. 2002; Nordmann and Puy 2002; Schneider-Yin et al. 2002).  PBGD 
mutations generally lead to low residual enzymatic activity, poor protein expression or 
instability or retention of the enzyme-intermediate complexes (Desnick et al. 1985; 
Brownlie et al. 1994; Solis et al. 2004; Fraunberg et al. 2005; Pischik et al. 2005).  Many 
single amino acid substitutions occur in conserved residues located in the interdomain 
active site cleft and conserved hydrophobic core (Brownlie et al. 1994; Puy et al. 1997; 
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Floderus et al. 2002; Shoolingin-Jordan et al. 2003a).  They have been shown to disrupt 
protein fold and stability, cofactor assembly, substrate binding and polypyrrole formation 
and release (Brownlie et al. 1994; Puy et al. 1997; Floderus et al. 2002; Shoolingin-
Jordan et al. 2003a).  
Two conventional therapeutic methods have been found to benefit some patients 
which involve high carbohydrate intake and intravenous hematin administration 
(Tschudy et al. 1975; Anderson et al. 2005). Nonetheless, recurrent severe AIP attacks 
are difficult to treat and can lead to high mortality rate.  Liver transplantation has been 
shown to be curative for some severe cases (Soonawalla et al. 2004).  The first gene 
therapy trial based on recombinant adenoviral transduction of functional PBGD has 
successfully increased enzymatic expression in hepatic tissues and restored metabolism 
of porphyrin precursors ALA and PBG in an AIP mouse model (Johansson et al. 2004).  
This approach points to the potential for effective gene therapy in human AIP.  
 
Uroporphyrinogen III synthase  
The fourth enzyme in the heme biosynthetic pathway is uroporphyrinogen III 
synthase (UROS) (EC 4.2.1.75).  UROS catalyzes cyclization of hydroxymethylbilane 
with concurrent D ring flipping to form uroporphyrinogen III (Bogorad 1958b; 1958c; 
Shoolingin-Jordan et al. 1979).  Uroporphyrinogen III is the first tetrapyrrole macrocycle 
in the heme biosynthetic pathway and a ubiquitous precursor of all other tetrapyrrole 
compounds including chlorophyll, siroheme, F430 and vitamin B12 (Schubert et al. 2002).  
While non-enzymatic cyclization of HMB produces uroporphyrinogen I isomer, D ring 
inversion is exclusive to the enzymatic cyclization of linear bilane (Battersby 1978).  
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Asymmetry of the D ring thus serves as a hallmark of all biosynthetic porphyrins 
(Battersby 1978).   
From bacteria to human, UROS has been found as a small cytosolic protein 
comprising ~250-300 residues (Tsai et al. 1988; Alwan et al. 1989; Mathews et al. 2001).  
The protein sequence is highly diverged throughout evolution and retains only a small 
number of conserved residues scattered in the central portion of the sequence. (Mathews 
et al. 2001).  UROS has been purified from bacteria, plant and mammals, and it is 
typically present as a  monomer of ~30 kDa (Higuchi and Bogorad 1975; Clement et al. 
1982; Hart and Battersby 1985; Tsai et al. 1987; Shoolingin-Jordan et al. 1988; Smythe 
and Williams 1988; Tsai et al. 1988; Alwan et al. 1989; Omata et al. 2004). Interestingly, 
both prokaryotic and eukaryotic UROS have been shown to be extremely thermolabile 
(Tsai et al. 1987; Alwan et al. 1989).  For purified human erythrocyte UROS, the half life 
at 37, 45, and 60 °C was around 30, 4 and 1 min, respectively (Tsai et al. 1987).  E. coli 
UROS was completely inactivated at 60°C in 1 min (Alwan et al. 1989). Another 
interesting feature of human UROS is that although there is only a single enzyme in all 
tissues, distinct housekeeping and erythroid-specific transcripts are generated by 
alternative promoter elements (Aizencang et al. 2000a; Aizencang et al. 2000b).  While 
expression of the housekeeping form is driven by a TATA-less promoter, the erythroid 
promoter contains binding sites for erythroid-specific transcription factors GATA-1 and 
NF-E2 (Aizencang et al. 2000a; Aizencang et al. 2000b).  
According to a widely accepted catalytic model, the reaction pathway of UROS 
involves a spiro mechanism to allow D ring rearrangement  (Battersby and Leeper 1990; 
Leeper 1994).  In this scheme, enzymatic reaction is initiated with rearranging the A ring 
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of HMB to remove the C20 hydroxyl group, followed by electrophilic attack of C16 of the 
D ring by C20 carbon-cation to generate a spirocyclic pyrrolenine (Battersby and Leeper 
1990; Leeper 1994).  This intermediate is resolved in the opposite direction yielding an 
azafluvene, which cyclizes to form uroporphyrinogen III concomitant with D ring 
inversion (Battersby and Leeper 1990; Leeper 1994).  This model is in agreement with  
the observation that UROS is inhibited by spirolactam with a Ki of 1-2 μM (Stark et al. 
1986; Cassidy et al. 1991).   
To date the structure of UROS has only been determined for the human enzyme 
(Mathews et al. 2001).  The crystal structure shows that human UROS is an elongated bi-
lobed monomer (Mathews et al. 2001).  The protein is folded into two separate domains 
with similar topology and  interconnected via a two-stranded anti-parallel β-ladder 
(Mathews et al. 2001).  Each domain comprises a parallel β-sheet surrounded by α-
helices (Mathews et al. 2001).  Domain 1 contains the N- and C-terminal sequences and 
belongs to a flavodoxin-like fold family, while domain 2 adopts a DNA glycosylase-like 
fold (Mathews et al. 2001).  The active site is proposed to be located in a large open cleft 
between the two domains on the basis of structural modeling of a putative product-UROS 
complex and clustering of conserved residues along the lining of the interdomain cleft 
(Mathews et al. 2001).  While mutational analysis indicated that the conserved residues 
are not absolutely required for activity, substrate binding is thought to involve a large 
number of weaker interactions in the active site and enzymatic reaction may not require 
acid/base catalysis (Mathews et al. 2001).  Opening and closing of the cleft appears to be 
mediated, at least in part, by movement of the bridging β-ladder residues (Mathews et al. 
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2001).  This intrinsic flexibility of the interdomain cleft is likely to play a key role in 
substrate recognition and product release (Mathews et al. 2001).   
The first porphyria ever described, congenital erythropoietic porphyria (CEP), or 
Gunther’s disease, is caused by enzymatic deficiency of UROS (Romeo and Levin 1969).  
CEP is a rare autosomal recessive disease with variable clinical severity (Desnick and 
Astrin 2002).  Characteristic symptoms include severe cutaneous photosensitivity, red 
urine and red teeth (Desnick and Astrin 2002).  Hemolytic anemia and splenomegaly are 
observed in some patients (Desnick and Astrin 2002).  Cutaneous lesions often begin in 
early childhood, and the disease can be fatal without treatment (Desnick and Astrin 
2002).  CEP is usually diagnosed by elevated concentrations of urinary uroporphyrin I 
and coproporphyrin I (Desnick and Astrin 2002).  The disease symptoms develop as a 
result of marked decrease of UROS activity usually to <1% normal level (Desnick and 
Astrin 2002).  UROS deficiency leads to accumulation of hydroxymethylbilane, which 
undergoes non-enzymatic conversion to yield isomer I porphyrinogens, including the 
non-enzymatically cyclized uroporphyrinogen I and its decarboxylation product 
coproporphyrinogen I (Desnick and Astrin 2002).  Because isomer I porphyrinogens 
cannot be further metabolized towards heme synthesis, they undergo autoxidation to yield 
uroporphyrin I and coproporphyrin I (Desnick and Astrin 2002).  Excess type I 
porphyrins are cytotoxic to the developing erythrocytes in bone marrow, cause skin 
photosensitivity and give the bright red color in urine and deposited tissues (Desnick and 
Astrin 2002).  
To date nearly 40 mutations in UROS have been attributed to CEP pathogenesis 
(Desnick and Astrin 2002).  They include more than 20 missense mutations, and a small 
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number of deletions, insertions, splicing defects and erythroid-specific promoter 
mutations (Desnick and Astrin 2002).  Most of the missense mutations occur at conserved 
residues in UROS (Desnick and Astrin 2002).  Only a few residues affected are mapped 
close to the active site cleft, most substitutions are scattered throughout the tertiary 
structure making it possible that the primary mutational effect results from disruption of  
protein fold (Mathews et al. 2001).  The majority of mutant enzymes are inactive or show 
very low residual activity at less than 2% normal level (Xu et al. 1995; Fontanellas et al. 
1996; Shady et al. 2002).  Only a few mutants have been found to retain up to 1/3rd 
normal level activity, although they also become less thermostable (Xu et al. 1995; Shady 
et al. 2002).  Further, these less severe mutations also seem to produce milder clinical 
expression (Xu et al. 1995; Shady et al. 2002).  The invariant residue C73 has been found 
to be a mutational hotspot (Xu et al. 1995).  C73R is the most commonly found CEP 
allele with an observed frequency of ~30% (Desnick and Astrin 2002).  C73R mutant 
enzyme retains less than 1% residual activity (Boulechfar et al. 1992).  Among all CEP 
alleles, C73R homozygotes manifest the most severe clinical symptoms (Desnick and 
Astrin 2002).  Structural mapping indicates that C73 residue is buried in the second 
domain hydrophobic core and does not appear to be catalytically essential (Mathews et al. 
2001).  Instead, loss of activity in C73R is most likely due to destabilization of the 
enzyme structure (Omata et al. 2004).   
CEP patients generally need to avoid sun and require skin protection (Mathews-
Roth 1998).  More severe cases may require treatment which reduces bone marrow 
erythropoiesis and thereby decreases porphyrin production, and these therapies include 
frequent blood transfusions, hydroxyurea treatment and splenectomy (Desnick and Astrin 
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2002).  Bone marrow transplant has proved curative for severely affected young patients 
resulting in correction of enzymatic deficiency in the bone marrow and marked reduction 
of porphyrin levels and cutaneous lesions (Dupuis-Girod et al. 2005).  Current efforts are 
focused on developing hematopoietic stem cell-mediated gene therapy towards an 
effective cure (Desnick and Astrin 2002).  This method is becoming feasible with 
progress in viral transduction of hematopoietic stem cells with functional UROS and 
murine model studies (de Verneuil et al. 2003; Géronimi et al. 2003; Bishop et al. 2005). 
 
Uroporphyrinogen III decarboyxlase  
The fifth enzyme, uroporphyrinogen III decarboyxlase (UROD) (EC 4.1.1.37), 
catalyzes four successive decarboxylation reactions on acetate groups of 
uroporphyrinogen III to yield the four corresponding β-pyrrole methyl groups of 
coproporphyrinogen III (Mauzerall and Granick 1958; Romeo and Levin 1971).  
Although uroporphyrinogen III is the normal physiological substrate, both naturally 
occurring uroporphyrinogen isomers (I and III) may serve as substrates (Mauzerall and 
Granick 1958; de Verneuil et al. 1983b; Elder et al. 1983; Straka and Kushner 1983).  
The  decarboxylation product of isomer I, coproporphyrinogen I, cannot be processed by 
the next enzyme coproporphyrinogen oxidase, but undergoes autoxidation to 
uroporphyrin I (Bogorad 1958a). 
UROD has been identified in many species.  The proteins typically contain 300-
400 residues and the sequence is considerably conserved throughout evolution with the 
highest degree of identity found in the N-terminal region (Romeo et al. 1986; Jones and 
Jordan 1993; Nishimura et al. 1993; Mock et al. 1995; Wyckoff et al. 1996; Whitby et al. 
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1998)  In most species, UROD has an apparent monomeric molecular weight of 40-50  
kDa (Jones and Jordan 1993; Wyckoff et al. 1996).  In bacterial, yeast and animal cells, 
UROD is a cytosolic enzyme (Romeo and Levin 1971; Elder et al. 1983; Felix and 
Brouillet 1990).  In plants, UROD is synthesized in the cytosol as a precursor form and 
imported into the chloroplast using a N-terminal sequence of ~40 residues, and the transit 
peptide is cleaved in the mature protein (Mock et al. 1995).  While purified UROD is 
commonly monomeric (de Verneuil et al. 1983b; Elder et al. 1983; Straka and Kushner 
1983; Romeo et al. 1986; Juknat et al. 1989; Felix and Brouillet 1990; Jones and Jordan 
1993), dimeric UROD has also been shown in solution and in crystal structure 
(Kawanishi et al. 1983; Phillips et al. 1997; Whitby et al. 1998; Phillips et al. 2003).  The 
human UROD gene shows enhanced transcription and abundant expression in 
erythropoietic cells, whereas non-erythroid expression is constitutive but occurs at a low 
level (Romeo et al. 1986).  
In contrast to most decarboxylases, UROD does not require cofactors for 
catalysis, and its enzymatic activity is inhibited by divalent metal ions (de Verneuil et al. 
1983b; Elder et al. 1983; Kawanishi et al. 1983; Straka and Kushner 1983; Felix and 
Brouillet 1990).  It is known that the UROD-catalyzed decarboxylation produces three 
intermediates, the hepta-, hexa- and penta-carboxyporphyrinogens (Mauzerall and 
Granick 1958).  This reaction sequence appears to proceed via a preferred route that starts 
at the acetate side chain on the D ring pyrrole and proceeds around the macrocycle in 
alphabetical order (Jackson et al. 1976).  The rate-limiting step in the conversion of 
uroporphyrinogen III to coproporphyrinogen III is the decarboxylation of the first 
reaction intermediate heptacarboxylate porphyrinogen III (Straka and Kushner 1983; 
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Felix and Brouillet 1990).  While kinetic analysis of mammalian UROD suggested the 
possibility of multiple catalytic sites. (de Verneuil et al. 1980; Straka and Kushner 1983; 
Chaufan et al. 2005), an alternative model proposed that there is only a single active site 
which contains conserved residues for substrate binding (Chelstowska et al. 1992; Garey 
et al. 1992).  Decarboxylation may involve the protonated pyrrole ring of 
uroporphyrinogen substrate to function as an electron sink to promote electron withdrawl 
in a manner similar to the pyridine ring of PLP, e.g. in ALAS-catalyzed reaction (Barnard 
and Akhtar 1979).  This latter model is consistent with the crystal structures (Whitby et 
al. 1998; Martins et al. 2001; Phillips et al. 2003).  
The X-ray crystal structure of UROD has been solved for the human and tobacco 
enzymes, revealing a high degree of conservation in the overall topology (Whitby et al. 
1998; Martins et al. 2001; Phillips et al. 2003).  The protein crystallized as a homodimer 
with a globular tiertiary structure (Whitby et al. 1998; Martins et al. 2001; Phillips et al. 
2003).  Each monomer contains one domain consisting of a distorted (β/α)8 TIM (triose 
phosphate isomerase) barrel  (Whitby et al. 1998; Martins et al. 2001; Phillips et al. 
2003).  A single active site is proposed to be located in a deep cleft which extends from 
the hydrophobic β-barrel core to the dimer interface (Whitby et al. 1998; Martins et al. 
2001; Phillips et al. 2003).  Highly conserved residues are clustered around the active site 
cleft (Whitby et al. 1998; Martins et al. 2001; Phillips et al. 2003).   
Most recently, the structure was determined for the complex between human 
UROD and product coproporphyrinogen (Phillips et al. 2003).  Both coproporphyrinogen 
I and III isomers were found at the same position in the active site cavity in each 
monomeric subunit and both active sites in the UROD dimer were occupied (Phillips et 
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al. 2003).  Specificity for the I and III isomers appears to involve differential localization 
of the D-ring propionate side chain which is mediated by interaction with adjacent 
residues including conserved arginines (Phillips et al. 2003).  Most interestingly, the 
bound coproporphyrinogen was found to adopt a distorted conformation, i.e. a domed 
macrocycle, and one face of the macrocycle was aligned against a hydrophobic surface of 
the active site formed by a ring of conserved residues centrally located in the β-barrel 
core (Phillips et al. 2003).  An invariant aspartate (human D86), which provides the only 
acidic side chain in the active site, was shown to approach the center of the bound 
macrocycle and its carboxylate side chain was situated in an optimal position for 
hydrogen-bonding with all four pyrrole nitrogens (Phillips et al. 2003).   The active site 
geometry is consistent with a previous proposal suggesting that a hypothetical protonated 
intermediate serves as an electron sink to accept the electrons retained when the acetyl 
side chain is released as CO2 (Barnard and Akhtar 1979; Akhtar 1994).  Further, the 
invariant active site aspartate (D86) seems very likely to function in substrate binding by 
coordinating the four pyrrole nitrogens in a domed conformation, and it might also 
directly promote catalysis by electrostatic stabilization of a protonated intermediate 
(Phillips et al. 2003).  Kinetic and structural analysis of the site-directed D86 mutants 
provided additional support for the proposed catalytic model (Phillips et al. 2003).   
The most common form of porphyria in humans, porphyria cutanea tarda (PCT), 
is associated with subnormal UROD activity (Kushner et al. 1976).  Clinically PCT is 
characterized by cutaneous hyperpigmentation (Fritsch et al. 1998).  The patients 
typically exhibit severe photosensitivity associated with skin lesions as a result of the 
deposition of uroporphyrin and partially decarboxylated porphyrins (Fritsch et al. 1998).  
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Excessive uroporphyrins are generated and accumulated in the liver, circulate in plasma 
and excreted in the urine (Fritsch et al. 1998).  The disease is classified as either familial 
or sporadic (Kushner et al. 1976).  Familial PCT (F-PCT) is transmitted as an autosomal 
dominant trait (Kushner et al. 1976).  F-PCT patients are heterozygous for mutant UROD 
alleles and typically exhibit half-normal UROD activity in all tissues (Phillips et al. 
2001).  Most carriers of mutant UROD alleles do not have clinical expression unless 
additional factors are present that further reduce UROD activity in the liver (Bulaj et al. 
2000).  In sporadic PCT (S-PCT) patients, deficiency of UROD activity is restricted to 
the liver, although no mutation in UROD has been identified (de Verneuil et al. 1978; 
Elder et al. 1978b; Garey et al. 1993).  To date more than 30 mutations in UROD have 
been associated with F-PCT, and a majority of them are single amino acid substitutions 
scattered throughout the protein scaffold (Whitby et al. 1998; Phillips et al. 2001).  None 
of the residues affected is directly involved in catalysis in the active site (Whitby et al. 
1998; Phillips et al. 2001).  Most mutations are located near the dimer interface or 
regions remote from the active site (Whitby et al. 1998; Phillips et al. 2001).   They are 
likely to disrupt protein fold or stability resulting in activity decrease or rapid degradation 
of the enzyme (de Verneuil et al. 1986; Whitby et al. 1998; Phillips et al. 2001).   
An interesting aspect of PCT is its well-known association with 
hemochromatosis, an autosomal recessive disease characterized by hepatic iron overload 
(Berlin and Brante 1962).  Hereditary hemochromotosis is most commonly caused by 
mutations in the HFE locus (Feder et al. 1996).  In many clinical studies, mutant HFE 
alleles, primarily with the single substitution C282Y, have been shown to occur at 
increased frequencies in overt PCT patients compared to the general population (Roberts 
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et al. 1997; Bygum et al. 2003; Harper et al. 2004; Mehrany et al. 2004).  It has been 
widely accepted that inheritance of the hemochromatosis gene is a primary risk factor for 
PCT (Elder and Worwood 1998; Bulaj et al. 2000).  Other susceptibility factors include 
hepatitis C viral infection, alcohol consumption, heavy metal exposure and estrogen use,  
although the mechanism by which PCT pathogenesis is promoted by these risk factors  is 
not yet clear (Bulaj et al. 2000; Egger et al. 2002; Sams et al. 2004).  PCT can usually be 
treated with sunscreen for skin protection and phlebotomy therapy for iron removal 
(Thunell and Harper 2000; Sarkany 2001; Nordmann and Puy 2002).  Repeated 
phlebotomies deplete hepatic iron stores and thereby lead to clinical and biochemical 
remission (Lundvall and Weinfeld 1968).  
 
Coproporphyrinogen III oxidase  
The sixth enzyme in the pathway, coproporphyrinogen III oxidase (CPO) (EC 
1.3.3.3), converts coproporphyrinogen III to protoporphyrinogen IX.  CPO catalyzes the 
oxidative decarboxylation of two propionate side chains on pyrrole rings A and B in 
coproporphyrinogen III to yield two vinyl groups in protoporphyrinogen IX (Sano and 
Granick 1961; Sano 1966).  There are two distinct CPOs, oxygen-dependent and oxygen-
independent.  These enzymes share no sequence or structural similarity (Dailey 2002).   
In eukaryotes and some aerobic prokaryotes, there is a single, oxygen-dependent 
CPO (odCPO) (Dailey 2002).  The odCPOs use molecular oxygen to convert 
coproporphyrinogen and releases CO2 (Dailey 2002).  In contrast to many other 
decarboxylases, odCPO-catalyzed reaction does not require any cofactor or metal ions 
(Yoshinaga and Sano 1980; Camadro et al. 1986a; Medlock and Dailey 1996; Dailey 
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2002).  odCPO is highly conserved throughout evolution and contains a large number of 
invariant residues (Martasek et al. 1994; Medlock and Dailey 1996; Lamoril et al. 2001; 
Phillips et al. 2004).  From bacteria to human, the protein typically occurs as a 
homodimer of 70-80 kDa (Yoshinaga and Sano 1980; Camadro et al. 1986a; Bogard et al. 
1989; Kohno et al. 1993; Kruse et al. 1995; Martasek et al. 1997; Macieira et al. 2003).    
While odCPOs from yeast S. cerevisiae and E. coli are cytosolic proteins 
(Camadro et al. 1986b; Zagorec et al. 1988; Macieira et al. 2003), odCPO is present in 
the intermembrane space between the inner and outer mitochondrial membranes in higher 
animal cells (Elder and Evans 1978a; Grandchamp et al. 1978).  This results from 
translocation of a cytosolic precursor into mitochondria, mediated by a N-terminal leader 
sequence which is then proteolytically removed (Kohno et al. 1993; Delfau-Larue et al. 
1994; Martasek et al. 1994; Susa et al. 2003).  An unusually long bipartite signal 
sequence consisting of ~120 N-terminal residues is found to be essential for mammalian 
CPO targeting (Susa et al. 2003; Dailey et al. 2005).   
Kinetic studies of odCPO suggest that the rate-limiting step for the overall 
reaction is the first decarboxylation with transient formation of the tricarboxylic 
intermediate, harderoporphyrinogen (Elder and Evans 1978b; Elder et al. 1978a).  
Although deprotonation of the pyrrole ring and peroxide formation have been implicated, 
the catalytic mechanism is not well understood (Seehra et al. 1983; Colloc'h et al. 2002).  
Recently, new insights have begun to develop with the structural determination of odCPO 
(Phillips et al. 2004; Lee et al. 2005).  
Crystal structures have been solved first for the yeast S. cerevisiae enzyme 
(hem13p), and most recently, for the human protein revealing a homologous folding 
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pattern (Phillips et al. 2004; Lee et al. 2005).  The yeast odCPO crystallized as a 
homodimer of ~70 kDa.  Each monomer contains a single domain consisting of a 
relatively flat 7-stranded anti-parallel β-sheet flanked on both sides by α-helices (Phillips 
et al. 2004).  There is one active site in each subunit, which is located in a deep cavity 
sandwiched between one face of the β-sheet and a C-terminal helical surface (Phillips et 
al. 2004).  The crystal structures revealed two conformations, an open form and a more 
closed form. Active site closure appears to be mediated by movement of two short α-
helices positioned above the opening.  Possibly, substrate binding induces the closed 
conformation, which allows sequestration of the active site from the bulk solvent and 
leaves a cavity with a size and shape comparable to the substrate molecule (Phillips et al. 
2004).  As indicated by a structural model of coproporphyrinogen III docking into the 
CPO open conformer, the substrate fits tightly into the active site and is surrounded by 
many conserved residues possibly involved in coproporphyrinogen binding (Phillips et al. 
2004).  Interestingly, an invariant aspartate (D274) which belongs to a short, 
conformationally mobile helix covering the pocket is found directly above the center of 
the macrocycle.  This led to the suggestion that D274 plays a crucial role in substrate 
binding by interacting with the four pyrrole nitrogen groups via its carboxylate side 
chain.   
An updated catalytic model has been proposed based on the structural features of 
odCPO (Lash 2005).  It emphasizes the importance of substrate straining in the oxidative 
reaction, e.g. by bending coproporphyrinogen macrocycle into a domed conformation 
(Lash 2005).  Distortion of the substrate facilitates interaction with an adjacent acidic 
residue, which deprotonates the pyrrole nitrogens (Lash 2005).  The deprotonated 
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pyrrolic ring favors reaction with molecular oxygen to generate an anionic peroxide 
intermediate (Lash 2005).  This intermediate is resolved to yield a vinyl pyrrole 
derivative concomitant with the release of CO2 and peroxide (Lash 2005).  Indeed, 
peroxide formation has been observed in the reaction catalyzed by E. coli odCPO 
(Breckau et al. 2003).   
Oxidative decarboxylation of coproporphyrinogen in anaerobic organisms is 
catalyzed by an oxygen-independent CPO encoded by the hemN gene (Dailey 2002).  
Although both hemF and hemN genes are present in facultative bacteria such as E. coli 
and Salmonella typhimurium, the hemN product is selectively upregulated during growth 
under low oxygen tension or anaerobic conditions, while the hemF product (odCPO) is 
synthesized only aerobically (Xu et al. 1992; Troup et al. 1995).  Unlike odCPO, the 
reaction catalyzed by the hemN-encoded CPO requires Mg2+, ATP, NAD(P)+, methionine 
and an FeS cluster (Coomber et al. 1992; Layer et al. 2002).  Also, the enzyme is entirely 
unrelated to odCPO on a structural level.  The crystal structure of the E. coli hemN 
product reveals features common to the radical SAM enzymes (Layer et al. 2003).  The 
protein is a monomer of ~53 kDa (Layer et al. 2002; Layer et al. 2003).  It is folded into 
two domains featuring a curved parallel β-sheet and contains a [4Fe-4S] cluster and S-
adenosylmethionine (SAM) which are necessary for enzymatic activity (Layer et al. 
2002; Layer et al. 2003).  
Partial enzymatic deficiency of CPO causes two distinct forms of porphyria  
hereditary coproporphyria and harderoporphyria (Lamoril et al. 2001; Nordmann and Puy 
2002).  Hereditary coproporphyria (HCP) is a rare acute hepatic porphyria (Delfau-Larue 
et al. 1994).   The disease is transmitted as an autosomal dominant trait with low 
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penetrance (Martasek 1998; Nordmann and Puy 2002).  Clinical symptoms are primarily 
acute neurovisceral attacks commonly associated with abdominal pain, hypertension and 
peripheral neuropathy (Martasek 1998; Kuhnel et al. 2000; Nordmann and Puy 2002).  
The symptoms are often provoked by drugs, alcohol consumption or fasting (Nordmann 
and Puy 2002; Anderson et al. 2005; Kauppinen 2005).  Urinary and fecal excretion of 
coproporphyrin III is elevated (Kuhnel et al. 2000; Gross et al. 2002a).  Sometimes 
patients also exhibit photosensitive skin lesions (Kuhnel et al. 2000).  Enzymatic activity 
of CPO is reduced, typically to half-normal in heterozygous patients (Gross et al. 2002a; 
Nordmann and Puy 2002).  Harderoporphyria is a rare erythropoietic variation of HCP 
(Nordmann et al. 1983).  While the patients do not have acute attacks of neurological 
dysfunction, their clinical manifestations are characterized by fecal excretion of a large 
amount of harderoporphyrin and hemolytic anemia associated with iron overload 
(Nordmann et al. 1983; Lamoril et al. 1995; Lamoril et al. 1998; Schmitt et al. 2005).    
Currently nearly 40 mutations in human CPO have been described including 
small insertions, deletions, splice site mutations and missense mutations (Rosipal et al. 
1999; Lamoril et al. 2001; Wiman et al. 2003a; Schmitt et al. 2005).  More than half of 
the defects are single amino acid substitutions which occur mostly in the conserved 
residues spread throughout the protein, and they are likely to disrupt protein fold or 
dimerization (Lamoril et al. 2001; Phillips et al. 2004; Lee et al. 2005).  While active site 
mutations are very rare, CPO defects identified in harderoporphyria patients are restricted 
to K404E and R401W substitutions (Lamoril et al. 1995; Lamoril et al. 1998; Schmitt et 
al. 2005).  Both residues are located in a short mobile α-helix (D400-K404), which 
covers the active site cavity (Phillips et al. 2004).  The mutant enzymes are thermolabile, 
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and exhibit markedly decreased binding affinities for substrate coproporphyrinogen and 
the first reaction intermediate harderoporphyrinogen (Nordmann et al. 1983; Lamoril et 
al. 1995; Schmitt et al. 2005).  Structural analysis suggests that the mutations may 
interfere with active site closure, and thus promote diffusion of the harderoporphyrinogen 
intermediate out of the substrate-binding pocket (Phillips et al. 2004).  Intravenous hemin 
arginate infusion has been shown to effectively alleviate acute porphyric attacks and 
remains a preferable therapy for severely affected HCP patients (Kuhnel et al. 2000; 
Gross et al. 2002b; Nordmann and Puy 2002).  
 
Protoporphyrinogen IX oxidase 
Protoporphyrinogen IX oxidase (PPO) (EC 1.3.3.4), the penultimate enzyme in 
heme biosynthesis, catalyzes the six-electron oxidation of protoporphyrinogen IX to form 
fully conjugated macrocyclic protoporphyrin IX (Porra and Falk 1964).  PPO utilizes 
three molecules of molecular oxygen, reducing them to three molecules of H2O2 and 
generating the protoporphyrin product. The oxidation reaction requires a noncovalently 
bound cofactor flavin adenine dinucleotide (FAD) (Shoolingin-Jordan 1991).   PPO has 
been widely identified in bacteria, yeast, plants and higher animals (Dailey and Karr 
1983; Dailey et al. 1994b; Nishimura et al. 1995b; Camadro and Labbe 1996; Dailey and 
Dailey 1996a; Dailey and Dailey 1996b; Narita et al. 1996; Wang et al. 2001).  Although 
its sequence became significantly diversified during evolution, the protein generally has a 
monomeric molecular mass of ~50-60 kDa and contains a highly conserved N-terminal 
dinucleotide-binding motif G-X-G-X2-G which mediates the coordination of a FAD 
cofactor (Dailey and Karr 1983; Proulx and Dailey 1992; Dailey et al. 1995; Dailey and 
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Dailey 1996b; Wang et al. 2001).  Plant PPO has two isozymes, with PPO1 found in the 
plastid chloroplast and PPO2 in the mitochondrion (Narita et al. 1996; Lermontova et al. 
1997).  Eukaryotic PPO is tightly bound to the inner mitochondrial membrane (Dailey 
and Karr 1983) (Deybach et al. 1985; Nishimura et al. 1995b).  It is typically found as a 
homodimer of ~100 kDa (Dailey and Dailey 1996b).  Interestingly, the monomeric 
subunit exhibits a highly protease-resistant, compact domain structure  (Arnould and 
Camadro 1998; Arnould et al. 1999).  A block of ~60 conserved residues near the N-
terminal region has been implicated to serve as a membrane anchor for the enzyme 
(Arnould and Camadro 1998; Koch et al. 2004; Morgan et al. 2004), although a short 
conserved N-terminal sequence appears sufficient for mitochondrial import (Fraunberg et 
al. 2003; Dailey et al. 2005).  It is possible that the two regions interact to optimize the 
efficiency of mitochondrial targeting.  
In prokaryotes, as with CPO, PPO has two forms, but only a single form is present 
in a given cell (Dailey 2002).  One is the oxygen-dependent form encoded by the hemY 
gene; the other is the oxygen-independent form encoded by the hemG gene (Dailey 
2002).  In most bacteria, oxygen-dependent PPO is associated with the plasma membrane 
as a monomer or homodimer (Dailey and Dailey 1996a; Wang et al. 2001).  However, B. 
subtilis PPO (hemYp) is water soluble and exists in a monomeric form of ~51 kDa 
(Hansson and Hederstedt 1992; Dailey et al. 1994b).  In addition to protoporphyrinogen, 
this enzyme can efficiently oxidize coproporphyrinogen to coproporphyrin (Hansson et 
al. 1997).  An interesting feature of B. subtilis PPO is that it is only very weakly inhibited 
by diphenyl ether herbicides  (Dailey et al. 1994b).  This family of herbicides are known 
as potent inhibitors of eukaryotic PPOs and cause light-dependent phytotoxicity in plants 
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as a result of substrate protoporphyrinogen accumulation in the inappropriate cellular 
compartment (Matringe et al. 1989; Camadro and Labbe 1996; Narita et al. 1996).  
Overexpression of B. subtilis PPO in the plastids of transgenic plants has been achieved 
and conferred resistance to the herbicide oxyfluorfen  (Li and Nicholl 2005).  In 
anaerobic and facultative bacteria, protoporphyrinogen oxidation is catalyzed by the 
hemG-encoded PPO, which belongs to a multimeric protein complex in the cellular 
respiratory chain (Klemm and Barton 1987; Dailey 2002).  E. coli PPO (hemGp) product 
is a small, cytosolic soluble, monomeric protein of ~21 kDa containing 181 residues 
(Sasarman et al. 1993; Nishimura et al. 1995a).   
The structure of PPO was recently determined for the mitochondrial isozyme 
(PPO2) from common tobacco Nicotiana tabacum (Koch et al. 2004).  The X-ray crystal 
structure of PPO2 was solved at 2.9 Å resolution with the inhibitor 4-bromo-3-(5'-
carboxy-4'-chloro-2'-fluoro-phenyl)-1-methyl-5-trifluoromethyl-pyrazol bound in the 
active site (Koch et al. 2004).  The protein is a homodimer of ~110 kDa and contains one 
non-covalently attached FAD cofactor in each subunit.  Each monomer consists of three 
domains, which are proposed for binding to FAD, substrate and the mitochondrial 
membrane, respectively.  Detergent Triton X-100 used for solubilization and 
crystallization was found in the interdomain cleft.  While PPO has long been known to 
possess a FAD-binding motif commonly found in a superfamily of flavoproteins 
including monoamine oxidases and some phytoene dehydrogenases (Dailey and Dailey 
1996b), the FAD-binding domain of PPO2 also exhibits significant overall structural 
resemblance to this family of flavin-dependent enzymes.  The substrate-binding domain, 
suggested by the orientation of the bound inhibitor, contains mostly β-strands (Koch et al. 
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2004).  The active site is thought to lie in a narrow cavity between the FAD and 
substrate-binding domains of each monomer (Koch et al. 2004).  The docking model of 
protoporphyrinogen binding to PPO2 indicated that the vinyl groups of pyrrole rings A 
and B are buried deeply in the interior of the active site cavity, while the propionyl 
groups of pyrrole rings C and D are directed outwards to the solvent-exposed end (Koch 
et al. 2004).  Since the reactive group of FAD lies adjacent to pyrrole rings A and D, the 
methylene bridge between rings A and D is proposed to be the site of initial oxidation 
(Koch et al. 2004).  This arrangement appears to be required for protoporphyrinogen 
binding and catalysis, as macrocycle rotation is unlikely due to steric constraint within 
the active site.  The putative membrane-binding domain protrudes from the globular core 
and consists primarily of a group of α-helices formed by a consecutive N-terminal 
sequence of ~100 residues (Koch et al. 2004).  As was found with monotopic membrane 
proteins (Binda et al. 2004), a conserved helical region forms a hydrophobic surface at 
the base of PPO and probably mediates membrane insertion in a monotopical manner.   
The domain structure of PPO2 lends support to a previous model which suggested 
that the active site of PPO faces the cytosolic side of the inner mitochondria membrane 
and substrate channeling might occur between the terminal heme synthetic enzymes 
(Ferreira et al. 1988).   Spatially, it seems possible that the product protoporphyrin can be 
translocated to the next enzyme ferrochelatase via a U-shaped channel which connects 
the active site cavity to the membrane (Koch et al. 2004).   
Enzymatic deficiency in PPO causes the disease variegate porphyria (VP)  
(Brenner and Bloomer 1980; Deybach et al. 1981; Meissner et al. 1986).  VP is an 
autosomal dominant disease with low penetrance (Nordmann and Puy 2002).  Patients 
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typically exhibit skin photosensitivity, or less commonly have acute episodes of 
neuropathy, or sometimes show both symptoms (Bales et al. 1980; Whatley et al. 1999; 
Fraunberg et al. 2002; Wiman et al. 2003b; Hift et al. 2004).  Neurovisceral attacks are 
often precipitated by porphyrinogenic drugs (Hift and Meissner 2005).  PPO activity is 
approximately half-normal in all tissues of the clinically overt patients as well as 
asymptomatic carriers (Brenner and Bloomer 1980; Deybach et al. 1981; Da Silva et al. 
1995).  Currently about 130 mutations of PPO have been associated with VP (Kauppinen 
2005).  They include splice site mutations, exon deletions, frameshifts, non-sense 
mutations, and half of all are missense mutations (Deybach et al. 1996; Whatley et al. 
1999; Frank et al. 2001; Fraunberg et al. 2001; Morgan et al. 2002; Wiman et al. 2003b).  
Single mutations are spread throughout the protein, and many occur at conserved 
residues.  Most VP mutations cause total or near complete (<10%) loss of enzymatic 
activity, thus exhibiting complete haplodeficiency (Deybach et al. 1996; Meissner et al. 
1996; Fraunberg et al. 2001; Morgan et al. 2002).  Recently, the first case report has been 
described for a patient recovery from VP after liver transplantation (Stojeba et al. 2004).  
Interestingly, one of the best known PPO mutations R59W gives a prime example 
of the founder gene effect.  VP is highly prevalent in the Afrikaner population of South 
Africa, which can be traced back to an ancestral PPO allele with R59W substitution 
(Meissner et al. 1996; Hift et al. 2004). Only minimal activity is retained in R59W 
mutant, probably because the R59 residue is required for catalysis and active site integrity 
(Manelia et al. 2003).  Modeling based on the tobacco PPO2 crystal structure indicates 
that the equivalent residue (N67 in tobacco enzyme) occupies an active site position 
between FAD and substrate-binding site, which implies that a single mutation can 
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interfere with FAD-substrate interaction and disturb the active site geometry (Koch et al. 
2004). 
 
Ferrochelatase  
The last enzyme in heme biosynthesis pathway is ferrochelatase (FECH) (E.C. 
4.99.1.1).  Ferrochelatase catalyzes the insertion of ferrous iron into protoporphyrin IX to 
form protoheme (Figure 3).  Ferrochelatase activity was first described by Goldberg’s 
group in 1956 using crude preparations of avian erythrocytes (Goldberg et al. 1956).  
Subsequently, its enzymatic role in biological porphyrin metallation was further 
examined in a variety of cell types and organisms (Porra and Jones 1963a; 1963b; 
Neuberger and Tait 1964; Porra and Ross 1965; Jones 1969; 1970).  With the 
identification of ferrochelatase-deficient, heme auxotrophic mutants in the bacterium 
Spirillum itersonii and yeast S. cerevisiae, ferrochelatase was recognized as the genetic 
basis for iron chelation in heme biosynthesis (Dailey and Lascelles 1974; Gollub et al. 
1977). Ferrochelatase was first successfully cloned from S. cerevisiae in 1990 (Labbe-
Bois 1990), followed with the cloning of human and murine genes (Nakahashi et al. 
1990; Taketani et al. 1990; Brenner and Frasier 1991).  As high yield bacterial expression 
systems for recombinant mammalian ferrochelatases became available, purified enzymes 
were given extensive biophysical and biochemical examination (Ferreira 1994; Sellers 
and Dailey 1997; Dailey et al. 2000).  Significantly, the X-ray crystal structure was 
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Figure 3.   The reaction catalyzed by ferrochelatase.   
Adapted from (Al-Karadaghi et al. 1997).  
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determined first for B. subtilis ferrochelatase in 1997 (Al-Karadaghi et al. 1997), 
followed by the human (Wu et al. 2001) and yeast proteins (Karlberg et al. 2002)  In the 
past decade, the ease of cloning, expression and purification of ferrochelatase and the 
extent to which they have been characterized have grown rapidly and expanded to diverse 
organisms, thus a more complete understanding of ferrochelatase evolution has emerged 
(Dailey and Dailey 2003).   
In most organisms, ferrochelatase is found as a membrane protein (Dailey and 
Dailey 2003).  In animal cells and yeast, ferrochelatase is synthesized in the cytoplasm as 
a nuclear-encoded precursor protein and translocated into the mitochondria using a N-
terminal leader sequence consisting of ~50 residues (Camadro and Labbe 1988; Karr and 
Dailey 1988; Taketani et al. 1990; Dailey et al. 2005).  The mature form, typically 
consisting of 400-500 residues, is associated with the matrix side of the inner 
mitochondrial membrane, and the enzymatic reaction it catalyzes takes place in the 
mitochondria (Jones and Jones 1968; Jones 1969; Harbin and Dailey 1985; Prasad and 
Dailey 1995).  Prokaryotic ferrochelatases are smaller, and while most of them are bound 
to the plasma membrane, some are soluble (Hansson and Hederstedt 1994; Wang et al. 
2001; Dailey and Dailey 2002).  
Biochemical characterization of ferrochelatase from different species has revealed 
that the reaction mechanism is conserved (Dailey and Dailey 2003).  The catalytic model 
was initially proposed nearly two decades ago, and has been advanced to incorporate a 
multitude of details (Dailey and Dailey 2003).  During catalysis the enzyme transiently 
binds the iron (II) and porphyrin substrates.  Metal chelation occurs only when the 
porphyrin ring is distorted from planarity, concomitant with proton release from the 
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pyrrole nitrogen atoms.  The product heme is flat and exits the active site once formed.  
An important feature of ferrochelatase-catalyzed metallation is the distortion of porphyrin 
macrocycle.  The original proposal drew on the observation that porphyrin analog, N-
methyl-protoporphyrin, acts as a tight-binding competitive inhibitor of ferrochelatase 
with a Ki in the nanomolar range (Dailey et al. 1989).  N–alkyl porphyrins have an 
alkylated pyrrole ring bent 20-30o out of the otherwise planar porphyrin core, and this 
nonplanar conformation has been thought to yield high affinity binding in the active site 
(Dailey and Fleming 1983; Dailey et al. 1989).  Based on quantum mechanical 
calculation of porphyrin binding to B. subtilis ferrochelatase, tilting of a pyrrole ring 
induced by the enzyme significantly lowers the energy required for metal insertion, 
suggesting that macrocycle distortion may be a thermodynamically favorable process 
(Sigfridsson and Ryde 2003). Actually, antibodies made against N–methyl-
mesoporphyrin were found to catalyze metal chelation into porphyrins and thus possess 
ferrochelatase-like activity (Cochran and Schultz 1990).  Resonance Raman 
spectroscopic studies revealed that murine ferrochelatase is able to induce formation of a 
saddled porphyrin even in the absence of metal substrate (Franco et al. 2000), whereas 
yeast ferrochelatase binds and distorts porphyrin into a domed or ruffled conformation in 
the presence of the inhibitor Hg2+ (Blackwood et al. 1997; Blackwood et al. 1998).  A 
direct observation comes from the crystal structure of B. subtilis ferrochelatase with 
bound N-methyl-mesoporphyrin, which clearly showed that a distorted macrocycle is 
held tightly in the active site (Lecerof et al. 2000).  In comparison, deformation of 
porphyrin in the binding sites of catalytic antibodies has also been demonstrated using 
resonance Raman spectroscopy and crystal structure analysis, which lends additional 
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support that macrocycle distortion is a crucial step in enzymatic metallation (Yin et al. 
2003; Venkateshrao et al. 2004). 
Although the importance of porphyrin deformation was widely recognized, little 
was known about the porphyrin substrate binding site and residues responsible for 
porphyrin distortion in the enzyme (Dailey and Dailey 2003).  With the structure 
determination of ferrochelatase, it became possible to address this important question so 
as to understand the structural basis of porphyrin-enzyme interaction.  The X-ray crystal 
structure first solved was that of the  small, cytosolic soluble, monomeric enzyme from 
the Gram-positive bacterium B. subtilis (Al-Karadaghi et al. 1997).  Secondly, the 
structure of human ferrochelatase was determined (Wu et al. 2001).  This structure 
revealed a homodimer with one [2Fe-2S] cluster associated with each subunit, which is 
characteristic of animal ferrochelatases (Wu et al. 2001).  More recently, the structure of 
yeast S. cerevisiae ferrochelatase was solved, showing a homodimeric protein without the 
FeS cluster (Karlberg et al. 2002).  Although the overall sequence identity is only ~20% 
for these proteins, they exhibit remarkably similar folds and active site geometries (Al-
Karadaghi et al. 1997; Wu et al. 2001; Karlberg et al. 2002).  A monomeric unit of the 
enzyme comprises two structurally-related domains, each of which consists of a 
Rossmann-type fold, which is characterized by a four-stranded, parallel β-sheet flanked 
by α-helices on both sides.  The active site is situated in a deep cavity between the two 
domains.  The cavity is enriched with many conserved residues, some of which have been 
shown to play important roles in catalysis (Al-Karadaghi et al. 1997; Lecerof et al. 2000; 
Wu et al. 2001; Karlberg et al. 2002).   
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The opening of the active site cleft consists of two sides, with one side composed 
of residues from the first two N-terminal α-helices, α1, α2, and an intervening loop.  The 
opposite side is formed by a short loop connecting a β-strand and an α-helix in the 
second domain (Al-Karadaghi et al. 1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg 
et al. 2002).  The ferrochelatase loop shows a high degree of sequence identity across a 
wide taxonomic range (Shi and Ferreira 2004).  It was located in close proximity to the 
porphyrin macrocycle in the crystal structure of inhibited B. subtilis ferrochelatase 
(Lecerof et al. 2000).  Consistent with this observation, the loop was predicted to contact 
the porphyrin based on molecular dynamics-based docking of nickel-protoporphyrin in B. 
subtilis ferrochelatase (Franco et al. 2000).  Thereby, it was hypothesized that the 
conserved loop residues are involved in substrate porphyrin binding and distortion during 
enzymatic reaction.  In agreement with this proposal, structural features of human and 
yeast ferrochelatases indicate that the active site opening defines the membrane-facing 
side of ferrochelatase and provides an entry site for substrate porphyrin (Gora et al. 
1996a; Wu et al. 2001; Karlberg et al. 2002).  The experiments described in the following 
chapters were aimed at detailed characterization of the loop motif in order to gain further 
understanding of the structural basis of the ferrochelatase-catalyzed reaction.   
Metal substrate binding to ferrochelatase has been studied in detail over the past 
decade.  Current models suggest that a channeling mechanism is involved in the transfer 
of metal ions from the protein exterior into the internal reaction center near the distorted 
porphyrin (Sellers et al. 2001; Lecerof et al. 2003).  This notion received support from 
studies of bacterial and yeast ferrochelatases (Karlberg et al. 2002; Lecerof et al. 2003).  
In the active site, an invariant catalytic histidine residue (H183 in B. subtilis enyzme) has 
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been found necessary for metal chelation (Kohno et al. 1994; Gora et al. 1996b; Lecerof 
et al. 2000; Lecerof et al. 2003; Shipovskov et al. 2005), while an invariant glutamate and 
a conserved serine can also serve as metal ligands (Karlberg et al. 2002; Lecerof et al. 
2003).  These residues constitute an interior site for metal-coordination; and possibly, this 
site may interact with a second, surface-exposed metal-binding site, which is likely to 
play a regulatory role (Karlberg et al. 2002; Lecerof et al. 2003).  Transport of metal ions 
between the two sites is mediated by a group of conserved acidic residues aligned along a 
π-helix on an exposed surface inside the active site cavity (Karlberg et al. 2002; Lecerof 
et al. 2003).  Further, recent studies have provided evidence that accelerating the rate of 
ligand exchange for metal ions is an important element of the catalytic mechanism 
(Shipovskov et al. 2005).  Examination of human ferrochelatase has led to the proposal 
that iron binding involves the conserved arginine and tyrosine residues in the interior 
active site cavity, whereas a conduit formed by a group of conserved, mostly aromatic 
residue shuttles the iron substrate from an external location into the catalytic center 
(Sellers et al. 2001).   
 In eukaryotic cells, the iron substrate is thought to be supplied by the 
mitochondrial membrane (Taketani et al. 1986; Lange et al. 1999; Napier et al. 2005).  
Recently, the iron chaperone frataxin and additional carrier proteins have been implicated 
as iron donors for ferrochelatase (Lesuisse et al. 2003; He et al. 2004; Yoon and Cowan 
2004; Zhang et al. 2005).  Frataxin, a small, evolutionarily conserved, mitochondrial 
protein, is known for its role in iron homeostasis by sequestering iron and making iron 
available for FeS cluster biogenesis and heme synthesis inside the mitochondria (Lesuisse 
et al. 2003; Park et al. 2003; Yoon and Cowan 2003).  In yeast and human 
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ferrochelatases, frataxin is shown to recruit ferrous iron and mediate its delivery to 
ferrochelatase by binding to the enzyme surface (Lesuisse et al. 2003; He et al. 2004; 
Yoon and Cowan 2004).  Additionally, other carrier proteins including the yeast 
mitochondrial membrane proteins Mrs3p and Mrs4p have been suggested to cooperate 
with frataxin in a rapid transport system to move iron into mitochondria and direct its 
utilization in heme synthesis (Zhang et al. 2005).  
One of the least understood aspects of ferrochelatase concerns the role of the FeS 
cluster.  Although it is not present in ferrochelatases from some species including B. 
subtilis (Hansson and Hederstedt 1994), E. coli (Miyamoto et al. 1991) and S. cerevisiae 
(Labbe-Bois 1990; Gora et al. 1996b), cluster-containing ferrochelatases are commonly 
found in evolution and a [2Fe-2S] cluster is associated with the enzyme in animals  
(Dailey et al. 1994a; Ferreira et al. 1994; Sellers et al. 1998b), yeast 
Schizosaccharomyces pombe (Medlock and Dailey 2000) and bacteria Caulobacter 
crescentus and Mycobacterium tuberculosis (Dailey and Dailey 2002).  In mammalian 
ferrochelatase, the [2Fe-2S] cluster is bound to a 30-50 residue long C-terminal tail, 
which constitutes a domain distinct from the structurally conserved catalytic core (Dailey 
et al. 1994a).  The cluster is coordinated by four cysteine residues, with three ligands 
provided by a conserved C-X2-C-X4-C motif in the C-terminal tail and one much further 
removed in the N-terminal region (Crouse et al. 1996; Sellers et al. 1998b; Wu et al. 
2001).  In human ferrochelatase, the cluster is labile, and is rapidly destroyed upon 
exposure to nitric oxide concomitant with loss of enzymatic activity (Furukawa et al. 
1995; Sellers et al. 1996).  It is known that the cluster iron does not serve as substrate iron 
and its redox state does not affect enzymatic activity (Dailey et al. 1994a; Ferreira et al. 
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1994).  Although mutations in the cysteine ligands can abolish catalytic activity (Sellers 
et al. 1998b; Schneider-Yin et al. 2000b), the cluster does not appear to be indispensable 
for enzymatic function (Medlock and Dailey 2000; Najahi-Missaoui and Dailey 2005; 
Ohgari et al. 2005).  Instead, it may help to enhance protein stability in mammalian 
ferrochelatases (Medlock and Dailey 2000; Najahi-Missaoui and Dailey 2005; Ohgari et 
al. 2005).  Further, FeS cluster assembly has been implicated in regulating overall heme 
production by modulating ferrochelatase activity (Taketani et al. 2003; Lange et al. 
2004).  In human ferrochelatase, the C-terminal cluster-containing region is involved in 
binding ABC7, a member of the mitochondrial half-type ATP-binding cassette (ABC) 
transporters (Taketani et al. 2003).  This interaction is thought to mediate an increase in 
heme synthesis during erythroid differentiation, which contributes to elevated 
hemoglobin production in erythropoiesis (Taketani et al. 2003).    
In mammals, naturally occurring genetic defects cause decrease in ferrochelatase 
activity leading to the disease erythropoietic protoporphyria (EPP) (Magnus et al. 1961; 
Todd 1994).  Typical symptoms of EPP include skin photosensitivity beginning in 
childhood which results from accumulation of free protoporphyrin primarily generated in 
the erythropoietic tissues (Todd 1994).  Although EPP is generally not life threatening, 
retention of excessive porphyrins in the liver can cause hepatobiliary diseases and entails 
liver transplantation in a small fraction of patients (Bloomer 1988).  In humans, EPP is 
primarily transmitted as an autosomal dominant trait with incomplete penetrance and 
variable clinical expression (DeLeo et al. 1976).  A puzzling feature of clinical EPP is 
that the patients exhibit ferrochelatase activity at only ~10-30% of the normal level, 
lower than the expected, 50% residual activity (Bonkowsky et al. 1975; Norris et al. 
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1990).  One explanation based on the multiallelic inheritance model is that clinical 
manifestations of EPP require the inheritance of a low expression wild-type allele in 
combination with a defective ferrochelatase allele (Gouya et al. 1996; Gouya et al. 1999).  
In support of this model, an intronic polymorphism mapped to the intron/exon splice 
acceptor site, i.e. an IVS3-48C/T allele, was shown to cause rapid degradation of 
aberrantly spliced transcripts and significantly reduce the steady-state mRNA levels, thus 
resulting in decreased expression from an otherwise functional ferrochelatase allele 
(Gouya et al. 2002).  Indeed, the low expression IVS3-48C allele is prevalent in families 
with overt EPP from diverse human populations  (Risheg et al. 2003; Wiman et al. 2003a; 
Whatley et al. 2004; Bloomer et al. 2005).  Additional factors including individual 
genetic background have also been implicated in modulating ferrochelatase expression 
level and EPP pathogenesis (Chen et al. 2002; Gouya et al. 2004; Abitbol et al. 2005; 
Cooperman et al. 2005; Navarro et al. 2005; Zhou et al. 2005).  
While the size (45 kb) of the human FECH gene locus (chromosome 18q21.31) 
precludes the use of a comprehensive analysis of gene defects as routine examination for 
EPP most patients exhibit mutations in the protein coding region (Rufenacht et al. 1998).  
To date ~80 deleterious mutations have been identified in human ferrochelatase (Whatley 
et al. 2004).  Exon skipping, frameshifts and nonsense mutations are common and result 
in inactive enzymes (Gouya et al. 1996; Rufenacht et al. 1998; Sellers et al. 1998a; 
Schneider-Yin et al. 2000c).  Over 30 missense EPP mutations have been identified, and 
they typically occur in conserved residues and result in large reduction of enzymatic 
activity (Rufenacht et al. 1998; Schneider-Yin et al. 2000b; Schneider-Yin et al. 2000c; 
Rufenacht et al. 2001; Whatley et al. 2004).  Structural mapping indicates that relatively 
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few mutations are located in the active site, and the majority are scattered throughout the 
protein scaffold (Najahi-Missaoui and Dailey 2005).  Interestingly, mutations near the 
dimer interface or FeS cluster are highly detrimental to residual enzymatic activity 
(Schneider-Yin et al. 2000b; Najahi-Missaoui and Dailey 2005; Ohgari et al. 2005). 
A common treatment for EPP consists of preventing or lessening photosensitivity 
by β-carotene ingestion, but this method is refractory to some patients and does not 
protect against liver damage (Mathews-Roth 1993; Todd 1994).   Long-term intake of L-
cysteine has also been shown to ameliorate photosensitivity (Mathews-Roth and Rosner 
2002).  Bone marrow transplantation and hematopoietic stem cell gene therapy offer the 
potential of more effective cures (Pawliuk et al. 1999; Fontanellas et al. 2000; Richard et 
al. 2004).  In an EPP mouse model, it has been feasible to correct photosensitization by 
transplanting bone marrows containing hematopoietic stem cells transduced with human 
ferrochelatase (Pawliuk et al. 1999; Fontanellas et al. 2001; Richard et al. 2004).  
Recently, localized skin graft has been demonstrated to effectively protect against dermal 
photosensitivity (Pawliuk et al. 2005).  However, liver damage remains difficult to cure 
(Bloomer et al. 1996; Bloomer et al. 2005).  Bone marrow transplantation in young 
patients has been suggested as an option to prevent hepatobiliary complications 
(Fontanellas et al. 2000).  
 
In summary, with the availaibility of crystal structures for all the heme 
biosynthetic enzymes, it has become increasingly possible to carry out extensive 
structure-activity characterization for each protein.  Altogether, these studies shall lead to 
a better comprehension of the driving forces underlying the biological process of heme 
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synthesis.  More importantly, extending molecular analysis into clinical settings offers 
promise toward improving the diagnosis and treatment of porphyria and anemia.   
The experimental investigation presented in this dissertation focuses on the 
terminal enzyme, ferrochelatase.  As described above, although enzymatic studies of 
ferrochelatase have been carried out for decades and encompass a wide range of 
biochemical and biophysical characterization, only in the past few years have the crystal 
structures been solved for ferrochelatase isolated from different organisms (Dailey and 
Dailey 2003).  This opens up the possibility of conducting structure-based functional 
assays to probe ligand-protein interactions and to infer the enzymatic reaction 
mechanism.  The primary purpose of this study is to explore the structural basis of 
substrate porphyrin binding and distortion with regard to ferrochelatase catalysis.  This 
investigation was initiated based on crystallographic observation and molecular modeling 
that a highly conserved loop motif was located in the active site and appeared to interact 
with bound porphyrin.  The loop was subjected to random mutagenesis and the properties 
of the active variants were characterized.  This study revealed a number of important 
results regarding the molecular details of ferrochelatase function.  In support of the initial 
proposal, the loop residues are shown to play a role in substrate porphyrin binding.  The 
loop also regulates active site conformation resulting in modulation of reaction rate and 
substrate interaction.  The loop residues are directly involved in distortion of the 
porphyrin macrocycle into a non-planar conformation, which contributes to the catalytic 
efficiency of ferrochelatase.  Structural changes in the loop are also found to play a role 
in determining the sensitivity to the inhibitor N-methyl-protoporphyrin.  One unexpected 
finding is that loop mutations allow the enzyme to retain activity even without FeS 
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cluster assembly and adopt an alternative oligomeric states.  Overall, the results described 
here provide new insights into the structural basis of porphyrin metallation catalyzed by 
ferrochelatase.     
Ferrochelatase is present at the convergence of the intracellular tetrapyrrole 
biosynthetic and iron supply pathways.  Because accumulation of unmetallated 
porphyrins and ferrous iron are cytotoxic, integration of both pathways by ferrochelatase 
is crucial for cellular metabolism, especially in the process of erythroid cell development 
(Ponka 1999).  While enzymatic deficiency of ferrochelatase leads to the disease 
erythropioetic protoporphyria (Gouya et al. 2002), growing evidence indicates that 
ferrochelatase function is also intimately related to iron metabolism (Taketani 2005).  
Therefore, it is hoped that ferrochelatase shall contribute to a better understanding of its 
physiological importance, for instance, towards the pathogenesis mechanism and therapy 
of erythropoietic porphyria as well as diseases associated with aberrant iron metabolism.  
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Chapter Two 
 
Materials 
 
Plasmid pGF42 contains the mature form of wild-type murine ferrochelatase 
subcloned into the pCASS3 vector (Ferreira 1994).  Plasmid pGF47 contains the mature 
form of wild-type murine ferrochelatase with a N-terminal 5X-His-tag (Franco et al. 
2000).  Plasmid pGF23 contains the murine erythroid 5-aminolevulinate synthase cDNA 
cloned into the pCASS3 vector (Ferreira and Dailey 1993).  E. coli strain Δvis was a kind 
gift of Dr. H. Inokuchi at Kyoto University (Nakahigashi et al. 1991).  E.  coli strains 
PK4331 (iscS-) and RZ4500 were from Dr. P. Kiley at the University of Wisconsin 
(Schwartz et al. 2000).  
Oligonucleotides were synthesized by Cybersyn, IDT Integrated Technologies 
and Invitrogen.  Protoporphyrin IX, Ni-protoporphyrin, zinc-protoporphyrin and N-
methyl protoporphyrin were obtained from Frontier Scientific and were used without 
further purification.  Hemin, tris(hydroxymethyl)amino-methane carbonate (Trizma 
base), MOPS, tricine, thiamine, cholic acid, sodium citrate, polyethylene glycol sorbitan 
monooleate (Tween-80), polyethylene glycol sorbitan monolaurate (Tween-20), agarose, 
bovine serum albumin standard solution ampules, the bicinchonic acid protein 
determination reagents, gel filtration molecular weight markers, CelLytic B II bacterial 
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cell lysis extraction reagent, ExtrAvidin-peroxidase, palmitic acid, stearic acid, oleic acid, 
linoleic acid, arachidonic acid and N-(biotinoyl)-1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine triethyl-ammonium salt (biotin-DHPE) were obtained from Sigma 
Chemicals.  Bacto agar, Bacto tryptone, yeast extract, vitamin assay casamino acids, 
dextrose and ferrous ammonium sulfate were from Fisher Scientific.  Restriction 
enzymes, DNA ligase and DNA polymerases were from New England Biolabs.  Plasmid 
purification kit, QiaQuick gel extraction kit and Ni-NTA agarose resins were from 
Qiagen.  Talon metal chelate affinity resins and Talon HT 96-well plate were from BD 
Biosciences.  Blue-sepharose CL-6B, PD-10 columns and Microspin S200-HR columns 
were from Pharmacia.  Amicon stirred cells, centricon, microcon, Amicon Ultra-4 and 
Ultra-15 centrifugal filter units were from Millipore.  Chelex-100 resins, sodium dodecyl 
sulfate-polyacylamide gel electrophoresis reagents and silver staining kit were from Bio-
Rad Laboratories.  Superdex-200 gel filtration matrix, T7 sequenase version 2.0 DNA 
sequencing kit, ECL chemiluminescent Western blotting detection reagents and 
Hyperfilm ECL were from GE Healthecare.  Superblock blocking buffer and Gelcode 
blue stain were from Pierce.   Protran BA85 nitrocellulose membrane (0.45 μm) was 
from Schleicher and Schuell.  Phosphatidylcholine (bovine liver), 
phosphatidylethanolamine (bovine liver), phosphatidylinositol (bovine liver), 
phosphatidylserine (porcine brain), lysophosphatidylcholine (soy), lysophosphatidyl-
ethanolamine (chicken egg), cardiolipin (bovine heart), cholesterol, diacylglycerol and 
sphingomyelin (porcine brain) were from Avanti Polar Lipids.  Microtiter and gas-tight 
syringes were from Hamilton.  Screw-cap fluorescence cuvettes and magnetic stir bars 
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were from Starna Cells.  Septum caps were from Supelco.  All reagents were of the 
highest purity available.   
 
 
Experimental Methods 
 
Media preparation for bacterial cultures 
All the media for bacteria growth were prepared and stored aseptically.  
LB medium (for routine growth of E. coli cells) contains 1% Bacto tryptone, 0.5% 
yeast extract, 1% NaCl.   
LB/agar plate contains: 1% Bacto tryptone, 0.5% yeast extract, 1% NaCl., and 
1.5% agar.    
Terrific broth (enriched medium for growing E. coli cells) contains:  1.2% Bacto 
tryptone, 2.4% yeast extract, 0.4% glycerol, 0.17 M KH2PO4, and 0.72 M K2HPO4.  
SOB media (for recovery of transformed E. coli DH5α and BL21 cells) contains: 
2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2 
and 10 mM MgSO4.   
SOC media (for recovery of transformed Δvis cells) contains: 2% Bacto tryptone, 
0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 
20 mM glucose.  
MOPS media (for induced protein expression in E. coli cells) consists of the 
following components:  1 liter complete medium is prepared by mixing 200 mL M 
solution (described below), 2 mL O solution (described below), 0.1 mL P solution 
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(described below), 1 mL S solution (described below), 0.5 mL 0.2% thiamine, 40 mL 
3.75% vitamin assay casamino acids, 20 mL 20% glucose, and supplemented with sterile 
H2O to a final volume of 1 liter.   
200 mL M solution is composed of 4.2 % (w/v) MOPS, 0.4% (w/v) tricine, 0.8% 
(w/v) KOH, 1.46% (w/v) NaCl, 0.26% (w/v) NH4Cl and 0.42% (w/v) NaHCO3.  M 
solution is sterilized by autoclaving and kept at 4 oC.  
50 mL O solution is prepared by dissolving 0.1g FeCl2·4H2O in 10 mL HCl and 
10 mL H2O, mixing with 1 mL T solution (described below), adding 2.68 g MgCl2·H2O, 
and filled with H2O to a final volume of 50 mL.  O solution is filter-sterilized and kept at 
4 oC. 
100 mL P solution is prepared by dissolving 13.6 g KH2PO4 in 100 mL H2O.  P 
solution is sterilized by autoclaving and kept at 23 oC. 
100 mL S solution is prepared by dissolving 4.81 g K2SO4 in 100 mL H2O. S 
solution is sterilized by autoclaving and kept at 23 oC. 
100 mL T solution is prepared by dissolving 184 mg CaCl2·2H2O, 64 mg H3BO3, 
40 mg MnCl2·4H2O, 18 mg CoCl2·6H2O, 4 mg CuCl2·2H2O, 340 mg ZnCl2 and 605 mg 
Na2MoO4·2H2O in 8 mL concentrated HCl, and filled with H2O to a final volume of 100 
mL.  T solution is filter-sterilized and kept at 23 oC.  
 
Competent cell preparation and bacterial transformation 
The procedures described here were used to prepare competent cells for 
electroporation for the bacterial strain BL21(DE3) and DH5α.  All reagents used were 
prepared sterilely.  LB medium was inoculated with E. coli cells stored as a frozen 
59 
glycerol stock and the inoculum was grown on a LB/agar plate at 37 oC for 16 hr.  
Bacterial cells from a single colony were used as an inoculum to grow a 20 mL culture in 
LB medium at 37 oC overnight with shaking at 220 RPM on a platform shaker.  The 
saturated bacterial culture was diluted 50-fold into 1 liter LB medium.  The freshly 
diluted culture was incubated at 37 oC with shaking at 220 RPM, until OD600 reached 
~0.6 when measured using a 1 cm path-length cuvette, which usually took ~1-2 hr.  The 
cells were pelleted by centrifuging at 6000 RPM in a Beckman JA-10 rotor for 10 min at 
4 oC.  Cell pellets were washed twice in ice-cold H2O, followed by two washes in ice-
cold 10% glycerol.  After the washes, cells were resuspended in 10% glycerol to a total of 
~6 mL and aliquoted in ~200 μL to pre-chilled microfuge tubes.  The aliquots were 
quickly frozen in liquid N2 and stored at -80 oC.  For electro-transformation, typically, 40 
μL competent cells were incubated on ice with 1-2 μL solution containing a total of ~1 
ng to 1 μg DNAs.  The mixture was transferred to a pre-chilled 0.1 cm electroporation 
cuvette and electroporated using a Bio-Rad Gene Pulser under the setting of 1.8 KV and 
25 μF.  The mixture was grown in 1 mL SOC medium for 1-3 hr at 37 oC in a platform 
shaker at 220 RPM.  100-200 μl of the transformation was spread on an agar plate and 
incubated at 37 oC overnight.  Transformants were obtained from colonies developed on 
the plate.  
 
Glycerol stock preparation for bacterial cells 
An individual colony developed on an agar plate was inoculated into ~5 mL 
growth media and the culture was incubated at 37 oC overnight with shaking at 220 RPM.  
The next day, the culture was collected and mixed with glycerol to make a stock solution 
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containing 10% glycerol.  Aliquots of ~1 mL were transferred to microfuge tubes and 
stored at –80 oC.  
 
Plasmid DNA purification 
Plasmids from bacterial cultures were isolated using Qiagen Tip-20 or Tip-100 
according to the manufacturer’s protocol.  For small-scale preparation, colonies of BL21 
or DH5α cells were inoculated into ~10 mL growth media.  The culture was grown 
overnight at 37 oC, and the plasmids were extracted usually at a yield of ~1 μg/mL 
culture.  Concentration of double-stranded DNA was determined by measuring OD260 in 
a 1 cm path-length cuvette using an extinction coefficient of 1OD = 50 μg/mL DNA.  An 
aliquot of the preparation, usually 0.2-0.5 μg, was run on agarose gel, typically 0.8%, to 
assess purity of the plasmid.  
 
Sodium dodecyl sulfate-polyacylamide gel electrophoresis and protein concentration 
determination  
SDS-polyacrylamide gel electrophoresis was run as described by LaemmLi 
(Laemmli 1970).  Typically, 1-10 μg of denatured protein samples were run on 15% 
acrylamide and 0.75-mm thick mini-gels.  The denatured protein sample was prepared by 
mixing proteins with loading buffer containing 50 mM TrisCl pH 6.8, 2% SDS, 0.1% 
bromophenol blue and 10% glycerol, along with 0.1 M dithiothreitol dissolved in 1 mM 
NaAcetate pH 5.2.  The mixture was boiled at 95 oC for 2-3 min, and an aliquot of ~10-
15 μL was loaded onto a gel.  Usually, gels were run at 100-120 V for 2-3 hr at 23 oC. 
Protein bands were visualized using Coomassie Brilliant blue (R-250) staining by 
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incubating gels in 0.25% Coomassie blue solution in 45% methanol and 10% acetic acid 
for a few hours, followed by destaining in 30% methanol and 10% acetic acid for 
overnight.  Alternatively, gels were stained using Gelcode blue stain (Pierce). Gels were 
rinsed in ddH2O several times, followed by overnight incubation in Gelcode solution and 
destained in ddH2O for a few hours.  Both methods allow ~1 μg or more proteins to be 
shown.  For improved sensitivity, gels were silver stained, which allows visualization of 
~ 10 ng or more proteins.    
Protein concentrations were determined by the bicinchoninic acid assay.  In a 2 
mL reaction, bicinchoninic acid and 4% (w/v) CuSO4 solution were mixed at a 50:1 ratio, 
and the mixture was incubated with 100 μl protein sample.  The reactions were allowed 
to proceed for 30 min at 37 oC, or 2 hr at 23 oC.  At the end, the absorbance of each 
sample at 562 nm was measured using 1 cm path-length cuvette on a UVPC-2100U dual-
beam spectrophotometer.  A standard curve was generated using dilutions of 1 mg/mL 
bovine serum albumin (BSA) stock solution in the reaction.  
 
Construction of a random library and genetic selection of functional ferrochelatase 
loop variants   
Electro-competent cells of the E. coli strain Δvis were prepared following a 
standard procedure.  To complement deficiency in the endogenous ferrochelatase activity, 
LB medium was supplemented with 10 μg/mL hemin and 0.4 % (w/v) glucose to allow 
growth of Δvis cells.  To eliminate background from wild-type ferrochelatase in library 
construction, a mock vector was generated by replacing the segment in the murine 
ferrochelatase expression plasmid pGF47 which spans the ten codons for the loop motif 
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Figure 4.  Random mutagenesis of the ferrochelatase active site loop motif and 
biological selection of the functional variants.  
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with a stuffer sequence derived from the murine ALAS expression plasmid pGF23 via 
two unique restrictions sites BstEII and PspOMI (Figure 4).  The ferrochelatase random 
library was constructed based on previously described protocols (Munir et al. 1992; Gong 
and Ferreira 1995; Landis and Loeb 1998) (Figure 4).  Two single-stranded DNA oligos 
with 15 complementary base pairs at their 3’ ends were annealed.  Oligo 1 (5’-ATG GAA 
AAG CTG GGT TAC CCC AAC CCC TAC CGA CTG GTT TGG-3’) is a 42mer 
corresponding to the sense strand nucleotides and contains a BstEII site (italics) for 
cloning.  Oligo 2 (5’-AGC GTC ATC TGT CTG AGG GCC CAA CCA GGG TAC TGG 
ACC AAC CTT GGA CTG CCA AAC CAG TCG GTA-3’) is a 66mer spanning the 
antisense strand nucleotides with a PspOMI restriction site (italics) for cloning.  Oligo 2 
contains degenerate nucleotides (underlined) corresponding to codons 248-257 of the 
mature murine ferrochelatase loop residues.  Each of the ten loop codons was randomized 
using 85% wild-type nucleotides and 15% mixture of the other three nucleotides.  A 60 
μL annealing reaction, containing 0.5 nmole of each oligo, 200 mM Tris-HCl, pH 7.5, 
100 mM MgCl2 and 250 mM NaCl, was incubated at 80 °C for 5 min, followed by 55 °C 
for 15 min, 37 °C for 15 min and finally at 23 °C for 30 min.  The hybrid was extended 
using the Klenow fragment of E. coli DNA polymerase I (5 units) in a 40 μL mixture 
containing 50 pmole of annealed oligos, 62.5 µM of each of the four dNTPs and EcoPol 
buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl2 and 7.5 mM dithiothreitol).  The extension 
reaction was carried out at 37 °C for 2 hr.  The generated double-stranded mutagenic 
DNA was then amplified by the polymerase chain reaction (PCR) using two primers 
corresponding to the 5’ termini of oligos 1 and 2. The two primers used were: FC-66, 5’-
ATG GAA AAG CTG GGT TAC CCC AA-3’, which covers the first 23 nucleotides of 
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the 5’ terminus of oligo 1 and FC-R67, 5’-AGC GTC ATC TGT CTG AGG-3’, which 
corresponds to the 18 nucleotides of the 5’ terminus of oligo 2.  The PCR reactions were 
performed in 100 µL reaction volumes consisting of 20 pmole of primers FC-66 and FC-
R67, 3-50 pmole of the extended double-stranded DNA as template, 50 µM each of the 
four dNTPs, 1 unit of VentR DNA polymerase, and ThermoPol reaction buffer (20 mM 
Tris-HCl, pH 8.8, 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4 and 0.1% Triton X-
100).  The reaction mixture was subjected to temperature cycling in a MJ Research 
programmable thermal controller by running 1 cycle of 95 °C for 2 min, followed by 30 
cycles of 95 °C for 1 min, 45 °C for 2 min, and 72 °C for 1 min, and a final extension at 
72 °C for 10 min.  The PCR product of 93 bp was purified using Microspin S200-HR 
columns, and subsequently digested with BstEII and PspOMI.  The ~60 bp digested 
fragment was isolated from an agarose gel using GLASSFOG matrix and buffers in the 
MERmaid kit and subcloned into the mock vector previously digested with the same 
enzymes.   
The 20 μL reaction ligation contained the randomLy mutagenized insert and 
vector at a 5:1 molar ratio, 1 mM ATP, 7 units of T4 DNA ligase, ligase buffer (50 mM 
Tris-HCl, pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, and 25 µg/mL 
bovine serum albumin), 100 mM NaCl and 10% PEG 6000.  After 16-20 hr incubation at 
16 °C, the ligation reaction was purified by passing through Microspin S200-HR columns 
(Pharmacia), and used to transform competent Δvis cells with an Electroporator II 
(Invitrogen).  Aliquots of 1-2 μL of the ligated products were electroporated into 40 μL 
Δvis cells, using 0.1 cm cuvettes (Invitrogen) at 1.5 KV, 50 μF and 150 Ω.  After the 
pulse, transformants were resuspended in 1 mL SOC medium (2% Bacto tryptone, 0.5% 
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Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 
mM glucose) supplemented with 10 μg/mL hemin, and incubated at 37 0C for 4 hr with 
continuous shaking.  To assess transformation efficiency, a small portion of the 
transformed cells was spread onto LB plates containing 50 μg/mL ampicilin, 0.4 % (w/v) 
glucose and 10 μg/mL hemin.  The remaining transformed cells were plated onto 
LB/ampicilin plates to allow selection of the active variants.  
Only Δvis cells expressing functional ferrochelatase can form colonies on hemin-
free media.  Aliquots of Δvis cells transformed with the random library ligation products 
were plated on LB/agar medium containing 50 μg/mL ampicilin and 0.4 % (w/v) glucose, 
and incubated at 37 °C for 24-30 hr.  Plasmids were isolated from all of the surviving 
colonies, and the randomized regions were sequenced to determine the permissible amino 
acid substitutions.  To prepare double-stranded DNA templates, ~20 mL of Δvis culture 
for each clone was grown overnight in terrific broth containing 50 μg/mL ampicilin and 
0.4 % (w/v) glucose, and plasmids were purified using Qiagen Tip-20 (Qiagen).  
Sequences were determined for the sense strand using the primer MFC-73: 5’-AGA GGG 
GAC CCC TAT CCC CAA GAG GTA-3’, which is 63 bp 5’ to the randomized loop 
region.  166 clones were sequenced by the dideoxynucleotide chain termination method 
using a T7 sequenase 2.0 DNA sequencing kit and 35S-dATP.  The remaining 48 clones 
were sequenced by the ABI automated DNA sequencers at the University of Florida.  
 
Large-scale purification of the wild-type ferrochelatase and loop variants 
 The wild-type murine ferrochelatase and the functional loop variants were 
expressed under the E. coli alkaline phosphatase promoter phoA in BL21(DE3) cells or 
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DH5α cells as described previously (Ferreira 1994).  Bacterial colonies were used to 
inoculate ~100 mL LB/amp media and the culture was grown overnight at 37 oC with 
shaking at 220 RPM.  Approximately 10 mL of the overnight culture was used to 
inoculate 1 liter of MOPS medium containing 50 mg/liter ampicilin.  The MOPS culture 
was grown at 37 oC for 4 hr with shaking at 220 RPM in a Beckman platform shaker, and 
the growth was continued at 25-30 oC for 16-20 hr.  Typically, 8 liters of MOPS culture 
were grown.  Bacterial cells were pelleted at 6,000 RPM for 10 min at 4 oC in a Beckman 
JA-10 rotor.  Cells were resuspended in ~30 mL solution containing 20 mM TrisCl pH 8 
and 10% glycerol.  Cells were homogenized, and ruptured using a French press with 3-4 
passages at 14,000 psi.  To reduce proteolysis, 0.0017% (w/v) phenylmethylsulfonyl 
fluoride was included in the lysate.  Lysate was resuspended in a solution containing 0.6 
M NaCl, 0.5% cholate, 20 mM TrisCl pH 8 and 10% glycerol under constant stirring at 4 
oC for 30 min.  The solubilized lysate was centrifuged at 44,000 RPM using a 50.2Ti 
rotor in a Beckman ultracentrifuge for 1 hr at 4 oC.  The supernatant fraction was saved 
and used for loading onto the affinity columns.  
 For protein purification using blue sepharose resins, the supernatant from 
ultracentrifugation was mixed with 35% (NH4)2SO4 and stirred at 4 oC for 20 min.  The 
mixture was centrifuged at 11,000 RPM for 30 min.  The pellet fraction was 
homogenized in ~20 mL equilibration buffer containing 20 mM TrisCl pH 8, 10% 
glycerol, 0.5 M NaCl and 0.5% NaCholate.  The homogenate was loaded onto a 15 x 2.5 
cm gravity column packed with ~20 mL blue sepharose resins.  The column was washed 
in ~150 mL equilibration buffer until A280 < 0.1.  Subsequently, the column was washed 
with ~100 mL wash buffer containing 20 mM TrisCl pH 8, 10% glycerol, 1 M NaCl and 
67 
0.5% NaCholate until A280 < 0.1.  Proteins were eluted in elution buffer containing 20 
mM TrisCl pH 8, 10% glycerol, 1.5 M NaCl and 1% NaCholate.  Elution fractions, ~50 
mL total, were pooled and concentrated in a 50 mL Amicon stirred cell to ~1-5 mL.  
Aliquots of ~200 μL of purified concentrated proteins were stored in liquid N2 until use.  
For purification of ferrochelatase with N-terminal His-tag using metal chelate 
affinity resins, the supernatant fraction obtained from ultracentrifugation was loaded onto 
a 17 x 1.5 cm gravity column packed with ~10 mL Talon resins equilibrated in buffer 
containing 20 mM TrisCl pH 8, 10% glycerol, 150 mM NaCl and 0.5% NaCholate.  The 
column was first washed with ~200 mL equilibration buffer until A280 < 0.1.  It was 
further washed in ~100 mL equilibration buffer supplemented with 10 mM, 20 mM and 
30 mM imidazole.  Proteins were eluted using equilibration buffer containing 100 mM 
imidazole.  The protein in the elution fractions in a total of ~100 mL was pooled and 
concentrated in an Amicon stirred cell.  To remove imidazole, purified samples were 
loaded onto a 100 x 2 cm HPLC column packed with ~150 mL Superdex-200 resins in 
equilibration buffer.  The proteins were eluted at a flow rate of 0.4 mL/min and elution 
fractions were collected and concentrated.  
 
UV-visible absorbance spectra of purified ferrochelatase 
UV-visible absorption spectra of purified ferrochelatase and variants were 
recorded using a UVPC-2100U dual-beam spectrophotometer (Shimadzu) with 1 cm 
path-length cuvette at 23 oC.  Typically, a protein solution at ~20 μM was added to the 
cuvette, and the absorption spectrum was collected across the wavelength range of 250-
700 nm.   
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Metal content analysis of purified ferrochelatase 
The metal ion content of purified ferrochelatase was determined using plasma 
emission spectroscopy.  His-tagged wild-type ferrochelatase was purified using blue-
sepharose affinity column chromatography and variant S249A/K250Q/V251C was 
purified using Talon metal chelate affinity column chromatography followed by gel 
filtration chromatography.  The proteins were concentrated in a centricon (MWCO 
10,000 Da).  The sample for plasma emission spectroscopy was prepared in 1 mL assay 
buffer containing 20 mM TrisCl pH 8, 10% glycerol and 150 mM NaCl.  Metal ion 
concentrations in 60 μM solution of His-tagged wild-type ferrochelatase, 40 μM and 23 
μM solutions of variant S249A/K250Q/V251C and the assay buffer alone, were 
determined using 20-element analysis at the Chemical Analysis Laboratory at the 
University of Georgia.  
                                                                                                                                                            
Pyridine-hemochromogen assay 
A conventional method to measure ferrochelatase activity is by quantifying heme 
production using the pyridine-hemochromogen assay.  A 2 mM protoporphyrin IX stock 
solution was prepared by dissolving protoporphyrin in 100 mM NH4OH and 0.5% (v/v) 
Tween-80.  A 4 mM ferrous iron stock solution was prepared anaerobically by dissolving 
15.7 mg Fe(NH4)2(SO4)2·6H2O and 27 mg Na3Citrate in 10 mL deaerated H2O.  A 
mixture containing the enzyme incubated with a solution containing 100 μM 
protoporphyrin and 100 mM TrisCl pH 8 was deareated under Argon flow.  Reaction was 
initiated by adding the ferrous iron solution to a final concentration of 100 μM.  The 
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entire reaction was incubated at 23 oC for 20 min.  At the end of incubation, 0.5 mL of 1 
N NaOH and 0.5 mL pyridine were added to the mixture.  Half of the sample was 
reduced with dithionite, and the other half was used as reference.  The difference 
spectrum of the reduced sample versus the oxidized sample was collected at 23 oC using 
a UVPC-2100U dual-beam spectrophotometer in 1 cm path-length cuvette.  Wavelength 
scan was run between 500 nm and 600 nm.  The absorbance differential between the 
maximum at 557 nm and minimum at 541 nm was recorded and used to calculate the 
amount of pyridine-hemochromogen formed using the extinction coefficient Δε(A557-
A541) of 20.7 mM-1 cm-1 (Porra and Jones 1963a).  
 
Continuous assay of ferrochelatase activity  
An initial rate assay was developed for ferrochelatase by monitoring the decrease 
of porphyrin fluorescence using protoporphyrin IX and ferrous iron as substrates. Caution 
was taken in preparing the assay reagents in order to minimize trace metal ion 
contamination.  All of the buffers and solutions including 1 M Tris-acetate pH 8.1 and 
10% (v/v) Tween-80 were made in HPLC-grade H2O and further purified using Chelex-
100 resins.  Protoporphyrin IX was prepared as 200 μM stock solution by dissolving 
porphyrin solid in 100 mM NH4OH and 0.5% (v/v) Tween-80.  The solution was adjusted 
to pH 8.1 with acetic acid, and kept in 0.1 M Tris-acetate pH 8.1.  Ferrous iron was 
prepared under anaerobic conditions as a 2 mM ferrous ammonium citrate stock by 
dissolving equimolar amounts of ferrous ammonium sulfate and sodium citrate, i.e. 7.8 
mg Fe(NH4)2(SO4)2·6H2O and 13.6 mg Na3Citrate in 10 mL H2O (Taketani and 
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Tokunaga 1981).  All glassware used in the assays was soaked in HCl overnight to 
remove traces of iron.   
Protoporphyrin fluorescence was monitored on a Shimadzu RF-5301PC 
fluorimeter equipped with a red-sensitive photomultiplier tube.  The thermostatically 
controlled cell holder was maintained at 30 oC.  A 2 mL solution containing 
protoporphyrin IX in 0.1 M Tris-acetate pH 8.1 and 0.5 % (v/v) Tween-80 was deaerated 
in a fluorescence cuvette sealed with a septum cap and containing a micro-magnetic 
stirring bar.  Deaeration continued for at least 30 minutes by applying repeated cycles of 
vacuum and purging with ultra-high purity argon gas.  The cuvette was then placed in the 
fluorimeter cell holder.  Purified ferrochelatase was added to the mixture by injection 
using a fixed-needle syringe, and the mixture was equilibrated for 5 min at 30 oC under 
constant stirring.  The reaction was initiated by injecting ferrous iron, and the progress of 
the reaction was monitored continuously by recording the emitted light through an 
emission monochromator set at 635 nm (5-nm slit width) upon excitation at 505 nm (3-
nm slit width).  The rate of change in fluorescence intensity (arbitrary unit min-1) was 
converted to velocity (nmol of protoporphyrin min-1) using a standard curve of 
fluorescence intensity versus protoporphyrin concentration.  The time course for each 
reaction was collected using the Shimadzu software RF-5301PC and the initial rates were 
calculated from the linear portion of the progress curves.   
The steady-state kinetic parameters KmFe2+, KmPPIX and kcat of wild-type 
ferrochelatase were determined at 30 oC using the continuous fluorimetric assay as 
described above.  The data were analyzed in matrices of five protoporphyrin and five 
Fe2+ concentrations by fitting the initial velocities to Equation 1: 
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where KmPPIX and KmFe2+ are the Michaelis constants for protoporphyrin and Fe2+, KiFe2+ is 
the dissociation constant for Fe2+, v is the initial velocity, and Vmax is the maximal 
velocity of the reaction.  Equation 1 describes the steady-state velocity equation for a bi-
reactant system in the absence of products (Segel 1975).  The kinetic constants and 
standard deviations were calculated from regression analysis using the statistical program 
DATAFIT (Oakdale Engineering).  
 
Steady-state kinetic analysis of the loop variants 
Ferrochelatase activity was determined by monitoring the consumption of 
substrate protoporphyrin using ferrous iron as the metal substrate in a continuous 
spectrofluorimetric assay conducted under strictly anaerobic conditions as described 
previously (Shi and Ferreira 2003).  Typically, a mixture containing 100 mM Tris-acetate 
pH 8.1, 0.5% (v/v) Tween-80 and protoporphyrin IX was incubated with ferrochelatase 
for ~5 min at 30 °C, and the enzymatic reaction was initiated by ferrous ammonium 
citrate injection.  Activities are expressed as nmole protoporphyrin consumed per minute 
per mg of enzyme.  The steady-state kinetic parameters were determined from matrices of 
five protoporphyrin and five Fe2+ concentrations.  The reported values and the standard 
deviations were obtained from the nonlinear least squares fit of the data to the Michaelis-
Menten equation for bi-reactant systems using the software DataFit.  
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Homology modeling of murine ferrochelatase  
Comparative protein modeling of the three-dimensional structures of wild-type 
murine ferrochelatase and selected loop variants was performed using the amino acid 
sequence and coordinates for human ferrochelatase (PDB code 1hrk) as the template.  
Sequence alignments, molecular modeling, energy minimization and PROCHECK model 
analyses were performed on the Geno3D servers provided by the Institute of Biology and 
Chemistry of Proteins (IBCP) in Lyon, France (Combet et al. 2002).  The monomeric 
models for wild-type ferrochelatase and the loop variants were visualized using the 
program VMD version 1.7 (Humphrey et al. 1996).  The secondary structures in the 
protein models were identified by the STRIDE algorithm included in VMD.   
 
Resonance Raman spectroscopy of porphyrin binding to the wild-type 
ferrochelatase and loop variants 
Stock solutions of protoporphyrin, hemin and Ni-protoporphyrin were prepared 
by dissolving porphyrins in 100 mM NH4OH and 0.5% (v/v) Tween-80.  Typically, 
porphyrin stocks were made as 2 mM solutions, and further diluted in equilibration buffer 
containing 20 mM TrisCl pH 8, 150 mM NaCl and 10% glycerol prior to incubation with 
proteins.  Wild-type ferrochelatase and the variants were purified by Talon metal chelate 
affinity column without adding detergent sodium cholate during the entire purification 
procedure. Aliquots of ~200 μL of purified proteins (typically at 100-150 μM) in 
equilibration buffer were stored in liquid N2 until use.  To prepare samples for resonance 
Raman spectroscopy, porphyrins (typically 6 μM) were incubated with ferrochelatase 
(typically 60 μM) in equilibration buffer on ice and the final concentration of detergent 
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Tween-80 was adjusted to 12 μM.  Each sample, in a final volume of ~100 μL, was 
transferred to a stoppered 3 x 3 mm cross-section optical cell (NSG Precision Cells) for 
spectra collection.  The spectra were routinely recorded at 26 oC for 2-10 min using 20 
mW laser power.  The spectra were recorded on a Raman spectrometer by applying the 
406.7-nm line of an INNOVA 304 Kr+ laser (Coherent) as previously described (Lu et al. 
2002).  Briefly, the spectrometer consists of a 0.75m monochromator with a 2048-
channel liquid N2-cooled CCD detector (Instruments, SA).   Position mode was used for 
CCD detection, with each section covering about 500 cm-1 of the Raman spectrum 
without moving the grating.  
The resonance Raman spectra were exported as even-X ASCII files for plotting 
with SigmaPlot (SPSS).  Lorentzian decomposition of the spectra was performed using 
the program PeakFit (SYSTAT).  Curve-fitting was used to obtain the frequencies for the 
centers of the structure-sensitive bands.  For the region near the saddling-symmetry (B2u) 
mode γ15, the spectral fitting procedure was adjusted to take into account the varying 
signal-to-noise characteristics of the low-frequency Raman spectra for protoporphyrin 
binding to the proteins.  First, the spectra of protoporphyrin bound to wild-type 
ferrochelatase and the quadruple mutant Q248P/S249G/K250P/G252W, which exhibited 
the highest signal-to-noise level, were fit with all parameters free, including the center, 
width and amplitude of each Lorentzian band, as well as the slope and intercept of a 
linear baseline.  Eight lines were used to fit the frequency region from 580 to 780 cm-1, 
and the average half-width at half maximum of γ15 was determined to be 2.814 cm-1.  
This value for the width was then fixed and the data were refit.  These parameters were 
used for the constrained fits to yield the simulation results.   
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Profiling the active variants by high-throughput protein purification 
Plasmids encoding all the active loop variants were transformed into BL21 cells 
and the variant proteins were purified using a TALON HT 96-well plate. BL21 
transformants were inoculated into ~10 mL LB/ampicilin media and grown at 37 oC 
overnight.  Typically, ~5 mL culture was inoculated into 150 mL MOPS media, and the 
culture was grown at 37 oC for 4 hr and then at 25 oC overnight.  Bacterial cells were 
pelleted at 4,000 RPM in an Eppendorf centrifuge, resuspended in a 10 mL solution 
containing 20 mM TrisCl pH 8 and 10% glycerol.  The cells were lysed by passing 
through the French press twice.  The lysate was solubilized in 20 mM TrisCl pH 8 
containing 0.6 M NaCl, 0.5% NaCholate and 10% glycerol with stirring for 1 hr at 4 oC.  
The mixture was centrifuged at 15,000 RPM for 30 min and the supernatant fraction was 
saved.  In a TALON 96-well plate, each well contained 200 mg BD Talon Superflow 
resin and the resin was equilibrated with a buffer of 20 mM TrisCl pH 8 containing 10% 
glycerol, 150 mM NaCl and 0.5% NaCholate.  The supernatant was loaded into each 
well.  The wells were then washed with ~15 mL equilibration buffer until A280 < 0.1.  
Further washes were in ~5-10 mL equilibration buffer supplemented with 10 mM and 20 
mM imidazole.  Ferrochelatase was eluted using 2 mL equilibration buffer supplemented 
with 100 mM imidazole.  The eluate was collected in a 96-well plate. Eluate for each 
sample was concentrated to ~100 μL in an Amicon Ultra-4 centrifugal filter unit (MWCO 
10,000).   Imidazole in the sample was removed by exchanging the proteins into a storage 
buffer of 20 mM TrisCl pH 8 containing 10% glycerol and 150 mM NaCl.  UV-visible 
absorbance scan was taken for each purified variant.  
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Liposomal binding assays of ferrochelatase variants 
Liposomes were formulated with a lipid composition similar to that found in the 
inner mitochondrial membranes of mouse liver cells (Ardail et al. 1990).  Biotinylated 
liposomes were prepared following a previously described procedure (Zhu et al. 2001).  
Each lipid was weighed and suspended in chloroform to make a 1 mg/mL stock solution.  
The lipid stocks were mixed in a glass tube at ratios (w/w) of 1% biotin-DHPE, 35% 
phosphatidylcholine, 26.5% phosphatidylethanolamine, 18% cardiolipin, 5% 
phosphatidylinositol, 2.3% cholesterol, 2.8% diacylglycerol, 0.7% sphingomyelin, 0.5% 
phosphatidylserine, 0.5% lysophosphatidylcholine, 0.3% lysophosphatidylethanolamine, 
2.2% palmitic acid, 1.2% stearic acid, 1.3% oleic acid, 1.8% linoleic acid and 0.9% 
arachidonic acid.  The mixture was dried under N2, resuspended in 25 mM TrisCl pH 7.6 
and 150 mM NaCl (TBS).  The resuspension was sonicated to obtain a 100 μg/mL 
solution for use as a 1000X liposome stock for protein-binding assay.  Liposome size 
distribution was determined by dynamic light scattering at 26 oC using a submicron 
particle size analyzer (Beckman Coulter) at the University of New Mexico.   
Purified ferrochelatase was diluted to 1 μg/μL in equilibration buffer containing 
20 mM TrisCl pH 8, 10% glycerol, 150 mM NaCl and 0.5% NaCholate.  A serial dilution 
by 70% was made for each protein stock.  10 μL of the diluted samples were spotted onto 
nitrocellulose membrane (~10 x 15 cm) and air-dried for 30 min.  The blot was then 
wetted in H2O followed by TBS.  For binding assay, the blot was first blocked with 50 
mL Superblock buffer (Pierce) for 2 hr at 23 oC, followed by washing in TBS with 0.05% 
(v/v) Tween-20 (TBST) 3 times for 10 min each.  The blot was then transferred to a 
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hybrization bottle (Amersham), and incubated with 50 μL liposome stock solution diluted 
in 50 mL TBS.  The hybridization bottle was placed on a rotor in a hybridization oven 
(Fisher Scientific) at 30 oC for 1 hr.  Subsequently, the blot was washed in TBST three 
times for 15 min each at 23 oC.  For biotin detection, the blot was incubated with 1 μL 
peroxidase-conjugated extravidin (Sigma) at 2 mg/mL diluted in 50 mL TBS for 30 min, 
at 23 oC.  Final washes were in TBST twice for 15 min each, and in TBS three times for 
15 min each.  In the last step, the blot was treated with chemiluminescence substrate 
solutions (Amersham Biosciences) according to the manufacturer’s instructions and 
exposed to a Hyperfilm (Amersham Biosciences).  The bound liposomes were quantified 
using the densitometry program supplied with ChemiImager 4400 (Alpha Innotech).  The 
relative binding affinity was calculated from the intensity of chemiluminescent signals 
plotted against the amount of protein spotted onto the nitrocellulose membrane.  Wild-
type ferrochelatase was run as the standard, and a variant (G252D/V254I) was used as an 
internal control; essentially G252D/V254I was included in every single blot to ensure that 
the ratio between the chemiluminescent signal intensity for wild-type protein and the 
variant remained constant from blot to blot.   
 
Inhibition assay of ferrochelatase by N-methyl protoporphyrin on agar plates 
A 2 mM stock solution of N-methyl protoporphyrin (NMPP) was made by 
dissolving NMPP in 20 mM NH4OH containing 2% (v/v) Tween-20. The solution was 
filter-sterilized and kept at 4 oC.  The stock solution was diluted 100-, 1000- and 10,000-
fold to prepare plates containing 20 μM, 2 μM and 0.2 μM NMPP.  All plates were kept 
at 4 oC in the dark.  Δ vis cells transformed with wild-type ferrochelatase and functional 
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variants were grown in LB medium containing 50 μg/mL ampicilin and 0.4 % (w/v) 
glucose at 37 oC overnight with shaking at 220 RPM.  Each of the overnight cultures was 
diluted 20-fold into fresh media, and grown at 37 oC for ~1 hr until OD600 reached ~0.4-
0.5.  Subsequently, these cultures were diluted with LB medium by 106-fold and 100 μL 
aliquots of the diluted stock were spread on plates containing LB/ampicilin only or with 
added NMPP at 0.2 μM, 2 μM and 20 μM, respectively.  The plates were incubated at 37 
oC for 16 hr, and the number of colonies developed on each plate was counted.  
 
Quantification of N-methyl protoporphyrin binding to ferrochelatase by 
fluorescence quenching measurements 
Purified wild-type ferrochelatase and variants P255R and P255G were diluted into 
a 3 mL solution containing 10 mM Tris-acetate and 0.05% (v/v) Tween-80 at pH 8.  
Protein fluorescence was excited at 283 nm and monitored at 331 nm at 23 oC using a 
Shimadzu RF-5301PC fluorimeter.  Equilibrium binding of N-methyl protoporphyrin to 
the protein was monitored by quenching the intrinsic protein fluorescence.  A stock 
solution of NMPP at 200 μM was made by dissolving NMPP in 100 mM NH4OH 
containing 0.5% (v/v) Tween-80.  Aliquots were added to the protein solution.  After 
incubating on ice for 1 hr, fluorescence of the mixture was measured as described above.  
The fluorescence intensity was plotted against NMPP concentration and the dissociation 
constant of NMPP for ferrochelatase was determined using the least-squares fit of each 
data set to Equation 2 by nonlinear regression (Anderson et al. 1988):  
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where Kd is the dissociation constant, F is the measured fluorescence, F0 is the 
fluorescence in the absence of NMPP, ΔF is the quenched fluorescence, Et is the total 
protein concentration, and L is the total NMPP concentration.   
 
Transient kinetic analysis of ferrochelatase activity 
The kinetic steps involved in NMPP binding to ferrochelatase were assessed using 
stopped-flow absorption spectroscopic analysis by monitoring the enzymatic reaction in 
the presence of various concentrations of the inhibitor NMPP.  The reactions were run on 
an OLIS model RSM-1000 stopped-flow spectrophotometer equipped with a stopped-
flow mixer and observation chamber of 4 mm optical path-length.  The dead time of the 
instrument is ~2 ms.  Wavelength scans spanning 347 nm to 574 nm were collected at 
1000 scan/sec. The syringes containing the reaction components and the stopped-flow 
cell were maintained at 30 °C using an external water-bath. The concentrations of 
reagents loaded into each syringe were twice the final concentrations in the observation 
chamber upon mixing, which were reported as the actual values. Enzymatic activity was 
monitored by following the increase in absorbance at 420 nm for zinc-protoporphyrin 
production using Zn2+ and protoporphyrin as substrates.  
The enzyme and substrate stock solutions were diluted in a buffer of 100 mM 
Tris-acetate pH 8 containing 0.5% (v/v) Tween-80.  A 3 mM zinc-acetate stock solution 
was made by dissolving zinc-acetate in ddH2O.  A 200 μM protoporphyrin stock solution 
was prepared by dissolving protoporphyrin in 50 mM NH4OH and 0.5% (v/v) Tween-80.  
A 2 mM N-methyl protoporphyrin stock solution was prepared by dissolving NMPP in 
100 mM NH4OH containing 0.5% (v/v) Tween-80.  Typically, a 2 mL solution 
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containing 1 μM ferrochelatase, 10 μM protoporphyrin and various amounts of NMPP 
was pre-incubated on ice for 30 min.  The mixture was subsequently transferred to one of 
the stopped-flow syringes.  The other stopped-flow syringe was loaded with ~2 mL 
reaction buffer containing 30 μM zinc-acetate.  The enzymatic reaction was initiated by 
mixing the contents from both syringes.  Reaction progression was monitored by 
following the increase in absorbance at 420 nm.  The data were analyzed by fitting the 
absorbance values to Equation 3: 
( )ktss ek vvtvAA −−−++= 100         (Eq.3) 
where A is the observed absorbance, A0 is the initial absorbance, νs is the steady-state 
velocity, ν0  is the initial velocity, and k is the pseudo-first order rate constant for inhibitor 
binding.  Equation 3 describes the progress of enzymatic reactions in the presence of 
tight-binding competitive inhibitors (Williams and Morrison 1979).  
 
Ligand binding pocket size measurement  
Structural models of wild-type ferrochelatase and variants P255R and P255G 
were generated using the amino acid sequence and coordinates for human ferrochelatase 
(PDB code 1hrk) as a template.  Sequence alignments, molecular modeling, energy 
minimization and PROCHECK model analysis were performed on the Geno3D servers at 
the Institute of Biology and Chemistry of Proteins (IBCP) in France (Combet et al. 2002).  
Dimensions of the porphyrin binding pocket in the monomeric models of wild-type 
protein and the variants were calculated on the CASTp server (Liang et al. 1998).  Values 
for the area and volume of Connolly’s surface of the active site cavity were determined 
using the CAST program (Liang et al. 1998).  
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Enzymatic activity of ferrochelatase in the absence of FeS cluster synthesis 
RZ4500 cells (iscS+) developed large colonies on LB/agar plates, whereas small 
colonies of PK4331 cells (iscS-) were formed on LB/agar plates containing 30 μg/mL 
kanamycin after overnight incubation 37 oC upon inoculating the cells stored as frozen 
glycerol stock (Schwartz et al. 2000).   Competent cells of both strains were prepared for 
electroporation following previously described procedures.  RZ4500 cells from a single 
colony were inoculated into 10 mL LB medium and grown overnight at 37 oC with 
shaking at 220 RPM.  The saturated culture was diluted 100-fold into 1 liter LB medium, 
and grown at 37 oC with shaking at 220 RPM until OD600 reached ~0.6, which usually 
took ~2 hr.  Cells were washed twice in H2O, then twice in 10% glycerol.  Cells were 
resuspended in 5 mL of 10% aqueous glycerol.  Aliquots of 0.5 mL suspension were 
rapidly frozen and stored at -80 oC.  PK4331 cells from a single colony were inoculated 
into 40 mL LB medium containing 30 μg/mL kanamycin and grown overnight at 37 oC.  
The saturated culture was diluted 100-fold into 4 liter LB/kanamycin medium, and grown 
at 37 oC with shaking at 220 RPM until OD600 reached ~0.6, which took ~6 hr.  Cells 
were washed twice in H2O, then twice in 10% glycerol.  Cells were resuspended in 20 
mL 10% glycerol.  Aliquots of 0.5 mL suspension were rapidly frozen and stored at -80 
oC. 
Aliquots of 40 μL electro-competent RZ4500 cells and 100 μL electro-competent 
PK4331 cells were mixed separately with plasmids encoding wild-type ferrochelatase, 
single mutant C341A, triple mutants S249A/K250Q/V251C and S249A/K250R/G252W.  
The mixtures were transferred to pre-chilled 0.1 cm electroporation cuvettes and 
81 
electroporated at 1.8 KV, 25 μF using a Bio-Rad Gene Pulser.   Transformation of 
RZ4500 cells was grown in SOB medium at 37 oC for 1 hr and plated onto LB/ampicilin 
plates.  Transformation of PK4331 cells was grown in SOB medium at 37 oC for 5 hr and 
plated onto LB/ampicilin/kanamycin plates.  Subsequently, 50 mL MOPS culture was 
grown for each transformant.  The culture was pelleted, and the pellet was resuspended in 
20 mM TrisCl pH 8 and 10% glycerol.  The resuspension was passed through French 
press twice, and the lysate was solubilized by incubating with 0.6 M NaCl and 0.5% 
NaCholate with stirring at 4 oC for 30 min.  10 mL total lysate was obtained for each 
transformant.  Enzymatic activity was measured using a zinc-chelatase assay as described 
previously (Shi and Ferreira 2004).  A 2 mL reaction mixture was set up by adding 200 
μL cell lysate, 3 μM ZnCl2 and 2 μM protoporphyrin in a buffer of 100 mM TrisCl pH 
7.6, and the mixture was incubated for 1 hr at 37 oC.  The amount of ZnPP formed was 
measured by monitoring fluorescence at 592 nm upon excitation at 421 nm.  
 
Molecular mass assessment of purified ferrochelatase  
The molecular mass of purified ferrochelatase was assessed using size exclusion 
column chromatography.  A 100 x 2 cm HPLC column packed with ~150 mL Superdex-
200 resin was equilibrated with 20 mM TrisCl pH 8 containing 150 mM NaCl and 5% 
glycerol.  The flow rate was 0.4 mL/min.  Purified wild-type ferrochelatase and variants 
S249A/K250R/G252W and S249A/K250Q/V251C were injected in 100-200 μL aliquots 
at a protein concentration of 240-800 μM.  Elution fractions were collected at 1 mL 
intervals, and absorbance at 280 nm of each fraction was measured using a Shimadzu 
UVPC-2100U dual-beam spectrophotometer with 1 cm path-length cuvette at 23 oC.  The 
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column was calibrated using marker proteins of known molecular masses which included 
amylase (200 kDa), alcohol dehydrogenase (150 kDa), albumin (66 kDa), carbonic 
anhydrase (29 kDa) and cytochrome c (12.4 kDa).  Enzymatic activity of the eluted 
protein was determined using a zinc-chelatase assay as described previously (Shi and 
Ferreira 2004).   
Dynamic light scattering was used as an alternative method for molecular size 
measurement.  Approximately 1 mg each of the purified wild-type ferrochelatase and 
variants S249A/K250Q/V251C and S249A/K250R/G252W was diluted into a 4 mL 
buffer of 20 mM TrisCl pH 8 containing 150 mM NaCl, 0.5% NaCholate and 10% 
glycerol.  The molecular mass distribution in each sample was analyzed at 23 oC on a 
particle size analyzer at the Particle Engineering Research Center at the University of 
Florida.   
 
Electron paramagnetic resonance spectroscopy of purified ferrochelatase 
EPR spectra were collected for wild-type ferrochelatase and variants 
S249A/K250R/G252W and S249A/K250Q/V251C.  Wild-type protein was purified 
using blue-sepharose affinity resin (Ferreira 1994; Shi and Ferreira 2003) or Talon metal 
chelate affinity resin (Shi and Ferreira 2004), while the variants were purified using 
Talon resin as described previously (Shi and Ferreira 2004).  X-band EPR spectra were 
collected in collaboration with Dr. David Tierney at the University of New Mexico.  
Purified proteins were reduced by titrating with dithionite at an equal molar ratio.  
Samples in the concentration range of 190-400 μM were analyzed by spectroscopy.   
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Chapter Three 
 
Results 
 
Purification of recombinant ferrochelatase 
 
Large-scale purification of wild-type ferrochelatase and loop variants 
In order to obtain large quantities of purified ferrochelatase for characterization, 
recombinant wild-type protein and variants were isolated from an overexpression system 
by growing the BL21 cells or DH5α transformants in complete MOPS media.  Wild-type 
protein and selected variants were typically purified by affinity column chromatography 
using blue-sepharose resins or metal chelate resins.  Interestingly, while certain variants, 
including triple mutant K250M/V251L/W256Y, were difficult to purify by either blue-
sepharose or Ni-NTA agarose resins following the standard procedures, the problem was 
circumvented by applying cobalt-based metal chelate affinity resins (Talon resins).  
Subsequently, Talon resins were used routinely to purify His-tagged ferrochelatase.  On 
average, 1-2 mg purified proteins could be obtained from 1 liter culture.  The yield was 
lower for some variants including K250M/V251L/W256Y and 
Q248P/S249G/K250P/G252W by 2-3 fold compared to wild-type ferrochelatase.  
Typically, purified proteins were concentrated to 1-10 mg/mL (20-200 μM) and stored in 
liquid N2. 
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The UV-visible absorption spectra of purified ferrochelatase exhibit distinct 
features derived from the FeS cluster (Figure 5).  In wild-type ferrochelatase, one 
monomeric unit is associated with one [2Fe-2S] cluster, giving rise to the characteristic 
absorbance band at 330 nm and shoulders at 440 nm and 525 nm.  Typically, for wild-
type protein, the absorbance ratio A330/A278 is 3 and A440/A278 is 6.  Most variants 
exhibited UV-visible spectra similar to wild-type ferrochelatase.  Variants 
S249A/K250R/G252W and S249A/K250Q/V251C showed absorption features with 
some alterations and were further analyzed.  Purity of the proteins was checked by SDS-
PAGE.  Similar to wild-type ferrochelatase, purified variants migrated on the SDS-PAGE 
gel with an estimated molecular mass of 42 kDa (Figure 6).  
 
Small-scale purification of ferrochelatase loop variants 
All of the 33 active variants generated in the random library were over-expressed 
and purified from BL21 cells using a Talon-HT 96-well plate.  The yield of purified 
proteins obtained by the plate method was similar to that obtained from large-scale 
cultures.  Typically, 1-2 μg ferrochelatase could be isolated from 1 mL MOPS culture.  
Purified proteins, 20-200 μg in total, were concentrated to 200 μL for use in the 
concentration range of 0.1-1 mg/mL (2-20 μM).  The triple mutant 
S249A/K250R/G252W was produced at a lower yield of ~0.3 μg/mL culture.  The lowest 
yield was observed in the double mutant V254I/L257K, which could only be obtained at 
~0.01 μg/mL culture.    
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Figure 5.  The UV-visible absorbance spectra of purified wild-type murine 
ferrochelatase and selected loop variants.  
The recombinant wild-type ferrochelatase and variants were over-produced in E. coli 
DH5α or BL21(DE3) cells and purified using blue-sepharose or metal chelate affinity 
column chromatography.  The absorption spectra are shown for: (a) wild-type protein 
(8.8 μM), (b) single mutant V251L (15.2 μM), (c) triple mutant 
S249A/K250Q/V251C (18.8 μM), (d) triple mutant K250M/V251L/W256Y (10.5 
μM), (e) quadruple mutant Q248P/S249G/K250P/G252W (19.4 μM).   Similar to 
wild-type ferrochelatase, most variants exhibited the electronic absorption features 
characteristic of [2Fe-2S] cluster-containing proteins, including absorption bands at 
330 nm, and shoulders at 440 nm and 525 nm.  Variant S249A/K250Q/V251C lacked 
the absorption shoulder at 440 nm.  
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Figure 6.  SDS-polyacrylamide gel electrophoresis of purified ferrochelatase.   
Migration of purified murine ferrochelatase with N-terminal 5X-His-tag on 15% SDS-
polyacrylamide gel is shown.  The estimated apparent molecular mass for wild-type 
protein (10 μg) was 42 kDa (lane 2).  Variant Q248P/S249G/K250P/G252W (5 μg) 
exhibited a similar size (lane 3).   
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Developing a continuous assay for steady-state kinetic analysis of ferrochelatase 
A continuous assay was developed to determine ferrochelatase activity based on 
the fluorescence properties of porphyrin.  The substrate protoporphyrin IX is fluorescent, 
whereas the reaction product protoheme does not fluoresce.  Thereby, it was possible to 
monitor the progress of the ferrochelatase-catalyzed reaction with ferrous iron and 
protoporphyrin IX as substrates by following the decrease of protoporphyrin 
fluorescence.  To minimize inner filter effect associated with excitation in the Soret band 
at 406 nm, porphyrin fluorescence was monitored using λex= 505 nm and λem = 635 nm 
(Figure 7).  Strictly anaerobic conditions were imposed during the assay in order to 
maintain iron substrate in the reduced state.  Reactions were conducted at the optimal pH 
of 8, and 0.5% (v/v) Tween-80 was included in the medium to optimize solubilization of 
protoporphyrin.  Under these conditions, the initial rate of the reaction was obtained from 
the slope of the progress curve by monitoring the disappearance of substrate porphyrin 
fluorescence (Figure 8).  The rate of porphyrin disappearance was found to be linearly 
dependent on the concentration of wild-type enzyme in the range of 25-150 nM (Figure 
9).  Thus, the assay allows enzymatic activity to be determined for ferrochelatase in the 
nM concentration range, in contrast to the conventional pyridine-hemochromogen 
method, which requires a relatively large amount of protein (>100 nM).  Steady-state 
kinetic analysis of wild-type ferrochelatase indicates that the enzymatic activity exhibited 
hyperbolic dependence on protoporphyrin concentration at various ferrous iron 
concentrations (Figure 10).  The calculated Km values for protoporphyrin IX and ferrous 
iron are 1.4 ± 0.2 μM and 1.9 ± 0.3 μM, respectively, while kcat is 4.0 ± 0.3 min-1.  
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Figure 7.  The fluorescence spectra of protoporphyrin.    
The spectra were shown for protoporphyrin IX (1 μM) in assay buffer containing 100 
mM Tris-acetate pH 8 and 0.5% (v/v) Tween-80.   (A) The excitation spectrum 
displayed four distinct bands at 406 nm, 505 nm, 541 nm and 576 nm (λem = 635 nm).  
(B) The emission spectrum exhibited a maximum at 635 nm (λex = 505 nm).   
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Figure 8.  Time course for the disappearance of protoporphyrin in the 
ferrochelatase-catalyzed reaction.   
Wild-type murine ferrochelatase (176 nM) was pre-incubated with protoporphyrin (2.7 
μM) at 30 oC under strictly anaerobic conditions.  Reaction was initiated by addition 
of ferrous iron (5 μM).  The decrease in fluorescence intensity at 635 nm (λex = 505 
nm) was continuously monitored over the course of the reaction.  The initial rate was 
determined from the slope of the tangent to the initial, linear part of the progress 
curve.  
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Figure 9.  Dependence of the initial rate of protoporphyrin consumption on 
ferrochelatase concentration.   
Initial rates were determined for enzymatic reactions by the continuous assay using 
protoporphyrin (2 μM), Fe2+ (4 μM) and purified wild-type ferrochelatase at various 
concentrations.  
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Figure 10.  Determination of the steady-state kinetic parameters of wild-type 
murine ferrochelatase.  
Enzymatic activity was measured using a continuous assay conducted at 30 oC under 
strictly anaerobic conditions.  The reactions contained purified ferrochelatase (70 nM), 
protoporphyrin and ferrous iron.   The hyperbolic curves represent the best fits to the 
Michaelis-Menten equation by plotting initial velocity against protoporphyrin 
concentration at constant Fe2+ concentrations of 0.5 μM (▲), 1 μM (□), 2 μM (●), 3 
μM (∇) and 4 μM (■).  The steady-state kinetic parameters of the wild-type 
ferrochelatase were determined to be KmPPIX = 1.4 ± 0.2 μM, Km Fe2+ = 1.9 ± 0.3 μM, 
and Vmax = 97.4 ± 7.9 nmol min-1 mg-1 enzyme.    
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Characterization of the functional ferrochelatase loop variants 
Crystal structural analysis of ferrochelatase reveals that the enzymes exhibit 
similar folding patterns and active site structures throughout evolution.  Each monomeric 
unit consists of two domains, with each domain folded into a Rossmann-type fold.  The 
active site is located in a deep cleft between the two domains.  One side of the cleft is 
formed by the first two N-terminal α-helices, α1, α2, and a loop between them, and the 
other side consists of a short loop sequence  (Al-Karadaghi et al. 1997; Lecerof et al. 
2000; Wu et al. 2001; Karlberg et al. 2002).  The loop motif exhibits a high degree of 
sequence identity among all known ferrochelatases (Figure 11).  The loop has been 
proposed to be directly involved in porphyrin interaction based on molecular dynamics 
calculations of B. subtilis ferrochelatase with bound nickel-protoporphyrin (NiPP) 
(Franco et al. 2000) and crystal structural analysis of ferrochelatase with the heme analog 
N-methyl mesoporphyrin bound in the active site (Lecerof et al. 2000).  To test this 
hypothesis, random mutations were introduced to the ten consecutive loop residues 
Q248-L257 in murine ferrochelatase and functional variants were further characterized.  
 
Biological selection of the active loop variants 
By incorporating a mixture of four nucleotides at each of the 30 bases in the target 
sequence, random substitutions were generated simultaneously in all the residues.  Using 
a combination of 85% of the wild-type nucleotides and 15% of the other three nucleotides 
at each position, the bias was set towards the wild-type sequence, thus increasing the 
probability of recovering active ferrochelatase variants.  Under these conditions, a full 
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Figure 11.  Sequence alignment of the loop motif in ferrochelatase.  
A representative subset illustrates high degree of identity in the loop motif among all
known sequences of ferrochelatase.  The amino acid sequences were obtained from NCBI
using BLAST search and aligned using CLUSTAL W (Thompson et al. 1994). 
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spectrum of permissible substitutions at each position was drawn.  To eliminate 
background activity from wild-type enzyme, a mock vector was constructed by replacing 
a segment of wild-type ferrochelatase plasmid with a nonfunctional stuffer sequence, and 
it was used as the cloning vector for the random nucleotide sequences.  In order to select 
the functional variants, E. coli strain Δvis was chosen as the host for the plasmid library 
containing the randomized loop sequences.  Because Δvis cells need hemin in the growth 
media for survival, transformants of Δvis cells carrying the mock vector with inactivated 
ferrochelatase could not grow in hemin-free media, while Δvis cells transformed with a 
functional ferrochelatase expression plasmid could override the requirement for hemin 
and form colonies on hemin-free plates.  Screening of the unselected library by genetic 
complementation showed that 90% of the random mutants were inactive.  This is 
consistent with the hypothesis that the loop motif is important for enzymatic function, 
and also demonstrates that the biological selection procedure was efficient.  From a total 
of 2,210 Δvis transformants harboring randomized loop mutations, 214 clones were able 
to grow in hemin-free medium, and the plasmids were sequenced to identify nucleotide 
changes in the loop region.  Most of them were single, double and triple mutants, with an 
average of 2.2 amino acid changes (Figure 12A).  For a relatively quick assessment of the 
active library, all of the functional Δvis transformants were assayed for enzymatic activity 
by monitoring zinc-protoporphyrin production using crude cell extracts.  Most variants 
showed zinc-chelatase activity reduced to less than 60% of the wild-type level, whereas a 
subset of triple mutants displayed activities comparable to, or even higher than, wild-type 
ferrochelatase (Figure 12B).  
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Figure 12.  Activity assessment and distribution of the number of the functional loop
variants.  
(A) Distribution of the number of the functional variants relative to the number of amino
acid changes.  Random substitutions were introduced into the ten residues encoding the
murine ferrochelatase loop motif.  Active variants were recovered by genetic
complementation in the E. coli strain Δvis, and mutations were identified by DNA 
sequencing.  (B) Zinc-chelatase activity of the variants relative to the number of amino
acid substitutions.  Zinc-chelatase activity was assayed by monitoring zinc-
protoporphyrin formation using cell extracts prepared from Δvis cells transformed with 
the active variants.  Enzymatic activity of each variant was normalized to the activity
level of wild-type enzyme.  
B 
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Distribution of the functional amino acid substitutions 
The spectrum and frequency of substitutions observed in the active variants are 
shown in Figure 13.  Functional mutations were detected at every residue in the loop 
motif.  However, single mutants were only recovered at five positions, i.e., K250, V251, 
P253, V254 and P255, and they are grouped as low informational content residues.  
Changes were mostly conservative at K250 and V251, while P253, V254 and P255 
tolerated a diverse set of alterations.  Mutations in any of the remaining five residues 
were rare and only occurred in conjunction with substitutions at other positions, and 
thereby they contain high informational content.  Permissible replacements at Q248, 
S249, G252, W256 and L257 were very restricted, with the exception of G252, which 
could be converted to residues of various sizes and charges in the context of double, 
triple, quadruple and penta mutants. 
 
Steady-state kinetic analysis of the active loop variants 
Five active variants were purified to homogeneity and characterized by steady-
state kinetic analysis.  The single mutant V251L was selected because it was the only 
point mutation allowed at the low information content residue V251 and was also co-
selected in a number of double, triple and quadruple mutants.  The single mutant P255R 
was selected because, although P255 has low information content, arginine replacement 
was a drastic amino acid alteration and was observed in single, double and quadruple 
mutants (Figure 13).  Due to the lack of single substitutions at the high information 
content positions, multiply-substituted variants were chosen for further analysis (Figure 
13).  By characterizing the triple mutants S249A/K250Q/V251C, K250M/V251L/W256Y 
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Single  mutants
K 5 G 1
N 2 L 15 T 4 N 22 R 12
Q248 S249 K250 V251 G252 P253 V254 P255 W256 L257
Double  mutants
N 4 A 4 A 11
Q 5 I 12 I 46
T 1 L 1 D 41 H 1 L 5 R 1 K 6
Q248 S249 K250 V251 G252 P253 V254 P255 W256 L257
Triple  mutants
G 2  
M 3
N 2 A 7 A 2
Q 28 C 10 G 2 D 1
R 1 D 16 K 6 H 16
S 1 I 11 R 18 L 8 G 1 S 2
T 4 A 17 T 6 L 3 W 1 Q 8 M 16 T 24 Y 3 Q 6
Q248 S249 K250 V251 G252 P253 V254 P255 W256 L257
Quadruple  mutants
M 1
N 1 A 5
A 1 P 1 F 5 S 1
P 1 G 1 T 5 L 1 W 1 A 5 L 1 R 1 G 1
Q248 S249 K250 V251 G252 P253 V254 P255 W256 L257
Penta  mutant
P 1 G 1 R 1 V 1 G 1
Q248 S249 K250 V251 G252 P253 V254 P255 W256 L257  
 
Figure 13.  Spectrum and frequency of amino acid substitutions in functional loop 
variants.   
Mutations at each residue are listed along with the number of times each substitution was
observed.  The wild-type loop sequence is shown on the bottom of each mutant category.  
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and the quadruple mutant Q248P/S249G/K250P/G252W, attempts were made to examine 
the mutational effects of Q248, S249, G252 and W256 in combination with changes at 
other positions.  
Steady-state analysis indicated that, with exception of the triple mutant 
K250M/V251L/W256Y, all of the variants had kcat values comparable to or higher than 
that of wild-type ferrochelatase (Table 1).  There was a 2-fold increase in kcat for the 
single mutants V251L and P255R, 4.5-fold increase for the triple mutant 
S249A/K250Q/V251C, and 3.5-fold increase for the quadruple mutant 
Q248P/S249G/K250P/G252W.  Relative to wild-type enzyme, the Km values for 
protoporphyrin (KmPPIX) were elevated ranging from a 2-fold increase for the single 
mutant P255R to 8-fold for the triple mutant K250M/V251L/W256Y, suggesting that the 
interaction with the porphyrin substrate was disrupted due to the loop mutations (Table 
1).  The Km values for ferrous iron (KmFe2+) in the single mutants V251L and P255R and 
triple mutant K250M/V251L/W256Y were of the same order of magnitude as that in 
wild-type enzyme.  The KmFe2+ value was 2.5-fold higher for the triple mutant 
S249A/K250Q/V251C, while a 4-fold decrease was observed for the quadruple mutant 
Q248P/S249G/K250P/G252W (Table 1).  
  
Homology modeling of wild-type murine ferrochelatase and selected loop variants 
To assess how loop mutations could possibly affect the three-dimensional 
structure of ferrochelatase and the active site architecture, structural models of the 
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Table 1.  Steady-state kinetic parameters of wild-type ferrochelatase and selected 
loop variants. 
Ferrochelatase activity was determined by a continuous assay using protoporphyrin and 
Fe
2+
 as substrates (Shi and Ferreira 2003).  The assays were conducted at 30 
o 
C under 
strictly anaerobic conditions.   Steady-state kinetic parameters were determined using 
matrices of concentrations for both substrate protoporphyrin and Fe2+ (Shi and Ferreira 
2004).  
Proteins 
kcat  
  (min-1) 
KmPPIX    
(μM) 
kcat / KmPPIX 
(min-1 μM-1)
KmFe2+  
  (μM) 
kcat / KmFe2+ 
(min- 1 μM-1)
Wild-type ferrochelatase 4.1 ± 0.3 1.40 ± 0.20 2.93 1.90 ± 0.30 2.16 
V251L 8.3 ± 1.2 1.82 ± 0.35 4.56 1.13 ± 0.53 7.35 
P255R 7.8 ± 0.8 2.65 ± 0.44 2.94 1.46 ± 0.38 5.34 
S249A/K250Q/V251C 18.0 ± 2.5 6.84 ± 1.74 2.63 5.15 ± 1.44 3.50 
K250M/V251L/W256Y 3.0 ± 0.4 11.25 ± 2.45 0.27 1.08 ± 0.48 2.78 
Q248P/S249G/K250P/G252W 14.1 ± 0.9 10.34 ± 1.14 1.36 0.48 ± 0.21 29.40 
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wild-type protein and loop variants were generated using the crystal structure of human 
ferrochelatase as a template.  The sequences used in modeling wild-type and mutant 
murine ferrochelatase were at least 91% similar to the human ferrochelatase template.  
The average free energy of the structural models was approximately 16 kcal/mol.  The 
Ramachandran plots showed a normal distribution of points with at least 99% residues 
occupying the allowed regions.  C-α chirality, amide torsion (ω) and side chain torsions 
(χ1 and χ2) showed no major deviation from the corresponding allowed values.  
Superimposition of the monomeric model of wild-type murine ferrochelatase with the X-
ray crystal structure of human ferrochelatase gave a RMSD of 1.23 Å for the Cα-atoms 
of the 357 aligned residues.  Structural models of the loop variants (Figure 14) exhibited 
slightly more resemblance to human ferrochelatase, as indicated by a small reduction in 
RMSD values (~0.8-0.9 Å).   
In the wild-type model, the N-terminal loop residues Q248 and S249 were buried 
deeply inside the active site cavity and in very close proximity  (about 4 Å) to H209 and 
E289, which were previously proposed to be essential for catalysis (Kohno et al. 1994; 
Gora et al. 1996b; Franco et al. 2001; Sellers et al. 2001).  K250 was solvent-exposed 
with the side chain projecting to the protein exterior and in close contact with the Q260 
residue.  V251 oriented its side chain towards the interior of the active site pocket, while 
G252 occupied the tip of the loop, and together with P253, V254 and P255, formed a 
solvent-exposed patch.  The indole ring of W256 was positioned nearly perpendicular to 
the H209 and E289 side chains, a d L257 was exposed to the protein surface with the side 
chain extended away from the active site pocket.  The spatial arrangement of the loop 
residues was not significantly altered by the functional substitutions in the selected  
101 
Figure 14.  Molecular modeling of wild-type murine ferrochelatase and selected loop 
variants.  
The structural models (monomeric) were generated by homology modeling on Geno3D 
servers (Combet et al. 2002) using the X-ray crystal structure of human ferrochelatase 
(PDB code 1hrk) as a template.  Substituted residues in the loop motif (red) are marked 
(green).  The color scheme for the secondary structures is: α-helix in blue, β-strand in 
yellow, 310-helix in lime, π-helix in purple, turns and coils in cyan.  The N-terminal α2 
helix and its extension in the loop variants are indicated by open arrows; the second
domain π-helix and its variations are indicated by filled arrows.  When not occluded by 
structural elements, the N- and C-termini are indicated.  The three-dimensional models 
are shown for: (A) wild-type murine ferrochelatase, (B) single mutant V251L, (C) single 
mutant P255R, (D) triple mutant S249A/K250Q/V251C, (E) triple mutant 
K250M/V251L/W256Y, (F) quadruple mutant Q248P/S249G/K250P/G252W.  Images
were generated using VMD 1.7 (Humphrey et al. 1996).  
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variants  (Figure 14).  
For all loop variants, changes in the secondary structure were observed in the N-
terminal domain forming one side of the active site cavity, and in the second domain π-
helix region located adjacent to the active site cleft (Figure 14).  At the N-terminus, 
immediately following the second α-helix (α2), the variants showed an increase of 
helical content in place of the relatively unstructured turns.  While in the structural model 
of wild-type protein the α2 helix consists of 10 residues Q52-K61 (Figure 14A), in the 
loop variants, the α2 helix was extended by a short α-helix or 310-helix to include 5-7 
additional residues (Figure 14B-F).  These additional residues along with the meandering 
loop that follows appear to contact residues in the second domain of the enzyme close to 
the active site cavity.   
The structural model of wild-type murine ferrochelatase revealed a short π-helix, 
consisting of five residues 290TLYEL294 in the second domain near the bottom of the 
active site pocket (Figure 14A), in an analogous fashion to the π-helix observed in the 
crystal structures of human (349ELDIE353) and yeast (318EIDLG322) ferrochelatases (Fodje 
and Al-Karadaghi 2002).   This π-helix was replaced by an α-helix in the triple mutant 
S249A/K250Q/V251C (Figure 14D).  In contrast, the quadruple mutant 
Q248P/S249G/K250P/G252W had a long π-helix comprising the 289ETLYELDIEY298 
sequence, which is enriched with acidic residues (Figure 14F).  In the single mutants 
V251L and P255R and the triple mutant K250M/V251L/W256Y, the π-helix shifted 
positions slightly to include two glutamate residues (Figure 14B, 14C, 14E).  In these 
structures, the π-helix was formed by groups of five residues including 293ELDIE297 in 
V251L and P255R and 289ETLYE293 in K250M/V251L/W256Y.  
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Interaction of ferrochelatase with mitochondrial membrane lipids  
Polarity distribution among the functional substitutions in the loop variants 
indicated that mutations in the three N-terminal loop residues, Q248, S249 and K250, 
reduced the hydrophilic environment of the N-terminal looplet (Figure 15A).  
Conversely, the seven non-polar C-terminal residues V251-L257 were replaced by 
mostly polar, acidic or basic amino acids (Figure 15A).  Furthermore, basic amino acid 
substitutions were enriched in the C-terminal loop region of the active variants.  In order 
to examine potential interaction of the variants with the negatively-charged membrane 
lipids, liposomes were formulated to mimic lipid composition of the mouse liver inner 
mitochondrial membrane, with which ferrochelatase is associated in vivo.  The average 
diameter of liposomes was determined to be approximately 170 nm by dynamic light 
scattering.  Liposomal binding assay results indicated that affinities for the membrane 
lipids can be modified by loop mutations (Figure 15B).  In general, the variants carrying 
basic residues in the C-terminal looplet exhibited stronger interaction with liposomes 
than wild-type protein, implying that the localized positive charges favor lipid interaction 
(Figure 15C).   
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Figure 15.  Interaction between ferrochelatase and the mitochondrial membrane 
lipids.   
(A) Polarity distribution at each loop position in the functional variants.  Basic amino 
acid substitutions accumulated in the C-terminal looplet positions G252, P253, V254, 
P255 and L257.  Hydrophobic residues include A, F, G, I, L, M, P, V and W; polar
residues include C, N, Q, S, T and Y; acidic residues include D and E; basic residues
include H, K and R.  (B) Protein-lipid interactions among wild-type ferrochelatase and 
active loop variants.  Proteins were purified in a 96-well format, spotted onto 
nitrocellulose membrane in a dilution series, and probed with biotinylated liposomes.
Bound liposomes were detected using peroxidase-conjugated extravidin and visualized 
using the enhanced chemiluminescence (ECL) system.  Examples are shown for 
enhanced lipid-binding to variant P253Q/V254K/P255T (row 1) and decreased binding to 
variant Q248P/S249G/K250P/G252W (row 2) relative to the wild-type protein (row 3). 
The variant G252D/V254I (row 4) was included as an internal control.  (C) Analysis of 
liposomal binding affinities of the active variants.  The right panel illustrates the
liposome-binding affinity of each variant normalized against that of the wild-type 
ferrochelatase.  The left panel indicates the polarity of individual loop residues in each
variant using a color code corresponding to: blue for hydrophobic residues, yellow for 
polar residues, black for acidic residues, and red for basic residues.  Mutated positions in 
each variant are marked by an X.  
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Resonance Raman spectroscopic analysis of porphyrin binding in the loop variants 
An important step in the enzymatic reaction catalyzed by ferrochelatase involves 
distortion of the porphyrin macrocycle to expose the lone-pair orbitals of pyrrole 
nitrogens to incoming metal ion, thereby facilitating metal chelation.  In order to assess 
the role of the loop residues in porphyrin deformation, the vibrational modes of 
porphyrins bound to wild-type enzyme and loop variants were examined by resonance 
Raman spectroscopy.  
 
Binding of substrate protoporphyrin to the variants  
Substrate (i.e., free-base protoporphyrin) binding in the active site of 
ferrochelatase loop variants was examined at a 0.1 porphyrin / protein molar ratio using 
RR spectroscopy in a similar fashion to that previously devised for wild-type murine 
ferrochelatase (Lu et al. 2002).  The RR spectra of the variant-bound porphyrin exhibited 
clear differences from those of unbound porphyrin in the detergent miscelle environment 
and porphyrin bound to wild-type enzyme (Figure 16).  In the low-frequency region, as 
was found previously for wild-type ferrochelatase [(Lu et al. 2002) and Figure 16A, 
spectrum b], the ν7 line upshifted from 666 cm-1 for unbound porphyrin in the 
equilibration buffer to 673-675 cm-1 in four variants (Figure 16A, spectra d-g); the largest 
shift (to 677 cm-1) was detected in porphyrin bound to the triple mutant 
K250M/V251L/W256Y (Figure 16A, spectrum c).  The ν16 line was at 738 cm-1 for 
unbound porphyrin (Figure 16A, spectrum a) and its intensity and frequency were 
reduced upon binding to wild-type protein and four variants (Figure 16A, spectra b, d-g)  
106 
 
 
 
Figure 16.  The resonance Raman spectra of protoporphyrin incubated with
ferrochelatase at a porphyrin-to-protein molar ratio of 0.1.   
The spectra are aligned in the (A) low-frequency (300-800 cm-1) and (B) high-frequency 
(1300-1700 cm-1) regions.  The spectra are shown for (a) unbound porphyrin in
equilibration buffer; (b) porphyrin bound to wild-type ferrochelatase; (c)-(g) porphyrin 
bound to loop variants including (c) triple mutant K250M/V251L/W256Y, (d) single 
mutant P255R, (e) single mutant P255G, (f) triple mutant S249A/K250Q/V251C, (g)
quadruple mutant Q248P/S249G/K250P/G252W.  Asterisks denote buffer lines. 
Vibrational bands of the major structure-sensitive modes are labeled. 
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in the triple mutant K250M/V251L/W256Y, the ν16 band was shifted to higher frequency 
albeit with diminished intensity (Figure 16A, spectrum c).  More importantly, the γ15 
mode was activated upon protein binding (Figure 16A).  The γ15 mode, a B2u symmetry 
saddling-like mode, was previously observed and attributed to saddling deformation of 
the porphyrin upon binding to wild-type enzyme (Hu et al. 1996; Lu et al. 2002).  The 
intensity of γ15 mode for porphyrin bound to the variants exhibited differences from that 
for wild-type protein.   
In the high-frequency region, the ν2 line was considerably diminished in intensity 
for porphyrin bound to both wild-type enzyme and the variants (Figure 16, spectra b-g) 
when compared to unbound porphyrin (Figure 16B, spectrum a).  In particular, the ν2 line 
upshifted by an additional 5 cm-1 in porphyrin bound to the triple mutant 
K250M/V251L/W256Y relative to wild-type protein (Figure 16B, spectra b, c), and this 
shift was the highest observed when all variants were considered and indicated important 
changes in the vinyl interaction with the protein (Figure 16B, spectra b-g).  Moreover, 
protein binding led to sharpening of the vinyl stretching mode νCa=Cb of free-base 
porphyrin (Figure 16B).  While the frequency of the νCa=Cb mode remained unchanged for 
porphyrin bound to wild-type protein and four variants (Figure 16B, spectra b, d-g), the 
νCa=Cb band was broadened and downshifted upon binding to the variant 
K250M/V251L/W256Y (Figure 16B, spectrum c), again implicating disruption of 
interaction between the porphyrin vinyl groups and the active site matrix.    
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Binding of hemin to the variants 
Interaction of the loop variants with hemin, an inhibitor of ferrochelatase (Dailey 
and Fleming 1983), was examined by comparing the RR spectra of protein-bound hemin 
with free hemin in the equilibration buffer (Figure 17).  Hemin binding to both P255 
variants resulted in a 5 cm-1 downshift of the ν2 band for P255R (Figure17B, spectrum d) 
and 4.2 cm-1 for P255G (Figure 17B, spectrum e), whereas all other variants produced 
smaller (typically 1.5 cm-1) shifts to higher frequencies (Figure 17B, spectra c, f, g).  The 
ν38 line, associated with the Cβ-Cβ and Cβ-C1 stretches, increased intensity in the variants 
P255R and P255G as compared to wild-type protein, although it did not appreciably shift 
(Figure 17B, spectra b, d, e).  Both the ν2 and ν38 lines derived from vinyl-associated 
modes, so the fact that they altered in tandem indicates significant structural changes in 
the vinyl groups of the variant-bound hemin.  In the low-frequency region, the ν7 line was 
upshifted by 1.8 cm-1 in the variant K250M/V251L/W256Y (Figure 17A, spectrum c) and 
1.5 cm-1 in the variant S249A/K250Q/V251C (Figure 17A, spectrum f) when compared 
to binding to wild-type ferrochelatase (Figure 17A, spectrum b).   
 
Binding of nickel-protoporphyrin to the variants  
NiPP is a strongly distortion-sensitive metalloporphyrin and has been shown to 
undergo deformation upon binding to wild-type ferrochelatase in previous RR studies (Lu 
et al. 2002).  Compared to unbound NiPP in the equilibration buffer, incubation with 
wild-type protein and the variants resulted in sharpening the RR lines of NiPP in the 
high-frequency region of the spectra (Figure 18B).  Protein binding also led to downshift 
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Figure  17.  The resonance Raman spectra of hemin incubated with ferrochelatase at
a hemin-to-protein molar ratio of 0.1.   
The spectra are aligned in the (A) low-frequency (300-800 cm-1) and (B) high-frequeny 
(1300-1700 cm-1) regions.  The spectra are shown for (a) unbound hemin in equilibration
buffer; (b) hemin bound to wild-type ferrochelatase; (c)-(g) hemin bound to the loop 
variants including (c) triple mutant K250M/V251L/W256Y, (d) single mutant P255R, (e)
single mutant P255G, (f) triple mutant S249A/K250Q/V251C, (g) quadruple mutant
Q248P/S249G/K250P/G252W.  Asterisks denote buffer lines.  Vibrational bands of the 
major structure-sensitive modes are labeled.  
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of the ν2 and ν10 bands of NiPP, while the vinyl stretching band νCa=Cb, was sharpened 
and enhanced in intensity (Figure 18B). Compared with NiPP bound to wild-type protein 
(Figure 18A, spectrum b), the low-frequency regions of the RR spectra for the variants 
K250M/V251L/W256Y (Figure 18A, spectrum c) and S249A/K250Q/V251C (Figure 
18A, spectrum f) exhibited broader ν7 lines and propionate lines with less pronounced 
frequency shifts.  These alterations make the spectra for the variant-bound NiPP resemble 
more closely the spectrum of unbound NiPP (Figure 18A, spectrum a) rather than that of 
NiPP bound to wild-type enzyme (Figure 18A, spectrum b).  This suggests that, relative 
to wild-type ferrochelatase, both triple mutants had lower affinity towards NiPP, or the 
bound NiPP was less conformationally constrained in the triple mutants.  
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Figure 18.  The resonance Raman spectra of nickel-protoporphyrin incubated with 
ferrochelatase at a porphyrin-to-protein molar ratio of 0.1.  
The spectra are aligned in the (A) low-frequency (300-800 cm-1) and (B) high-frequency 
(1300-1700 cm-1) regions.  The spectra are shown for (a) unbound NiPP in equilibration 
buffer; (b) NiPP bound to wild-type ferrochelatase; (c)-(g) NiPP bound to the loop 
variants including (c) triple mutant K250M/V251L/W256Y, (d) single mutant P255R, (e)
single mutant P255G, (f) triple mutant S249A/K250Q/V251C, (g) quadruple mutant 
Q248P/S249G/K250P/G252W.  Asterisks denote buffer lines.  Vibrational bands of the 
major structure-sensitive modes are labeled. 
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Inhibition of ferrochelatase by N-methyl protoporphyrin 
N-alkylated porphyrins have been known to competitively inhibit substrate 
porphyrin binding to mammalian ferrochelatase (Figure 19).  N-methyl protoporphyrin 
exhibits a very high binding affinity for ferrochelatase (Dailey and Fleming 1983; Cole 
and Marks 1984; Nunn et al. 1988)  The X-ray crystal structural analysis of B. subtilis 
enzyme with bound N-methyl mesoporphyrin indicated that the loop residues are in close 
contact with the porphyrin macrocycle (Lecerof et al. 2000).  This raises the possibility 
that mutations in the loop may modulate binding of N-alkylated porphyrins.  In order to 
test this hypothesis, loop variants were examined with respect to interaction with N-
methyl protoporphyrin.  
To find out whether loop mutations could possibly alter inhibitor binding, a subset 
of the functional loop variants including K250N, V251L, P255R, P255G, 
K250M/V251L/W256Y and Q248P/S249G/K250P/G252W were transformed into Δvis 
cells, and the cells were grown on agar plates with increasing concentrations of NMPP.  
Δvis cells transformed with variants P255R and P255G could not grow on plates in the 
presence of 20 μM NMPP, whereas Δvis cells transformed with wild-type protein and 
other variants could.  Based on this observation, P255 variants were selected for further 
characterization.  It is recognized that the current assay was not intended to be a 
comprehensive screen to cover the full spectrum of mutations that can affect interaction 
with the inhibitor.  However, it revealed the variants which behaved differently from 
wild-type enzyme and therefore provided support to the original hypothesis that mutation 
in the loop could modulate inhibitor binding.  This may serve as an initial step towards 
understanding the structural basis of ferrochelatase inhibition by N-alkylated porphyrins.  
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Figure 19.  The structural diagram of N-methyl protoporphyrin.  
An isomeric form containing methylated A ring pyrrole nitrogen atom is shown in the
diagram.  
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Equilibrium binding of inhibitor to ferrochelatase  
Binding affinity of NMPP to the enzyme was determined from fluorescence 
quenching measurements.  Intrinsic fluorescence derives from tryptophan residues in the 
protein and is sensitive to protein conformation (Eftink and Ghiron 1976).   In wild-type 
ferrochelatase, five tryptophan residues give rise to the intrinsic fluorescence which 
exhibits an excitation maximum near 280 nm and an emission maximum near 330 nm 
(Figure 20A).  The fluorescence is linearly dependent on protein concentration (Figure 
20B).  Interestingly, in a number of variants, the intensity of protein fluorescence 
appeared to be lower than that of wild-type ferrochelatase (Figure 20B).  The decrease in 
intrinsic fluorescence suggests that loop mutations lead to modification of protein 
conformation consistent with observations obtained from structural models (Shi and 
Ferreira 2004).  Because incubation of ferrochelatase with NMPP resulted in reduction of 
the intrinsic fluorescence, the dissociation constant of NMPP for the enzyme could be 
measured by quantifying the quenching effect.  While the inhibitor exhibited high affinity 
to wild-type protein with a Kd  of 9 ± 5 nM, binding affinity to the variants was decreased 
by one order of magnitude with a Kd of 160 ± 7 nM for P255R and Kd  of 300 ± 100 nM 
for P255G (Figure 21).  
  
Kinetic pathway of inhibition 
The kinetic steps involved in NMPP binding to ferrochelatase were investigated 
by monitoring enzymatic reaction with Zn2+ and protoporphyrin as substrates using 
stopped-flow absorbance spectroscopy (Figure 22A).  Kinetic traces for zinc-
protoporphyrin formation in the presence of various concentrations of NMPP were fitted 
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Figure 20.  The intrinsic fluorescence of ferrochelatase.   
(A) The excitation and emission spectra of wild-type ferrochelatase.  0.9 μM purified 
protein was diluted in 10 mM Tris-acetate pH 8 containing 0.05% (v/v) Tween-80.  The 
emission spectrum exhibited a maximum at 331 nm (λex = 283 nm), while the excitation 
spectrum showed a maximum at 283 nm (λem = 331 nm).   (B) The intrinsic fluorescence 
is proportional to protein concentration, and fluorescence intensity is diminished in the
loop variants.  Protein fluorescence was measured at 331 nm across a range of
concentrations for wild-type ferrochelatase (□), single mutant V251L (●), single mutant 
P255R (∆), quadruple mutant Q248P/S249G/K250P/G252W (♦), and triple mutant 
K250M/V251L/W256Y (○).  
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Figure 21.  Binding curves generated from protein fluorescence quenching
measurements following titration with N-methyl protoporphyrin.  
Aliquots of NMPP solution were mixed with purified ferrochelatase in quenching buffer
containing 10 mM Tris-acetate pH 8 and 0.05% (v/v) Tween-80.  The mixture was 
incubated on ice for 1 hr.  Fluorescence intensity of the solution was measured at 23 oC at 
331 nm (λex = 283 nm).  Kd for NMPP was determined by fitting data to Equation 2
( ) ( )
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−= .  Proteins used in each set of assays are: (A) 
wild-type ferrochelatase (40 nM); (B) variant P255R (250 nM); (C) variant P255G (120 
nM). 
B
C
A
117 
to Equation 3 (Williams and Morrison 1979) to obtain the pseudo first-order rate 
constants for inhibitor binding (Figure 22C):  
( )ktss ek vvtvAA −−−++= 100         (Eq.3) 
For wild-type enzyme and variant P255R, the rate constants exhibited a 
hyperbolic dependence on NMPP concentration (Figure 23A, 23B) suggesting that 
inhibitor binding occurred in two kinetic steps, i.e. 
k1
k-1
k2
FC + NMPP [FC · NMPP]1 [FC · NMPP]2k-2   
The first step was rapid and involved the initial binding of the inhibitor to ferrochelatase. 
The second step was slow, and possibly it was associated with a conformational change 
of the inhibitor-protein complex.  The hyperbola can be described by the equation:  
⎟⎟⎠
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m
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        (Eq.4) 
where k is the pseudo first-order rate constant for the approach to the steady-state phase, 
I0 is the inhibitor concentration, S0 is the initial substrate concentration, ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
m
i K
SK 01  is 
the apparent inhibition constant Kiapp, k2 and k-2  are the second step forward and reverse 
rate constants.  For wild-type protein, k2 was 6.4 ± 0.4 s-1, k-2 was 24.5 ± 0.3 s-1, and Kiapp 
was 2.8 ± 0.6 nM.  For variant P255R, k2 was 8.3 ± 1.1 s-1, k-2 was 19.3 ± 0.7 s-1, and Kiapp 
was 1.0 ± 0.5 μM.  In contrast, for variant P255G, the pseudo-first order rate constant k 
was linearly dependent upon inhibitor concentration (Figure 23C), consistent with a 
single kinetic step for NMPP binding, i.e. 
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Figure 22.  Transient kinetic analysis of the ferrochelatase-catalyzed reaction.  
Purified variant P255R (2 μM) was pre-incubated with protoporphyrin (10 μM) in 100 
mM Tris-acetate pH 8 containing 0.5% (v/v) Tween-80.  The solution was mixed with 
zinc-acetate (15 μM) to initiate enzymatic reaction.  (A) Wavelength scans of the reaction
mixture at different reaction times.  Spectra were collected at 96 ms, 144 ms, 192 ms, 240
ms and 288 ms since the inception of reaction.  Isosbestic point at 412 nm indicated
conversion of molecular species in the course of enzymatic reaction.  (B) The absorbance
spectrum of zinc-protoporphyrin.  The spectrum was shown for ZnPP (5 μM) in assay 
buffer with an absorbance maximum at 420 nm.  (C) The time course for ZnPP formation
catalyzed by ferrochelatase.  The increase of absorbance at 420 nm was continuously
monitored over the course of reaction.  Progress curve was fitted to Equation 3 
( )ktss ek vvtvAA −−−++= 100  to obtain the rate constant k for NMPP binding.  
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By fitting the line to the equation 
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the forward rate constant 
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 was determined to be 8.2 ± 0.7 s-1μM-1, the reverse rate 
constant k-1 was 18.7 ± 2.3 s-1.  Kiapp was calculated from ⎟⎟⎠
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⎛ +−
mK
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k
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1 1  and was found to 
be 2.3 μM. 
 
Size measurement of the active site pocket 
In order to compare the size of the active site in the variants with that of wild-type 
protein, the volume and Connolly’s surface area of the porphyrin-binding pocket in the 
structural models were estimated using the program CAST (Liang et al. 1998).  The 
active site of wild-type ferrochelatase was found to occupy a surface area of 2138 Å2 and 
a volume of 3015 Å3, while variant P255R had a smaller surface area of 1340 Å2 and a 
reduced volume of 1932 Å3, and variant P255G had the smallest surface area of only 
1048 Å2 and a volume of 1604 Å3.  Overall, the binding pocket size was significantly 
reduced as a result of P255 mutations.  Variant P255R retained ~70% of the volume and 
surface area relative to wild-type protein, whereas P255G only kept ~50% the size of 
wild-type porphyrin-binding pocket.  
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Figure 23.  Dependence of the rate constants for ferrochelatase binding on N-methyl 
protoporphyrin concentration.  
Ferrochelatase (0.5 μM) was reacted with protoporphyrin (5 μM) and zinc-acetate (15 
μM) in the presence of various concentrations of NMPP.  The pseudo first-order rate 
constant k for inhibitor binding was obtained from by analyzing progress curve as
described previously.  The values of k were plotted against inhibitor concentrations.  The
proteins used in each set are:  (A) wild-type ferrochelatase; (B) variant P255R; (C) 
variant P255G. 
NMPP concentration (nM)
0 5 10 15 20 25 30 35
k  
(s
ec
-1
)
24
26
28
30
32
A 
NMPP concentration (μM)
0 1 2 3 4 5 6 7
k 
(s
ec
-1
)
16
18
20
22
24
26
28
30
B
0
10
20
30
40
50
60
70
80
0 1 2 3 4 5 6 7
NMPP concentration (μM)
k 
(s
ec
-1
)
C
121 
 
FeS cluster and oligomeric assembly in ferrochelatase variants 
During profiling of the UV-vis absorbance spectra of the functional loop variants, 
a number of variants exhibited absorbance features with some differences from wild-type 
protein.  This raises the question of whether the variants have alterations in the FeS 
cluster.  Because the FeS cluster has been thought to be located near the dimer interface 
in wild-type ferrochelatase, it was suspected that dimeric interaction may be disrupted in 
the variants.  To address this issue, the variants were further examined with regard to 
their oligomerization state and the properties of FeS cluster.  
 
UV-visible absorbance spectra of the variants 
The UV-vis absorbance spectra of selected variants including triple mutants 
S249A/K250Q/V251C and S249A/K250R/G252W exhibited features somewhat different 
from wild-type protein (Figure 24).  In wild-type ferrochelatase, the absorbance 
maximum at 330 nm and the shoulder regions around 450 nm and 510 nm are consistent 
with the presence of a [2Fe-2S] cluster.  In the variants, the region around 450 nm 
appears blue-shifted to around 410 nm, while the absorbance maxima at 330 nm and 510 
nm remain.  These absorbance features bear some resemblance to those for biotin 
synthase, which contains mixtures of [2Fe-2S] and [4Fe-4S] clusters (Ugulava et al. 
2000; Ugulava et al. 2001).   
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Figure 24.  The UV-visible absorbance spectra of purified wild-type ferrochelatase 
and variants.   
The absorbance spectra are shown for (A) wild-type ferrochelatase (9 μM), (B) triple 
mutant S249A/K250Q/V251C (27 μM), and (C) triple mutant S249A/K250R/G252W 
(31 μM).  In wild-type protein, the absorbance maximum at 330 nm and the shoulder
regions around 450 nm and 510 nm are indicative of a [2Fe-2S] cluster.  In the variants, 
the absorbance shoulder region around 450 nm appears to blue-shift to around 400 nm, 
while the absorbance maximum at 330 nm and shoulder around 510 nm remain.  
A 
C 
B 
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Metal content analysis  
Determination of metal content of purified wild-type ferrochelatase and variant 
S249A/K250Q/V251C by plasma emission spectroscopy showed that the stoichiometry 
ratio of Fe/protein was 1.3 for each monomer of wild-type protein and 2 for variant 
S249A/K250Q/V251C (Shi and Ferreira 2004).  The ratio for wild-type protein is in 
agreement with a previous report indicating a stoichiometry of one [2Fe-2S] cluster per 
monomer (Lloyd et al. 1996).  The molar ratio of Fe/protein was approximately 50% 
higher in variant S249A/K250Q/V251C relative to wild-type enzyme.  
 
Dependence of enzymatic activity on FeS cluster synthesis 
The requirement of FeS cluster for enzymatic activity was assessed using the 
bacteria strain iscS- (PK4331), which is deficient in cluster assembly as a result of 
deletion of cysteine desulfurase, the sulfur donor for FeS cluster synthesis (Schwartz et 
al. 2000).  Growth in PK4331 cells rendered wild-type ferrochelatase catalytically 
inactive, whereas the enzyme was active in RZ4500 cells (Figure 25).  These results are 
consistent with the suggestion that FeS cluster is important to maintaining wild-type 
ferrochelatase activity (Sellers et al. 1998b; Schneider-Yin et al. 2000b).  Single mutant 
C341A was not functional in either RZ4500 or PK4331 cells and was used as a negative 
control (Figure 25).  Interestingly, both variants S249A/K250Q/V251C and 
S249A/K250R/G252W retained 50-75 % residual activities in PK4331 cells suggesting 
that catalysis could take place in the absence of FeS cluster assembly (Figure 25).  
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Figure 25.  Dependence of ferrochelatase activity on FeS cluster synthesis.   
RZ4500 (iscS+) and PK4331 (iscS-) cells were transformed with expression plasmids
encoding wild-type ferrochelatase, single mutant C341A, and triple mutants 
S249A/K250Q/V251C and S249A/K250R/G252W.  Enzymatic activities were 
determined by monitoring zinc-protoporphyrin formation using cell lysates prepared from 
each transformant.   
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Subunit assembly of purified ferrochelatase 
Consistent with previous observations that mammalian ferrochelatase is a 
homodimer (Straka et al. 1991; Wu et al. 2001), gel filtration chromatography of purified 
recombinant wild-type murine ferrochelatase yielded a single dimeric species with an 
approximate apparent molecular weight of 88 kDa (Figure 26).  Dynamic light scattering 
analysis showed that wild-type murine ferrochelatase in solution had an estimated 
hydrodynamic radius of 4.6 nm (Figure 27).  This is in agreement with the results 
obtained for purified human ferrochelatase, which showed a hydrodynamic radius of 4.4 
nm corresponding to an estimated molecular mass of 100 kDa for globular protein  
(Burden et al. 1999).  In contrast, gel filtration analysis of variants S249A/K250Q/V251C 
and S249A/K250R/G252W indicated the presence of higher order oligomers (Figure 
26B, 26C).  Interestingly, all of the molecular species eluted from the gel filtration 
column were enzymatically active and exhibited comparable specific activity.  Size 
distribution of the ferrochelatase oligomers was further analyzed using dynamic light 
scattering, and the results were comparable to those obtained from gel filtration 
chromatography.  Variant S249A/K250Q/V251C exhibited an estimated hydrodynamic 
radius of 20 nm suggesting that it is present as a homogeneous high molecular weight 
species in solution (Figure 27A).  Variant S249A/K250R/G252W also yielded oligomeric 
assembly larger than wild-type protein with a hydrodynamic diameter of 12.8 nm (Figure 
27B).   
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Figure 26.  Molecular weight assessment of purified wild-type ferrochelatase and 
variants by gel filtration chromatography.   
All the proteins were loaded onto a Superdex-200 HPLC column equilibrated with a 
buffer containing 20 mM TrisCl pH 8.0, 150 mM NaCl and 5% glycerol.  Purified wild-
type ferrochelatase (240 μM) and variants S249A/K250Q/V251C (600 μM) and 
S249A/K250R/G252W (800 μM) were injected separately.  Elution was monitored by
absorption at 280 nm.  (A) Calibration of the column with protein markers of known
molecular masses including amylase (200 kDa), alcohol dehydrogenase (150 kDa), 
albumin (66 kDa), carbonic anhydrase (29 kDa) and cytochrome c (12.4 kDa).  The void
volume (V0) was determined to be 38 mL based on the elution of blue dextran.  (B) 
Elution profiles of wild-type ferrochelatase (○) and variant S249A/K250Q/V251C (♦). 
(C) Elution profiles of wild-type ferrochelatase (○) and variant S249A/K250R/G252W 
(▲).    
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Figure 27.  Molecular size determination of purified wild-type ferrochelatase and 
variants by dynamic light scattering (DLS).   
Solutions of purified ferrochelatase (6 μM) in solubilization buffer containing 20 mM 
TrisCl pH 8.0, 150 mM NaCl, 0.5% NaCholate and 10% glycerol were examined on a 
particle size analyzer.  (A) DLS results for wild-type protein (○) and variant 
S249A/K250Q/V251C (♦).  (B) DLS results for wild-type protein (○) and variant 
S249A/K250R/G252W (▲).    
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Electron paramagnetic resonance spectra of ferrochelatase 
At high power level (25 mW) and high temperature (70 K), the EPR spectra of 
wild-type ferrochelatase exhibited features of a [2Fe-2S] cluster-containing protein 
(Figure 28A), consistent with the previous observations (Ferreira et al. 1994).  Both 
variants S249A/K250Q/V251C and S249A/K250R/G252W showed similar 
characteristics indicating they also contained [2Fe-2S] clusters (Figure 28B).  In order to 
examine whether [4Fe-4S] cluster was also present in the variants, temperature sweep of 
EPR signals was carried out.  Only variant S249A/K250Q/V251C was analyzed so far.  
Temperature-dependence of the signal intensity at g value of 1.93 exhibited a maximum 
at low power levels (0.002-25 mW) and became linear at higher power levels (25-200 
mW) (Figure 29).  
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Figure 28.  EPR spectra of purified wild-type ferrochelatase and variants. 
Typically purified proteins were reduced by dithionite prior to collecting EPR spectra.
X-band EPR spectra were recorded at 70 K and 25 mW.  (A) The spectra are shown for
dithionite-reduced wild-type ferrochelatase with 5X His-tag at 400 μM (▬), with 5X 
His-tag at 190 μM (▬), and without His-tag at 200 μM (▬).  The spectra of as purified 
wild-type ferrochelatase with 5X His-tag at 400 μM is also shown (▬).  (B) EPR spectra 
are shown for dithionite-reduced variants S249A/K250Q/V251C at 426 μM (▬) and 
S249A/K250R/G252W at 95 μM (▬). 
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Figure 29.  Temperature-dependence of the EPR signal intensity for a purified 
ferrochelatase variant.  
Purified variant S249A/K250Q/V251C (426 μM) was reduced with dithionite, and X-
band EPR spectra were collected.   Signal intensity at g value of 1.93 was plotted as a 
function of temperature at different microwave power levels.  
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Chapter Four 
 
Discussion 
 
Continuous assay for ferrochelatase activity 
Over the past four decades, a number of assays have been developed to determine 
ferrochelatase activity (Dailey and Dailey 2003).  One of the most commonly used 
methods is a discontinuous assay using ferrous iron and porphyrin as substrates.  In this 
method, synthesized heme is spectrophotometrically quantified following quantitative 
conversion to the pyridine-hemochromogen (Porra and Jones 1963a; 1963b; Porra et al. 
1967).  This assay facilitates quantification of enzymatic activities as low as 1 nmol 
protoheme min-1 (Taketani and Tokunaga 1981).  To maintain the iron substrate in the 
ferrous state, thiol compounds have been routinely included in the reaction mixture 
(Porra et al. 1967).  However, hemes degrade in the presence of thiol compounds (Porra 
et al. 1967); additionally, dithiothreitol competes with ferrochelatase for binding to free 
ferrous iron (Franco et al. 1995).  A second, dual-wavelength assay measures 
ferrochelatase activity by following the disappearance of the porphyrin substrate (Labbe 
et al. 1963; Porra et al. 1967; Jones 1969; Camadro and Labbe 1982).  Under these assay 
conditions, the absorption spectra of porphyrin and heme exhibit clear isosbestic points 
indicating conversion of substrate into product, and the progress of the reaction can be 
followed using electronic absorption spectroscopy (Porra et al. 1967).  While this assay 
offers the prospect for development of a continuous assay, its inherently reduced 
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sensitivity (Porra et al. 1967), compared to that of the pyridine-hemochromogen method, 
has restricted its application.  In addition, reducing reagents, such as glutathione, which 
appear to interfere with heme stability, were included in this procedure (Porra et al. 
1967).  A radiochemical assay for ferrochelatase activity quantifies the incorporation of 
59Fe into porphyrin (Goldberg et al. 1956).  However, this method has had limited use 
because of requirements for safety precautions, expense and labor (Goldberg et al. 1956; 
Jones and Jones 1968; Dailey 1977).  
To overcome the technical constraints of maintaining the iron substrate in the 
reduced state and the requirement of strict anaerobicity, alternative assays take advantage 
of the fact that ferrochelatase can catalyze the incorporation of other divalent metal ions 
(Johnson and Jones 1964; Neuberger and Tait 1964; Porra and Ross 1965; Jones 1969; 
Camadro and Labbe 1982; Taketani and Tokunaga 1982).  Indeed, a convenient method 
is to determine zinc-chelatase activity (Neuberger and Tait 1964), since the fluorescence 
of the zinc-protoporphyrin product can be followed continuously (Camadro and Labbe 
1982; Abbas and Labbe-Bois 1993).  Chelation of Co2+ has also been used to determine 
the enzymatic activity of ferrochelatase (Johnson and Jones 1964; Porra and Ross 1965; 
Jones 1969).  Cobalt-chelatase activity can be measured by the pyridine-hemochromogen 
assay or by monitoring the absorbance decrease of the porphyrin substrate (Jones 1969; 
1970; Canepa and Llambias 1988).  Despite the convenience of these assays using 
alternative metal substrates, kinetic and X-ray absorption studies (Camadro and Labbe 
1982; Ferreira et al. 2002) have provided evidence that chelation of non-physiological, 
metal substrates by ferrochelatase might not be mechanistically identical to that of the 
Fe2+ substrate.  While Fe2+ was a strong competitive inhibitor of zinc-chelatase activity, 
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Zn2+ competitively inhibited iron chelation with a Ki of only 1.5 μM (Camadro and Labbe 
1982).  Moreover, the recent X-ray absorption spectroscopy studies of metal binding sites 
in murine and yeast ferrochelatases indicated that coordination of Zn2+ was different from 
that of Fe2+ or Co2+  (Ferreira et al. 2002).   
Thus, while there are convenient methods available to determine the enzymatic 
activity of ferrochelatase, each has limitations that reduce its usefulness, particularly in 
enzyme kinetic studies.  In this study, a continuous, fluorimetric assay for ferrochelatase 
activity has been developed using the physiological substrates, ferrous iron and 
protoporphyrin, by measuring the rate of porphyrin consumption.  Using this method, the 
kinetic constants determined for the wild-type murine ferrochelatase were shown to be 
comparable to values reported for the wild-type human ferrochelatase (Table 2).  
Overall, the continuous assay offers significant advantages over the existing 
procedures.  Because the time course of reaction can be monitored by following the 
decrease of porphyrin fluorescence, this assay allows the initial rate to be determined 
from the slope of progress curves at the inception of enzymatic reaction, and thereby 
eliminates the problem of non-linearity in velocity calculations in end-point assays which 
results from prolonged incubation.  By imposing strictly anaerobic conditions, the assay 
permits the determination of ferrochelatase activity for the physiological substrate, 
ferrous iron, instead of metal ion substitutes, such as Zn2+ and Co2+.   Additionally, 
reducing agents are eliminated in the reaction, including the thiol-containing compounds, 
which are known to promote heme degradation (Porra et al. 1967).  The reaction medium  
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Ferrochelatase 
source 
Vmax  
(nmol mg-1 
min-1) 
KmPorp  
(μM) 
KmFe2+ 
(μM) 
Porphyrin 
substrate 
Reducing 
agent 
Assay Method Ref. 
Murine 
(recombinant) 
97.4 1.4 1.9 
Proto-
porphyrin 
None 
Continuous 
fluorimetric 
Assay 
(Shi and Ferreira 
2003) 
Murine 
(recombinant) 
136 95 112.5
Deutero-
porphyrin 
DTT 
Hemochromogen 
assay 
(Ferreira 1994)  
Human 
(recombinant) 
165 a 9.3 a 9.0 a 
Proto-
porphyrin 
Not specified 
in the text 
Porphyrin 
absorbance 
decrease 
(Sellers et al. 
2001) 
Human 
(recombinant) 
--- 8.19 a 9.35 a
Proto-
porphyrin 
β-mercapto-
ethanol 
Hemochromogen 
assay 
(Sellers and 
Dailey 1997) 
Yeast 
(mitochondrial 
membrane 
extracts) 
--- 5.9 a 1.63 a
Proto-
porphyrin 
None; 
anaerobiosis b
Porphyrin 
absorbance 
decrease 
(Camadro and 
Labbe 1982) 
Bovine (liver) 105 a 80 a 11 a 
Proto-
porphyrin 
DTT 
Hemochromogen 
assay 
(Dailey and 
Fleming 1983) 
Bovine (liver) 88 a 54 a 46 a 
Proto-
porphyrin 
DTT 
Hemochromogen 
assay 
(Taketani and 
Tokunaga 1982)
Rat (liver) 120 a 28.5 a 33.1 a
Proto-
porphyrin 
DTT 
Hemochromogen 
assay 
(Taketani and 
Tokunaga 1981)
 
Table 2.  Comparison of the steady-state kinetic parameters of ferrochelatase 
determined by various assay methods.  
 
 
a Apparent steady-state kinetic parameter values.  b Anaerobiosis was achieved by 
enzymatic oxygen uptake (Camadro and Labbe 1982).  
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is prepared at the optimal pH of 8.0 (Taketani and Tokunaga 1981; 1982; Franco et al. 
1995), and the detergent, Tween-80 [0.5% (v/v)], is included to allow maximal 
solubilization of protoporphyrin (Porra and Jones 1963a; Porra et al. 1967; Jones 1969; 
Camadro and Labbe 1982).  As ferrochelatase in the range of 10-100 nM has been found 
sufficient for the assay, the procedure allows the enzyme to be used in concentrations 
approximately one to two orders of magnitude lower than those routinely employed in 
non-fluorimetric assays.  Moreover, the calculated limit of reliable detection is improved 
up to two orders of magnitude over that of the pyridine-hemochromogen assay (Taketani 
and Tokunaga 1981).  Thus, the assay permits economical use of purified enzyme stocks, 
and also makes it possible to detect ferrochelatase in biological samples of low specific 
activity such as in porphyria patients.  
In summary, the continuous assay provides a novel method to measure 
ferrochelatase activity using the physiological ferrous iron substrate.  The sensitivity of 
this assay is enhanced up to two orders of magnitude over other assays currently in use, 
making it possible to determine the initial rate of enzymatic reaction at lower substrate 
concentrations than those previously reported.    
 
Characterization of the active site loop variants 
The overall fold and active site structure of ferrochelatase are highly conserved 
throughout evolution.  Crystal structures of B. subtilus, yeast and human enzymes reveal 
two domains in each monomeric unit and each domain is comprised of a Rossmann-type 
fold (Al-Karadaghi et al. 1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg et al. 2002).  
The active site is located in a deep cleft between the two domains.  This cleft is enriched 
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with many conserved residues that have been found to be important in metal binding and 
catalysis (Al-Karadaghi et al. 1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg et al. 
2002).  One side of the cleft is formed by the first two N-terminal α-helices, α1, α2, and 
a loop between them, and the other side consists of a short conserved loop sequence, 
which connects a β-strand and an α-helix in the second domain (Al-Karadaghi et al. 
1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg et al. 2002).  Although ferrochelatase 
only exhibits an overall sequence identity of no more than 20% in evolution, the loop 
motif is highly conserved (Figure 11).  Based on molecular dynamics calculations of B. 
subtilis ferrochelatase with bound nickel-protoporphyrin (NiPP) (Franco et al. 2000) and 
crystal structural analysis of ferrochelatase with bound porphyrin analog N-methyl 
mesoporphyrin (Lecerof et al. 2000), it has been proposed that the conserved loop is 
directly involved in porphyrin interaction.  To test this hypothesis, random mutagenesis 
and genetic complementation were applied to identify functional substitutions and to 
evaluate the information content of each of the 10 consecutive loop residues (Q248-
L257) in murine ferrochelatase.   
The results indicated that despite conservation of the loop (Figure 11), every 
amino acid within this sequence tolerated functionally permissible substitutions (Figure 
13).  The degree of acceptable substitutions varied, however, from position to position.  
K250, V251, P253, V254 and P255 tolerated diverse mutations including single 
substitutions and contained low informational content.  Interestingly, single amino acid 
substitutions identified at the low informational content positions were also co-selected in 
the multiply substituted variants (Figure 13), and a few of these amino acid substitutions 
are also present in nature (Figure 11). The remaining five loop positions Q248, S249, 
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G252, W256 and L257 had high informational content, because they only allowed very 
limited substiutions, and mutations were only possible when they were associated with 
changes in other loop residues whereas no single substitutions were observed (Figure 13). 
While G252 was the most amenable to change, even with drastic substitution such as W 
or R (Figure 13), substitutions at Q248, S249 and W256 were scarce, occurring primarily 
in triple and occasionally in quadruple mutants, suggesting that complementary changes 
in the loop are necessary to counterbalance the loss of wild-type residues at these 
positions.   
The attachment of ferrochelatase to the mitochondrial membrane has been 
proposed to play a role in facilitating uptake of the water-insoluble porphyrin substrates 
from a hydrophobic environment and also providing a pathway for heme release (Gora et 
al. 1996a; Wu et al. 2001).  As shown in the X-ray crystal structures of human and yeast 
ferrochelatases, the active site entrance is delimited by two, oppositely located loops, 
which are enriched with hydrophobic residues and possibly involved in mediating 
membrane association (Gora et al. 1996a; Wu et al. 2001; Karlberg et al. 2002).  Further, 
a number of positively charged residues in these loops have been implicated in 
interaction with the phosphate groups of the membrane phospholipids (Karlberg et al. 
2002).  One of these loops surrounding the active site entrance corresponds to the murine 
ferrochelatase sequence Q248-L257, and consistent with the above hypothesis, positively 
charged amino acid substitutions were found to accumulate at the C-terminal 
hydrophobic loop residues G252, P253, V254 and P255 (Figure 15A).  They conferred an 
overall increase in the binding affinities of the variants towards liposomes mimicking the 
composition of the inner mitochondrial membranes (Figure 15B, 15C).   
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An important step in ferrochelatase catalysis is the binding and distortion of 
porphyrin macrocycle to facilitate metal chelation.  An overall increase in the KmPPIX 
values of the selected loop variants (Table 1) supports the proposal that loop residues 
contribute to porphyrin-ferrochelatase interaction.  K250M/V251L/W256Y was the only 
variant with both a lower kcat and a higher KmPPIX than those of wild-type ferrochelatase 
(Table 1).  Indeed, this variant exhibited a catalytic efficiency towards porphyrin 10-fold 
lower than wild-type enzyme (Table 1).  Although three residues were mutated in variant 
K250M/V251L/W256Y, the primary effect was thought to derive from the W256Y 
mutation.  Specifically, the V251L mutation alone did not bring a decrease in the kcat 
value or a significant increase in the KmPPIX value (Table 1), and mutation of the K250 
residue was not expected to produce dramatic effect on the function of ferrochelatase, as 
it occupies a low information content position (Figure 13).  In addition, mutation of the 
corresponding residue in yeast ferrochelatase (W282) yielded a variant (W282L) showing 
a 10-fold decrease in KmPPIX and an unaltered Km for the metal substrate (Gora et al. 
1996b).  Actually, the homologous residue in B. subtilis ferrochelatase (W230) was 
shown to stack against the pyrrole ring, thereby stabilizing the position of the porphyrin 
ring in the crystal structure (Lecerof et al. 2000).   
The over 7-fold increase in the KmPPIX of the quadruple mutant 
Q248P/S249G/K250P/G252W (Table 1) most likely stemmed from the G252W mutation.  
Replacement of G252 with bulky aromatic tryptophan possibly blocked active site 
opening, thus hindering entry and binding of the porphyrin substrate.  This hypothesis 
agrees with the observation, based on the crystal structure of B. subtilis ferrochelatase 
(Al-Karadaghi et al. 1997), that any side chain other than glycine would introduce steric 
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hindrance at this position.  The triple mutant S249A/K250Q/V251C also exhibited a 
considerable increase (approximately 5-fold) in the KmPPIX.  While S249 contains high 
informational content (Figure 13) and is buried deeply in the active site cavity, the V251 
side chain is directed towards the path of porphyrin entry.  Possibly, combinatorial 
changes in the three positions led to misalignment or destabilization of porphyrin 
binding.  Unexpectedly, with the exception of the triple mutant K250M/V251L/W256Y, 
kcat, increased in all of the loop variants (Table 1).  The increase, ranging from 2- to 4.4-
fold, conceivably resulted from conformational flexibility of the loop motif.  Surface 
loops are frequently identified as mobile elements mediating protein conformational 
changes (Pompliano et al. 1990; Osborne et al. 2001).  They may control access to the 
active site by adopting an open conformation to permit substrate entry and product 
release, and a closed conformation to protect active site from the solvent and promote 
enzyme-substrate interactions required for catalysis (Pompliano et al. 1990).  It is likely 
that some variants prefer closed conformations which are more conducive to catalysis.  
For example, in variant Q248P/S249G/K250P/G252W, the indole ring and the 
pyrrolidine rings at the 252 and 248/250 positions, respectively, might restrict 
conformational plasticity of the loop region and promote a closed conformation more 
favorable to catalysis.  Alternatively, a higher kcat might result from stabilization of the 
transition state intermediates.   
Although the protein ligands for iron substrate remain to be unequivocally 
identified, nitrogenous and/or oxygenous side chains appear to coordinate metal substrate 
in ferrochelatase (Franco et al. 1995; Gora et al. 1996b; Ferreira et al. 2002).  The active 
site residues H209 and E289 (murine ferrochelatase numbering) have been recognized as 
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metal ligands and/or have an essential role in catalysis (Gora et al. 1996b; Lecerof et al. 
2000; Franco et al. 2001).  Analysis of the crystal structure of yeast ferrochelatase with 
bound metal ions suggested that yeast H235, E314 and S275 (equivalent to murine 
residues H209, E314 and S249, respectively) are involved in coordinating Co2+ and Cd2+ 
(Karlberg et al. 2002).  Thus, the increase in the KmFe2+ of the triple mutant 
S249A/K250Q/V251C may result from the loss of stabilization provided by S249 (Table 
1).  Curiously, the differences in the KmFe2+ values of the loop variants correlate with the 
presence of a π-helix in the second domain of ferrochelatase (Figure 14).  In a number of 
proteins, π-helix residues function to coordinate metal ions required for enzymatic 
activity (Weaver 2000; Fodje and Al-Karadaghi 2002; Shin et al. 2003).  In the structural 
model of murine ferrochelatase, residues arranged along the helical edge of the π-helix 
form a channel that connects the interior of the active site to the protein exterior (Figure 
30A).  The quadruple mutant Q248P/S249G/K250P/G252W, whose KmFe2+ value was the 
lowest among the analyzed variants (Table 1), exhibits a long (i.e., ten residues) π-helix 
(Figure 30C).  Given that the unit rise per residue of a π-helix is the shortest among all 
helical structures (Al-Karadaghi et al. 1997; Fodje and Al-Karadaghi 2002), the π-helical 
alignment of residues allows the side chains of E289, E293 and E297 to packed more 
closely and thereby might promote the efficiency of metal substrate uptake.  This is 
consistent with the observed decrease in the KmFe2+ value in the quadruple mutant.  In 
contrast, S249A/K250Q/V251C is the only variant with a regular α-helix in place of the 
π-helix (Figure 30B); this should result in a longer distance between the glutamate 
residues and thus slower metal transfer, which might account for a higher KmFe2+.  The 
mode of metal substrate interaction proposed here 
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Figure 30.   Structural features of the murine ferrochelatase models.  
The opening of the active site cavity consists of two N-terminal helices (lime) and the 
conserved loop (cyan).  Substituted residues in the loop are marked (green).  Three 
glutamate residues (purple) are located in the back of the active site cavity.  (A) In wild-
type ferrochelatase, two of the glutamate residues are arranged along a π-helix (red). 
(B) In triple mutant S249A/K250Q/V251C, the glutamate residues are located on the α-
helix which is in place of the π-helix.  (C) In quadruple mutant 
Q248P/S249G/K250P/G252W, three glutamate residues are aligned along a long π-
helix.    All images were generated using VMD 1.8.3 (Humphrey et al. 1996).  
 
A  
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is consistent with metal binding studies in yeast ferrochelatase (Karlberg et al. 2002; 
Lecerof et al. 2003).  According to this model, metal binding would require the conserved 
H209 and occur on the same side of active site as that of porphyrin binding, whereas the 
distal residues, including glutamates in the π-helical region, play a regulatory role by 
promoting metal release from the primary binding site (Lecerof et al. 2003).  
Overall, a mutational survey of the conserved loop motif (Q248-L257, murine 
ferrochelatase numbering) demonstrated that the loop possessed a considerable degree of 
plasticity.  While multiple functional substitutions were tolerated, the positions occupied 
by Q248, S249, G252, W256 and L257 exhibited the highest stringency.  Kinetic analysis 
of selected, active variants suggested that loop mutations result in a general disruption of 
interaction between the porphyrin substrate and ferrochelatase. Further, the loop motif 
was also shown to play an important role in maintaining the active site architecture as 
well as modulate ferrochelatase interaction with the metal substrate.   
 
Resonance Raman spectroscopy analysis of ferrochelatase-induced porphyrin 
distortion 
The most widely accepted reaction mechanism for ferrochelatase suggests that a 
critical step involves distortion of the porphyrin macrocycle to expose the lone-pair 
orbitals of pyrrole nitrogens to incoming metal ion (Dailey and Dailey 2003).  This 
notion has received support from both experimental and theoretical studies (Cochran and 
Schultz 1990; Blackwood et al. 1997; Blackwood et al. 1998; Lecerof et al. 2000).  
Antibodies raised against non-planar alkylated porphyrins were found to catalyze 
porphyrin metallation by Zn2+ and Cu2+ (Cochran and Schultz 1990).  Resonance Raman 
143 
(RR) spectra of antibody-bound mesoporphyrin revealed a saddling distortion 
(Blackwood et al. 1998), and X-ray crystal structure of the Michaelis complex of 
catalytic antibody bound to substrate mesoporphyrin in the absence of metal ions 
demonstrated out-of-plane macrocycle distortion including saddling, ruffling and some 
doming deformations (Yin et al. 2003). These studies indicated that antibody-induced 
porphyrin distortion resembles deformation observed in N-alkyl porphyrins (Blackwood 
et al. 1998; Yin et al. 2003).  Recent studies towards quantification of distortion led to the 
proposal that activation of the Raman band assigned to γ15, an out-of-plane vibrational 
mode for bound porphyrin, is directly related to the degree of affinity maturation of 
catalytic antibodies (Venkateshrao et al. 2004).  Theoretical methods including quantum 
and molecular mechanics calculations have been used to calculate the energetics 
associated with porphyrin distortion, especially within protein matrices (Sigfridsson and 
Ryde 2003).  These model studies indicated that, other than exposing pyrrole nitrogens to 
incoming metal ions, porphyrin deformation favors decreases in pKa of the macrocycle, 
thereby promoting deprotonation of the pyrrole rings.  Since deprotonation precedes 
metal insertion, catalytic reaction is allowed to progress.  In addition, porphyrin distortion 
may facilitate product release, as metalloporphyrins are harder to distort than free-base 
porphyrin and thus have lower affinity for the active site  (Sigfridsson and Ryde 2003).  
Previous RR spectroscopic analysis of porphyrin binding to wild-type murine 
ferrochelatase showed that the enzyme could induce porphyrin distortion even in the 
absence of metal substrate (Franco et al. 2000; Lu et al. 2002).  A high degree of 
specificity for porphyrin interaction with the protein was established by titrating 
ferrochelatase with a substoichiometric amount of porphyrin, which allowed observation 
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of the vibrational modes of bound porphyrins in the RR spectra, and revealed frequency 
shifts in the structure-sensitive lines upon protein binding (Lu et al. 2002).  In particular,  
γ15, an out-of-plane saddling-like mode of B2u symmetry, was activated in the RR spectra 
of free-base protoporphyrin bound to wild-type ferrochelatase (Lu et al. 2002).  Saddling 
was also shown to be a major component of the nonplanar distortion of N-methyl-
mesoporphyrin when bound to B. subtilis ferrochelatase by X-ray crystal structural 
analysis (Lecerof et al. 2000).  Significantly, saddling is an out-of-plane deformation that 
exposes both the protons and lone-pair orbitals of the nitrogen atoms of the macrocycle, 
thus consistent with a porphyrin set-up for metal insertion in a reaction facilitated by 
ferrochelatase.  
Previous studies have shown that a conserved active site loop motif mediates 
interaction of porphyrin with ferrochelatase (Shi and Ferreira 2004).  Porphyrin binding 
to the loop variants was examined using RR spectroscopy.  Analysis of the RR spectra for 
substrate protoporphyrin demonstrated that the γ15 mode was activated upon porphyrin 
binding to wild-type protein and variants (Figure 16A).  Consistent with previous RR 
studies (Franco et al. 2000; Lu et al. 2002), this observation confirmed porphyrin 
saddling is an important form of non-planarity induced by the enzyme.  Further, the 
extent of porphyrin saddling could be quantified by normalizing the integrated intensity 
of γ15 line to the intensity of ν7 line for the same spectrum (Table 3).  Interestingly, as the 
variants became deficient in producing saddled porphyrins, their catalytic efficiencies 
were diminished accordingly (Table 3).  The strongest reduction was observed in variant 
K250M/V251L/W256Y in which porphyrin saddling was less than 30% of that in the 
wild-type enzyme (Table 3).  This diminished out-of-plane distortion was accompanied  
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Proteins ν7 
(cm-1) 
ν7 
intensity 
(area) 
ν7 
total 
intensity 
(area) 
γ15 
(cm-1) 
γ15 
total 
intensity 
(area) 
γ15/ν7 
relative 
intensity 
 
% Wild- 
type 
γ15/ν7 
relative 
intensitya 
kcat / KmPPIX 
(min-1 μM-1) 
Wild-type 
ferrochelatase 
673.3 
678.0 
1624.5 
1408.8 
 
3033.3 
 
700.4 
 
455.8 
 
0.150 
 
100.0 
 
2.93 
P255R 674.3 
679.0 
1059.6 
745.6 
 
1805.2 
 
701.0 
 
244.4 
 
0.135 
 
90.1 
 
2.94 
S249A/K250Q/
V251C 
673.8 
678.5 
2166.5 
1517.9 
 
3684.4 
 
700.8 
 
481.8 
 
0.131 
 
87.0 
 
2.63 
P255G 675.3 
682.7 
1752.3 
514.4 
 
2266.7 
 
700.6 
 
126.0 
 
0.056 
 
37.0 
 
2.35 
Q248P/S249G/
K250P/G252W 
674.9 
679.8 
6632.7 
2349.2 
 
8981.9 
 
701.0 
 
1088.9 
 
0.121 
 
80.7 
 
1.36 
K250M/V251L
/W256Y 
676.8 
685.5 
3124.6 
531.9 
 
3656.5 
 
701.3 
 
158.6 
 
0.043 
 
28.8 
 
0.27 
Table 3.  Results of simulation for the low-frequency resonance Raman spectra of 
ferrochelatase-bound protoporphyrin.   
The Raman spectra were exported as even-X ASCII files, and spectral simulation for 
the frequency region from 580 to 780 cm-1 was based on least squares fitting with 
Lorentzian line shapes and a fixed half-width at half maximum (2.814 cm-1) for the γ15 
line using the program PeakFit (SYSTAT).    
 
a % wild-type γ15/ν7 relative intensity was determined by normalizing the relative
intensity  of the γ15 line versus the ν7 line observed in porphyrins bound to each variant
against that obtained from porphyrins bound to wild-type ferrochelatase.  
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by a catalytic efficiency (kcat/KmPPIX) one order of magnitude lower than the wild-type  
enzyme (Table 3).  Studies using synthetic non-planar porphyrins dissolved in solvents of 
different polarity suggested that saddling could affect the potential-energy surfaces to 
allow porphyrin to access multiple configurations with small energy barriers from the 
ground state (Sazanovich et al. 2001).  Conceivably, a similar mechanism might be used 
for ferrochelatase to solvate porphyrin substrate and to facilitate its conversion into 
catalytically competent forms.   
Similar observations have been made for porphyrin distortion by catalytic 
antibodies (Venkateshrao et al. 2004).  An out-of-plane vibrational mode, γ15, assigned to 
the Raman band at 680 cm-1, was activated in mesoporphyrin upon binding to affinity-
matured antibody, and its intensity was ~3-fold higher than that resulted from binding to 
the germLine precursor antibody (Venkateshrao et al. 2004).  Somatic mutations which 
allowed reversion to the germLine residues yielded intermediate intensity values for the 
γ15 band of bound porphyrins (Venkateshrao et al. 2004).  Indeed, an approximate linear 
correlation was shown between the logarithm of catalytic efficiency and the intensity of 
γ15 line normalized to ν7.  These results implied that the extent of γ15 activation was 
mainly proportional to activation energy of the reaction, and reiterated the idea that 
catalysis involves substrate straining, and binding energy is evolved to lower the 
activation energy required for reaction to proceed (Venkateshrao et al. 2004).  The 
mechanisms of porphyrin metallation seem to proceed through a highly conserved 
transition state, regardless of whether the reaction is catalyzed by a catalytic antibody or  
ferrochelatase.  Out-of-plane porphyrin distortion appears to be a common and crucial 
thread that connects all of the transition states.  
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It is likely that multiple factors can influence the competency of ferrochelatase to 
distort porphyrin from its naturally planar conformation.  Maximal porphyrin distortion 
may require optimal active site geometry.  Previous studies indicated that loop mutations 
led to alteration of the active site architecture (Shi and Ferreira 2004), and as a result, 
conformational changes of porphyrins bound in the active sites of the loop variants might 
not achieve those of the transition state for Fe2+ insertion.  This is consistent with the 
correlation between the decrease in porphyrin saddling observed in the variants and the 
loss of catalytic efficiency (kcat/KmPPIX) (Table 3).  Studies of catalytic antibodies 
suggested that specific residues appeared to play a dominant role in inducing porphyrin 
distortion (Venkateshrao et al. 2004).   Although residues of the loops in both light and 
heavy chains contributed to mesoporphyrin deformation, mutational analysis indicated 
that heavy chain residues dominated the activation of the γ15 mode. 
The dominant effect of certain amino acid residues on porphyrin deformation in 
ferrochelatase is best demonstrated by variant K250M/V251L/W256Y.  This variant was 
the least efficient in porphyrin distortion, as it induced only about 30% of the saddling 
seen in the wild-type enzyme.  Previous studies showed that while K250 and V251 
tolerated multiple replacements and were less likely to play a critical role in porphyrin 
interaction, functional substitutions at the W256 position were very limited suggesting 
the importance of W256 to enzymatic function (Shi and Ferreira 2004).  Thus, while the 
possibility that K250, V251 and W256 act synergistically in variant 
K250M/V251L/W256Y to promote deformation of the porphyrin substrate cannot be 
dismissed, it seems unlikely that K250 and V251 are themselves the major determinants 
in porphyrin distortion.  In the structural model of murine ferrochelatase, K250 side chain 
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was oriented towards the protein exterior, thus making it very unlikely that K250 would 
contact the bound porphyrin directly (Figure 31).  Although the side chain of V251 
pointed into active site pocket (Figure 31), porphyrin binding to variant V251L yielded 
RR spectra similar to that of wild-type protein (data not shown), indicating that the 
V251L mutation alone does not alter the degree of porphyrin distortion from that 
observed for the wild-type enzyme.  In agreement with these observations, variants 
S249A/K250Q/V251C and Q248P/S249G/K250P/G252W, which also contained K250 
and V251 substitutions, exhibited only a mild decrease in porphyrin saddling at 10-15% 
of the wild-type level (Table 3).  The invariant W256 oriented its bulky aromatic side 
group towards the interior of the active site cleft.  X-ray crystal structural analysis of B. 
subtilis ferrochelatase indicated that W230, equivalent to the murine W256 residue,  was 
in close proximity to the bound N-methyl-mesoporphyrin (Lecerof et al. 2000).  In 
particular, the minimum distance between the C6 of tryptophan indole group and the 
nitrogen of pyrrole ring C of porphyrin was only ~3 Å.  This made it possible for the 
tryptophanyl indole ring to be positioned to tilt down the pyrrole group in a manner 
required for generating the observed non-planar structure.  Based on this model, it seems 
likely that W256Y substitution in murine ferrochelatase would make it difficult for the 
side group to reach the proximal pyrrole ring and tilt it down, because tyrosine presents a 
shorter phenolic ring than the indole ring in tryptophan (Figure 31).  Taken together, the 
loop residue W256 appears to play a dominant role in producing porphyrin deformation 
in the active site matrix of murine ferrochelatase.  
In addition to modulating saddling of the porphyrin core, loop residues are found 
to mediate interaction of the porphyrin vinyl substituents with the active site.  While the 
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Figure 31.  Three-dimensional views of the porphyrin-binding cleft in ferrochelatase. 
 (A) The active site of B. subtilis ferrochelatase with bound N-MeMP as shown in the X-
ray crystal structure (PDB code 1C1H).  The side chain of the conserved W230 (green) in 
the loop motif (cyan) lies in close proximity to pyrrole ring C of bound porphyrin (red). 
(B)  The active site (arrow) in the structural model of wild-type murine ferrochelatase.  The 
side group of the conserved W256 (green) in the loop motif (cyan) is oriented towards the 
interior of porphyrin-binding pocket.  (C) The active site (arrow) in the structural model of 
variant K250M/V251L/W256Y.  Among the mutated residues in the loop (cyan), the side 
chains of L251 (blue) and Y256 (green) are directed towards the interior of the porphyrin-
binding cleft, while the side group of M250 (orange) points to the protein exterior.  
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vinyl groups adopted defined conformations upon porphyrin binding to wild-type protein, 
the interaction was generally weakened in loop variants, possibly due to global changes 
in the active site structure (Shi and Ferreira 2004).  The RR spectra of protoporphyrin and 
NiPP revealed sharpening of the vinyl stretching band νCa=Cb upon protein binding 
(Figures 16B, 18B), suggesting that vinyl groups had a reduced freedom of movement 
and adopted a more restricted orientation within the protein matrix.  However, in variant     
K250M/V251L/W256Y, the vinyl groups of protoporphyrin appeared less defined than in 
wild-type protein and other variants (Figure 16B).  Notably, the νCa=Cb band was 
downshifted suggesting rotation of the vinyl side chains into the plane of the porphyrin 
core, whereas broadening of the νCa=Cb line indicated that vinyl groups might take 
alternative conformations (Kalsbeck 1995; Marzocchi and Smulevich 2003).  
The loop residues may also function to restrict the configuration of porphyrin ring 
imposed by the active site. Using ν2 as a core-size marker (Parthasarathi 1987), hemin 
exhibited expansion of the macrocycle upon binding to wild-type ferrochelatase (Figure 
17B).  The ring was further enlarged in the variants P255R and P255G, as indicated by 
the downshift of the ν2 line for bound hemin (Figure 17B).  However, in the active sites 
of the variants K250M/V251L/W256Y, S249A/K250Q/V251C and 
Q248P/S249G/K250P/G252W, the macrocycle was more contracted as suggested by the 
upshift of ν2, making it resemble unbound hemin.  For NiPP binding, the ν2 and ν10 lines 
were downshifted in wild-type protein and the variants (Figure 18B), indicating that the 
ring was similarly expanded in the protein matrix.  While unbound NiPP adopted both 
planar and non-planar conformations in solution, as indicated by the deconvolution of the 
ν10 band into a planar and non-planar component, only the non-planar form was retained 
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in the protein environment (Figure 18B), reminiscent of the conformation previously 
observed for NiPP bound to wild-type enzyme (Franco et al. 2000). 
In conclusion, the conserved active site loop motif in ferrochelatase plays an 
important role in porphyrin binding and distortion.  Most significantly, the induced 
porphyrin saddling is shown to modulate catalytic efficiency of ferrochelatase towards its 
substrate, and the invariant tryptophan is a major protein determinant of the saddled 
conformation of the macrocycle.  Additionally, the loop residues function in specifically 
orienting the porphyrin vinyl substituents and likely the entire porphyrin ring.  
 
Inhibition of ferrochelatase by N-methyl protoporphyrin 
 N-methyl protoporphyrin has long been known as a potent inhibitor of 
mammalian ferrochelatase (Dailey and Fleming 1983; Cole and Marks 1984; Nunn et al. 
1988).  Since alkylation of a pyrrole nitrogen atom introduces non-planarity into the 
porphyrin macrocycle (Caughey and Iber 1963), NMPP is thought to bear structural 
resemblance to the distorted porphyrin intermediate in the enzymatic reaction, and 
therefore is strongly inhibitory to ferrochelatase catalysis.  N-alkylated porphyrins are 
generated in vivo from modification of the cytochrome P450 heme moiety upon drug 
exposure (Marks et al. 1988; Lavigne et al. 2002).   Xenobiotics taken up by hepatic cells 
have been shown to bind to the active site of P450 and inactivate the enzyme by N-
alkylation of a heme pyrrole ring (Marks et al. 1988).  Recently, N-alkylporphyrin 
formation has been associated with specific isoforms of P450 undergoing mechanism-
based inactivation in human liver microsomes (Gamble et al. 2003).   
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While wild-type ferrochelatase showed high affinity towards NMPP consistent 
with previous studies (Dailey and Fleming 1983), the stability of this complex was 
reduced due to mutations in loop residue P255.  Studies of enzymes including thrombin 
(Lewis et al. 1998) and pyruvate dehydrogenase (Nemeria et al. 2001) suggested that a 
slow conformational change of the protein-inhibitor complex could play an important 
role in providing high affinity binding of a substrate analog to the protein, because it 
would ensure optimal alignment of the ligand in the active site environment.  In order to 
find out whether this mechanism is applicable to ferrochelatase, the rate constants for 
NMPP binding to ferrochelatase were determined using stopped-flow analysis.  For wild-
type enzyme, the inhibitor binding process was found to consist of two kinetic steps.  
There was a fast step for initial binding of NMPP to the enzyme (Figure 23A).  It was 
followed by a slow step, which might be related to conformational rearrangement of the 
protein-inhibitor complex (Figure 23A).  Consistent with this mechanism, 
crystallographic studies revealed that binding of porphyrin analog N-methyl 
mesoporphyrin to B. subtilis ferrochelatase triggered a significant conformational change 
of the active site pocket involving the loop residues (Lecerof et al. 2000). 
Similar to wild-type enzyme, binding of NMPP to variant P255R also proceeded 
in two steps (Figure 23B).  For the slow step, i.e. the second step, the forward and reverse 
rate constants k2 and k-2, were comparable to those of wild-type protein.  Therefore 
diminished inhibition of variant P255R did not stem from changes in the rate of NMPP 
binding.  In variant P255G, NMPP binding occurred in one step and did not involve 
conformational change of the protein-inhibitor complex (Figure 23C).  Nevertheless, the 
rate constants k1 and k-1 for variant P255G were similar to those determined for the rate-
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limiting step, i.e. k2 and k-2, in wild-type protein and variant P255R, suggesting that the 
rate of NMPP binding was unlikely to contribute to its lessened inhibitory effect on 
P255G.   
It is possible that binding affinity for NMPP can be modulated by the steric 
features of the active site of ferrochelatase.  Structural modeling suggested that loop 
mutations result in alterations in the active site architecture (Shi and Ferreira 2004).  
Examination of the dimension of the active site cavity using the CAST program indicates 
that the size of porphyrin-binding pocket is reduced by 30% in variant P255R and 50% in 
variant P255G relative to wild-type protein.  Based on these observations, it seems 
plausible that the P255 residue plays a role in supporting an open conformation of the 
active site in wild-type ferrochelatase, whereas P255 variants are deficient in opening the 
active site cleft, which can lead to restricted NMPP entry and decreased binding affinity.  
This possibility is consistent with the function of proline as a conformational switch, 
which has been demonstrated in a variety of proteins such as interleukin-2 tyrosine kinase 
and serine proteases (Mallis et al. 2002; Bobofchak et al. 2005).   
In spite of marked differences with respect to NMPP binding, the variants 
exhibited kinetic properties similar to wild-type enzyme.   While wild-type ferrochelatase 
had a kcat of 4.1± 0.3 min-1, the catalytic activity was slightly increased in the variants, 
with a kcat of 7.8 ± 0.8 min-1 for P255R and 5.9 ± 1.4 min-1 for P255G (Table 1 and 
unpublished results).  The KmPPIX for wild-type enzyme was 1.4 ± 0.2 μM, and it was 
slightly higher in the variants with 2.65 ± 0.44 μM for P255R and 2.51 ± 0.80 μM for 
P255G (Table 1 and unpublished results).  Thus, the specificity constant for 
protoporphyrin, i.e. kcat/KmPPIX, was 2.92 for wild-type ferrochelatase, 2.94 for P255R and 
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2.35 for P255G.  These results imply that specificity towards the endogenous substrate 
porphyrin is distinct from selectivity towards NMPP, and the mechanism involving 
substrate porphyrin interaction in the catalytic pathway might be different from that for 
inhibitor binding.  Overall, while selectivity towards NMPP is prone to perturbation as a 
result of active site mutations, it is much more difficult to alter specificity towards 
substrate porphyrin.  It is conceivable that the active site of ferrochelatase is optimized 
for interaction with substrate protoporphyrin and retains a certain degree of plasticity 
towards this end.  Possibly, this facilitates induction of porphyrin deformation in the 
protein matrix, and in so doing, ensures catalytic reaction to proceed.  In contrast, active 
site does not appear to be flexible towards interaction with porphyrin analog such as 
NMPP.   
One potential application of the ferrochelatase variants with improved tolerance 
towards NMPP is to use them in the cell assay system for studying physiological 
responses resulted from heme deficiency.  Recent reports have suggested that heme 
deficiency is associated with various disorders such as Alzheimer’s disease, frataxin-
deficiency mediated diseases and oxidative damages resulted from hyperoxia (Atamna 
and Frey 2004; Campian et al. 2004; Schoenfeld et al. 2005).  In these studies, NMPP 
treatment of cultured cells has been used as a convenient model system to induce heme 
deficiency (Atamna et al. 2001; Campian et al. 2004).  Interestingly, NMPP-treated cells 
typically exhibited impaired enzymatic activity and assembly of mitochondrial electron 
transport complex IV, i.e. cytochrome c oxidase (COX) (Tangeras 1986; Atamna et al. 
2001; Campian et al. 2004).  COX has been proposed to have a cytoprotective role by 
removing reactive oxygen species, and COX deficiency renders cells more susceptible to 
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oxidative stress (Atamna et al. 2001; Campian et al. 2004).  It should be interesting to 
find whether the observed NMPP-induced cytotoxicity can be alleviated by expressing 
constitutively active ferrochelatase, for instance, the P255 variants which would confer 
resistance to NMPP inhibition and thereby keep heme synthesis uninterrupted.  
In summary, ferrochelatase variants P255R and P255G have been found to be 
much less inhibited by the porphyrin analog NMPP when compared to wild-type protein.  
This is likely to derive from structural features of the mutant active sites and not due to 
changes in the rate constants of inhibitor binding.  This raises the possibility of lowering 
selectivity towards active site-directed inhibitor without compromising substrate 
specificity and catalysis, for instance, through modification of protein conformation.  The 
variants can also be applied to disease studies relevant to heme deficiency, for example, 
to protect cells from cytotoxicity resulted from heme deficiency.  
 
FeS cluster assembly and oligomeric organization in ferrochelatase 
Wild-type mammalian ferrochelatase has been shown to exist as a homodimer 
(Straka et al. 1991; Wu et al. 2001), and there is one [2Fe-2S] cluster associated with 
each monomeric subunit (Wu et al. 2001).  FeS cluster is coordinated by four cysteine 
ligands C403, C406 and C411 in a conserved C-terminal motif and a distant C196 in the 
N-terminal portion [(Crouse et al. 1996; Wu et al. 2001) and Figure 32].  Mutations in the 
C-terminus including cysteine ligand substitutions resulted in deficiency in catalytic 
activity and cluster assembly, suggesting that the FeS cluster plays an important role in 
wild-type protein function (Brenner et al. 1992; Dailey et al. 1994a; Crouse et al. 1996).  
The current study indicates while FeS cluster assembly is important to enzymatic activity 
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Figure 32.  Position of the FeS cluster relative to the active site in ferrochelatase.  
Locations of the [2Fe-2S] cluster (sulfur atoms in pink and iron atoms in green) and the 
four coordinating cysteine ligands (red) are shown in the X-ray crystal structure of 
human ferrochelatase homodimer (PDB code 1hrk).  The active site cavity in a 
monomeric subunit is indicated by an arrow.  The loop motif is marked in cyan.  The 
homology model of murine ferrochelatase (lime) is superimposed onto the monomeric 
structure of human ferrochelatase (yellow).  Image was generated using VMD 1.8.3 
(Humphrey et al. 1996).  
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of wild-type murine ferrochelatase, it is dispensible in variants S249A/K250Q/V251C 
and S249A/K250R/G252W (Figure 25).  This implies that the catalytic mechanism of 
ferrochelatase may be independent of FeS cluster, which is in agreement with previous 
observations (Medlock and Dailey 2000).  Using chimeric constructs of human and yeast 
ferrochelatase, it has been shown that a fusion protein containing the C-terminal tail from 
yeast enzyme and the remaining of human enzyme was active without having the FeS 
cluster from human ferrochelatase (Medlock and Dailey 2000).  Also, truncated human 
ferrochelatase lacking the C-terminal cluster-coordinating region was catalytically active 
(Ohgari et al. 2005).  Because the catalytic core of ferrochelatase is highly conserved 
(Dailey and Dailey 2003),  it is likely that  the reaction pathway for mammalian enzyme 
is analogous to that for the clusterless enzyme from B. subtilis and S. cerevisiae and does 
not directly involve FeS cluster (Al-Karadaghi et al. 1997; Karlberg et al. 2002).  
Consistent with the notion that mammalian ferrochelatase exists as a homodimer 
(Straka et al. 1991; Wu et al. 2001), size determination by gel filtration analysis (Figure 
26) and dynamic light scattering (Figure 27) indicated that purified wild-type murine 
ferrochelatase is a homodimer in solution.  Nevertheless, higher order oligomers were 
found in variants S249A/K250Q/V251C and S249A/K250R/G252W and they remained 
enzymatically active (Figure 26 and 27).  These observations suggest that ferrochelatase 
can adopt alternative quaternary structures other than homodimer, and oligomerization 
state is not directly related to enzymatic activity.  In line with this proposal, recent studies 
of human ferrochelatase showed that a wild-type monomer was capable of forming a 
heterodimer with a mutant monomer encoded by alleles derived from EPP patients and 
the heterodimers were catalytically active (Najahi-Missaoui and Dailey 2005; Ohgari et 
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al. 2005).  Interestingly, the presence of high molecular weight species in loop variants 
S249A/K250Q/V251C and S249A/K250R/G252W suggest that the quaternary structure 
of ferrochelatase can be modified as a result of protein structural changes,  and therefore 
is not completely controlled by interaction of residues on the dimer interface as suggested 
in the crystal structural analysis of human ferrochelatase (Wu et al. 2001).  This result is 
reminiscent of a conformational study of porphobilinogen synthase, which exhibits 
dynamic equilibrium of quaternary structures (Jaffe 2005).  Determining subunit 
arrangement in the variants, for instance, by X-ray crystallography, may help to further 
understand the structural basis of ferrochelatase oligomerization.  
EPR spectroscopic analysis indicated that similar to wild-type protein, [2Fe-2S] is 
a predominant, if not the only, form of cluster in the variants (Figure 28).  Although 
attempts were made to examine the temperature-dependence of EPR spectra in order to 
differentiate the possibilities that there are mixed-type clusters such as the [4Fe-4S] and 
[2Fe-2S] forms, further analyses will be required to decipher the spectral features (Figure 
29).  Because variant S249A/K250Q/V251C and S249A/K250R/G252W can exist in 
large oligomeric assemblies, the FeS cluster does not appear to directly promote subunit 
interaction.  This proposal is consistent with recent studies of human ferrochelatase 
showing that homodimers and heterodimers could form among the wild-type and mutant 
protein subunits in the absence of cluster  (Najahi-Missaoui and Dailey 2005; Ohgari et 
al. 2005).  Therefore, although [2Fe-2S] cluster has been found near the dimer interface 
in human ferrochelatase crystal structure (Wu et al. 2001), the notion that the cluster acts 
to facilitate dimerization may be questionable.   
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Taken together, the current characterization of ferrochelatase variants suggests an 
interesting aspect of the catalytic mechanism.  It seems plausible that catalytic reaction 
may take place on a scaffold provided by higher order oligomeric forms as revealed in 
the variants, and the reaction may proceed even without FeS cluster.  This helps to 
explain the observation that variants S249A/K250Q/V251C and S249A/K250R/G252W 
retained significant amount of enzymatic activity in the absence of cluster assembly, i.e. 
in PK4331 cells, when compared to the control levels, i.e. in RZ4500 cells,  whereas 
wild-type protein was inactivated by the loss of cluster assembly (Figure 25).  An 
alternative hypothesis is that the FeS cluster plays a role in stabilizing the active site 
conformation (Dailey 1997).  Because the loop motif has been proposed to play a role in 
maintaining the active site structure (Shi and Ferreira 2004),  it is likely that the variants 
can adopt alternative active site conformations which support enzymatic reaction without 
the FeS cluster (Figure 32).  
Overall, the current results suggest that the FeS cluster is not directly involved in 
catalysis, but rather, it is more likely to regulate enzymatic activity.  One possibility is 
that the FeS cluster can sense the iron state in vivo and modulate enzymatic activity 
accordingly (Taketani et al. 2003; Lange et al. 2004).  This would imply that 
ferrochelatase is active if an adequate amount of cluster is assembled, whereas under 
conditions such as iron deprivation, FeS cluster assembly is diminished leading to 
inactivation of the enzyme and inhibition of the completion of heme synthesis.  This 
possibility is particularly interesting considering that FeS cluster assembly has very 
recently been shown to modulate erythroid heme synthesis by translational regulation of 
the first enzyme ALAS2 production (Wingert et al. 2005).  Thus, by extending the 
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regulatory role of the cluster to the terminal enzyme, ferrochelatase, FeS cluster assembly 
machinery becomes tightly coupled to heme biosynthesis pathway, thereby providing a 
rapid response to iron status under physiological conditions.  
Investigation of the mechanism of ferrochelatase oligomerization and FeS cluster 
assembly are relevant to the understanding of EPP pathogenesis.  Since EPP mutations 
found near the cluster and dimer interface are highly deleterious to ferrochelatase activity 
(Schneider-Yin et al. 2000b; Najahi-Missaoui and Dailey 2005; Ohgari et al. 2005), 
regulation of enzymatic activity and protein structure and stability is likely to play an 
important part in disease development.  One potential application of the variants 
described here is to study the regulation of ferrochelatase activity in mammalian cells.  
For instance, if ferrochelatase is regulated by FeS cluster assembly, expression of the 
variants may override this control and uncouple protoporphyrin IX accumulation from 
inadequate cluster assembly.  It is hoped that further studies of cluster assembly and 
oligomerization shall provide insights into the regulatory mechanism for ferrochelatase 
activity.   
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Appendix 1:  The primary sequence of the mature form of wild-type murine 
ferrochelatase.  The porphyrin-binding loop motif is underlined. 
 
         
 
TTKPQAQPERRKPKTGILMLNMGGPETLGEVQDFLQRLFLDRDLMTLPIQNKLAPFIAKR
RTPKIQEQYRRIGGGSPIKMWTSKQGEGMVKLLDELSPATAPHKYYIGFRYVHPLTEEAI
EEMERDGLERAIAFTQYPQYSCSTTGSSLNAIYRYYNEVGQKPTMKWSTIDRWPTHPLLI
QCFADHILKELNHFPEEKRSEVVILFSAHSLPMSVVNRGDPYPQEVGATVHKVMEKLGYP
NPYRLVWQSKVGPVPWLGPQTDEAIKGLCERGRKNILLVPIAFTSDHIETLYELDIEYSQ
VLAQKCGAENIRRAESLNGNPLFSKALADLVHSHIQSNKLCSTQLSLNCPLCVNPVCRKT
KSFFTSQQL 
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